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Membrane trafficking events are required to direct proteins to their precise subcellular 
locations. The cellular Phosphofurin Acidic Cluster Sorting protein – 1 (PACS-1) has 
emerged as a protein of interest in controlling the localization of a multitude of cellular and 
viral proteins. Specifically, PACS-1 is hijacked by type-1 Human Immunodeficiency Virus 
(HIV-1) to contribute to immune evasion in addition to regulating neuroendocrine hormone 
storage and release. To accomplish this, PACS-1 connects the cytoplasmic tail of cellular 
receptors to the heterotetrameric adaptor proteins (APs) to form a functional trafficking unit. 
Throughout this dissertation, I explored the role of PACS-1 and AP-1 to drive the 
localization of unique cargo proteins; the type-1 major histocompatibility complex (MHC-I) 
and the adrenocorticotropic hormone (ACTH). I have utilized the intracellular protein-protein 
interaction reporter assay: bimolecular fluorescence complementation (BiFC), in 
combination with super-resolution microscopy to uncover the membrane trafficking route 
undertaken by the HIV-viral accessory protein Nef and the cellular receptor MHC-I. 
Additionally, I have generated a tool termed “viral BiFC” to study virus:host interactions in 
cells.  These studies revealed a mechanism by which Nef re-routes MHC-I from the cell 
surface, toward the trans-Golgi Network (TGN) by hijacking both early and recycling 
endosomes. Interestingly, Nef requires PACS-1 to permit the transport of MHC-I from the 
endosomes to the TGN, a process which is also dependent on AP-1 recruitment. Moreover, 
the role of PACS-1 extends beyond its implication in HIV-1 infection. The regulation of 
neuroendocrine cell hormone storage and secretion is a tightly regulated process requiring 
coordinated trafficking of multiple proteins. Thus, I hypothesized that PACS-1 would 
promote proper storage of ACTH within specialized storage granules. These studies 
identified a key role for PACS-1 and AP-1 in directing ACTH to the storage granule. 
Undoubtedly, the function of PACS-1 is important in not only the immune evasive 
capabilities of HIV-1 Nef, but also in the regulation of hormone secretion. By understanding 
how cargo molecules are targeted throughout the cell by PACS-1, we can begin to unravel 
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1.1 General introduction to membrane trafficking 
Eukaryotic cells are characterized by the presence of intracellular membrane-bound 
compartments that are termed organelles. The development of such specialized 
compartments enables eukaryotic cells to carry out diverse cellular functions within 
precise cellular compartments (1). However, this compartmentalization also requires 
exquisite mechanisms that control the movement of compartmental contents from one 
area to another, and often relies on sub-organelle structures in the form of membrane 
bound vesicles. The net result of this control is a constant shuttling of vesicles and the 
proteins they carry, their cargo, throughout the cell. These trafficking steps are 
collectively controlled by the endomembrane system and the membrane trafficking 
machinery. Millions of years of evolution have led to a full network of interconnected 
organelles each with their own specialized functions, and controlled by multiple adaptor 
and connector proteins (Fig 1.1)(1-3).  
More specifically, eukaryotic cells contain a defined set of organelles that are critical for 
membrane trafficking. One such organelle, the endoplasmic reticulum (ER), is required 
for protein synthesis (4-6). Conversely, the Golgi apparatus fulfills a role of sorting 
proteins to their correct destination while also ensuring a diverse array of post-
translational modifications take place along the way (7-10). In addition, eukaryotic cells 
contain a plethora of vesicles, which can also be considered organelles. These vesicles 
include multiple types of endosomal vesicles and lysosomes, which together form the 
endolysosomal network (Fig 1.1).  
The identity of the various eukaryotic organelles is not only defined by their function but 
also by the proteins that coat their outer. Genomic studies have demonstrated that 
eukaryotes contain groups of proteins that form the basis of membrane trafficking and 
also define organelle identity (1, 2). These groups of proteins include: coat proteins 
which can induce membrane curvature and budding; guanine nucleotide exchange factors 
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(GEFs) and GTPase activating proteins (GAPs), which control the identity of endosomal 
membranes (11-13); vacuolar ATPases (14), which modulate intraluminal pH; and 
soluble N-ethylmaleiminde sensitive factor attachment protein receptor (SNARE) 
proteins that primarily serve to dock and fuse vesicles (15, 16). Taken together, this basic 
set of proteins provides the basis for membrane trafficking.  
1.2 Organization of the endomembrane system 
Within the endomembrane system exists two primary trafficking routes; the retrograde 
transport system (movement from the plasma membrane to the cell interior; 
encompassing the endolysosomal network), and the secretory transport system (10, 17) 
(movement of newly synthesized proteins to the cell surface). Elements encompassing the 
endolysosmal machinery include pathways that recycle cell surface proteins (18-20), and 
target cellular proteins for degradation via the acidic lysosomal organelle or traffic 
cellular receptors to the Golgi-network (21). Moreover, secretory transport can be further 
subdivided into the regulated, and constitutive secretion of proteins depending on specific 





Figure 1.1: Overview of the endomembrane system 
The endomembrane system can be classified into two primary networks; the 
endolysosomal network (retrograde transport; left), and the secretory network 
(anterograde transport; right). The endolysosomal network is responsible for sorting 
newly endocytosed molecules within the cell. Destinations include the recycling 
endosome; where molecules can be rapidly returned back to the cell surface, early and 
late endosomes; which represent increasingly acidifying compartments where molecules 
can be sorted to either the degradative lysosomal compartment, or back to the TGN to be 
further modified or sequestered. The secretory network (right) primarily targets newly 
synthesized proteins to the cell surface or for secretion. Two primary pathways exist: 





























cell types, and utilizes the ER to synthesize proteins, which are subsequently modified 
within the Golgi apparatus, and transported to the cell surface through transport vesicles. 
Regulated secretion is present within specialized cell types such as endocrine and 
neuroendocrine cells, and packages cargo within a dense core secretory granule organelle 




1.3 Membrane trafficking and disease 
While membrane trafficking is fundamental in nature, it plays a critical role in health and 
disease (23). For example, within the regulated secretory pathway of neuroendocrine 
cells (Fig. 1.1), neurotransmitter synthesis and release will require fine-tuned intracellular 
storage and release mechanisms (24, 25). Similarly, hormonal regulation also requires the 
regulated secretory pathway (26). Moreover, the trafficking of functional receptors to the 
cell surface for immune cell signaling and communication is critical for cellular 
homeostasis and immunity (27-30). As such, multiple human diseases are the result of 
defects in membrane trafficking. Cystic fibrosis patients, for example, may carry 
mutations within the cystic fibrosis conductase regulator gene (ctfr)(31, 32), which 
results in the intracellular mis-localization of CFTR. Conversely, patients with 
Hermansky-Pudlak syndrome, a rare disorder resulting in albinism and bleeding 
problems, carry mutations within the trafficking machinery involved in the formation of 
vesicles, resulting in platelet dysfunction and decreased melanin storage (33-35).  
These fundamental membrane trafficking processes are also utilized by pathogens such as 
viruses, which have evolved methods to traffic within eukaryotic cells. As viruses are 
unable to replicate in the absence of their host, they hijack components of the 
endomembrane system in order to gain access to sites permissive for viral replication and 
assembly within the cell (36). This viral manipulation of the endolysosomal network is 
required by multiple viruses to ensure the completion of viral lifecycles (37-39). For 
example, viral proteins can alter the location of host cellular proteins normally located on 
the cell surface thereby inhibiting antiviral signaling pathways, apoptosis, and 
communication (40-42). These activities can render the cellular environment more 
permissive to viral replication. The type-1 human immune deficiency virus (HIV-1) is no 
exception to this as the viral accessory proteins Nef and Vpu modify the surface 
expression of over 35 receptors for the purposes of viral immune evasion, propagation 
and cell-to-cell signaling (41). Thus, the endomembrane system while fundamental in 
nature is a central component that is often deregulated during diseased states.   
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1.4 Trafficking motifs and proteins 
1.4.1 Sorting motifs 
The movement of proteins within the cell is not a random process. For example, proteins 
that contain transmembrane domains are properly routed to the cell surface where they 
fulfill critical cellular functions dependent on their differential abilities to bind or 
transport ligands, thereby serving as functional receptors (43, 44). The trafficking of 
receptors is dependent on sorting motifs within their cytoplasmic domains. These motifs 
enable key interactions with cytosolic trafficking molecules (45). Sorting motifs were 
initially proposed by the Nobel Prize laureate Gunter Bobel (46, 47). They are amino acid 
sequences that direct proteins to a precise subcellular locale. Several motifs have been 
described in eukaryotes that traffic proteins containing transmembrane domains to and 
from the cell surface, between endosomes, the endoplasmic reticulum, and the Golgi 
apparatus (See Table 1) (45). Interestingly, these sorting motifs have evolved to be 
specific as different sorting motifs can recruit various trafficking proteins, termed adaptor 
proteins (APs)(48). In general, adaptor proteins interact with cytoplasmic tails of cellular 
receptors and allow the recruitment of additional structural and movement proteins 
required for vesicular trafficking (48, 49). 
One of the most well studied set of adaptor proteins are the heterotetrameric clathrin 
adaptor proteins (APs) (49). Most notably, these proteins directly interact with sorting 
motifs and permit the formation of vesicles by recruiting the structural coat protein 
clathrin. Two well described sorting motifs characteristic of this family are the tyrosine, 
and dileucine sorting motifs (48, 50). An additional mode of controlling vesicular 
trafficking is through post-transcriptional modifications, which can also serve as sorting 
signals. For example, the phosphorylation of two serine residues within the furin’s 
endopeptidase’s acidic cluster (S773DS775EEDE) directs furin’s recycling between the 
TGN and endosomes (51, 52). Furthermore, newly synthesized transmembrane proteins 
requiring exit from the ER possess ER exit signals (di-acidic motifs)(53). In contrast, ER 
resident receptors contain di-basic motifs (KKxx/ KxKxx)(54). Importantly, these motifs 
allow the recruitment of various connector, adaptor and structural proteins to facilitate 
vesicle biogenesis, movement and docking which will be discussed below.  
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Table 1: Sorting motifs within the endomembrane system.  










Tyrosine motif (Yxxθ) Furin, CI-MPR AP-1/2/3/4/5 Endosome - TGN 






KDEL-receptor COP-I Cis-Golgi to ER 
Di-Acidic Motif 
(D/E)xx(D/E),  
ERGIC-53 COP-II ER exit signal 
Acidic Cluster Motif 
(E/D)4 
Furin, VAMP4 PACS-1 Endosomes – 
TGN 
 
1.4.2  Adaptor protein complexes 
One of the most well studied family of trafficking molecules that bind and recognize 
sorting motifs to traffic receptors within cells is the heterotetrameric adaptor proteins 
(APs) complex family. Currently, five AP complex types (AP-1 through 5) have been 
described to mediate trafficking to diverse locations within the cell (49, 55). Each AP 
complex contains four subunits; two large subunits (either an α, γ, δ, ε or ζ plus a β1-β5 
subunit), one medium (μ1-μ5), and one small subunit (σ1-σ5) (55). Each subunit, of the 
heterotetramer has a specific function. The α, γ, δ and ε large subunits associate with 
specific lipids on membranes (56, 57), and the β subunits recruit the coat protein clathrin 
through the LθxθD/E amino acid motif, where θ represents a bulky hydrophobic residue. 
The medium subunit primarily recognizes tyrosine (Υxxθ) and dileucine sorting (LL) 
motifs, and is also able to interact with lipids located in membranes. The small σ subunits 
(σ1-5) do not have a defined role in receptor or lipid binding, and instead provide 
stability to the AP complex (58).  
Each AP controls distinct trafficking steps within cells. AP-1 is primarily found within 
endosomes and the Golgi apparatus (59). Its principal function is to traffic receptors to 
and from the Golgi apparatus and endosomes (59). Alternatively, AP-2 is localized to the 
plasma membrane and recycling endosomes, where it controls clathrin-mediated 
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endocytosis of cargo and recycling (60). Like AP-1, AP-3 is also localized to the Golgi 
and endosomes, but primarily regulates cargo destined for lysosomal organelles and 
synaptic vesicles (33, 61). Unlike the other APs, both AP-4 and AP-5 are much less 
studied and mediate cargo movement from the Golgi to the plasma membrane (62, 63).  
During membrane trafficking, APs can directly interact with cytoplasmic domains of 
trans-membrane receptors (64). A sample of these interactions have been described 
(Table 1). In addition, APs themselves interact with other trafficking molecules to form 
trafficking complexes. Indeed, AP-1 and AP-3 are in complex with the phosphofurin 
acidic cluster sorting proteins (PACS) membrane trafficking molecules (65). These AP-
PACS interactions occur independently of their canonical sorting motifs and are believed 
to assist in the recruitment of various coat proteins which are essential components of the 
membrane trafficking machinery (66, 67). Indeed, clathrin is believed to coat vesicles 
that mediate PACS-1/AP-1-dependent trafficking whereas COP-I coats vesicles are 
mediated by PACS-2-dependent trafficking (68). These trafficking paradigms will serve 
as a model for the remainder of this dissertation.  
1.4.3  Membrane coat proteins  
Clathrin 
Vesicles require a structural component to induce the mechanical forces implicated in the 
bending and curvature processes which ensure movement during membrane trafficking 
events. Membrane morphology is critical for the binding of several different effector 
molecules which sense membrane curvature (69). This is often ensured by membrane 
coat proteins. The clathrin coat protein, initially described by Roth and Porter in 1964, 
represents this class of protein (70). These scientists used electron microscopy to identify 
an electron dense lattice formed on invaginated membranes in mosquito oocytes (70). 
Further biochemical characterization later identified clathrin as a hexamer composed of 3 
heavy subunit and 3 light subunit domains, that self-assemble along membranes to form 
an ordered lattice (71). This structure can ultimately shape and form vesicles. These sites 
of clathrin assembly often include AP-1, AP-2, AP-3 or AP-4 proteins, which potently 
recruit clathrin to the cytoplasmic tails of cargo containing tyrosine and dileucine sorting 
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motifs (72) (Table 1). Trafficking of the cellular endopeptidase furin, requires the 
interactions with both AP-2 and AP-1 via furin’s dileucine/isoleucine motif (LI756) and 
tyrosine motif (Y759KGL) to facilitate clathrin-dependent endocytosis and subsequent 
intracellular sorting (51, 73).  Clathrin can recruit additional proteins that also serve as 
effector molecules, such as dynamin (74), a protein which polymerizes along the neck of 
the newly budding vesicle. Indeed, dynamin is required to pinch off newly formed 
vesicles via the constriction of the dynamin ring catalyzed by its GTPase activity (74, 
75). Importantly, the membrane trafficking regulator protein PACS-1 is central to AP-1-
dependent trafficking events which in turn can also be clathrin-dependent.  
Coatomer proteins 
In addition to clathrin, another family of coat proteins are also implicated in the 
formation of trafficking vesicles within the secretory network. This family represent an 
additional class of eukaryotic coat proteins and consists of coatomer protein – I (COPI) 
and coatomer protein II (COPII)(76). In contrast to clathrin, COP-I and COP-II 
complexes primarily function during trafficking events that occur between the ER and the 
cis-Golgi compartments (76).  
COP-II 
The minimal COP-II complex contains the small GTPase Sar1p, and the translocation 
secretory machinery proteins Sec23/24p and Sec13/31p (75). Sarlp regulates recruitment 
of the COP-II complex by acting as GTP-regulated on/off switch (77, 78). In its GDP-
bound state, it is primarily cytosolic, and cannot recruit the COP-II coat. Recruitment to 
ER-membranes is controlled by the guanine exchange factor Sec13, which exchanges 
GDP for GTP, thereby turning the COP-II complex “on”(79, 80). Once recruited, both 
Sec23/24p and Sec13/31p heterodimers can assemble to promote membrane curvature. It 
is unclear whether transmembrane proteins destined for ER exit are targeted prior to 
Sec23/24p and Sec13/31p recruitment (81). Two sorting motifs have been identified for 
COP-II trafficking; the di-acidic motif and a modified tyrosine motif (Table 1). It is these 
cytoplasmic sequences which directly interact with Sec23/24p at sites of membrane 




The COP-I complex functions similarly to COP-II, but regulates the retrograde transport 
of receptors from the cis-Golgi to the ER. The basic components of the of COP-I 
complex includes the GTPase Arf1 (82), and seven coatomer proteins α-, β-, β’-, γ-, δ-, ε- 
and  ζ-COP(83). Similar to Sar1p of the COP-II initiation complex, vesicle formation 
from the cis-Golgi membrane is initiated when GTP-bound Arf1 embeds into the lipid 
bilayer (82). The coatomer can then self-assemble, resulting in the recruitment of proteins 
which provide the structural basis for membrane curvature. In vitro studies have provided 
evidence supporting the role of α-COP, β-COP, and δ-COP in the direct recognition and 
binding of dibasic motif (KKXX)-containing receptors, allowing for the concentration of 
multiple COP-I-specific proteins to a single vesicle (84, 85).  
The second member of the PACS family of membrane trafficking proteins, PACS-2, has 
been implicated in a functional interaction that implicates a COP family protein. Simmen 
et al. demonstrated that PACS-2 regulates ER-mitochondrial communication in a manner 
dependent on an interaction between PACS-2 and COP-I (86). Indeed, disruption of this 
interaction resulted in the induction of the intrinsic apoptotic pathway, marked by the 
translocation of the pro-apoptotic receptor Bid to the mitochondrial membrane (86). 
PACS-2 involvement in COP-I trafficking is not limited to ER-mitochondrial 
communication, but also in the relocalization of the non-selective cation channel 
polycystin-2 from the plasma membrane to the ER (87).  
Overall, the roles of PACS-1 and PACS-2 in pathways implicating clathrin and COP-I, 
respectively, highlight the essential role of this family of proteins in the regulation of 
membrane trafficking. 
1.5 The Phosphofurin Acidic Cluster Sorting proteins: 
multifaceted membrane trafficking regulators 
The increased complexity of the tree of life required a corresponding increase in the 
complexity of the endomembrane system. This complexity requires specific membrane 
trafficking regulators, such as the PACS proteins, to shuttle diverse cargo in an 
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increasingly sophisticated manner throughout the cell (88, 89). A single PACS protein 
made its first appearance in lower metazoans, such as arthropods and nematodes, and was 
almost exclusively mediating membrane trafficking events (90). It was not until the 
evolution of vertebrates, that the PACS gene duplicated, giving rise to PACS-1 and 
PACS-2 (88). The duplicated PACS proteins were expressed in order to accommodate the 
many client cargo proteins and act in concert with the greater quantities of multiple APs 
and coat proteins found in higher order metazoans (2). PACS-1 was originally discovered 
in 1998 by Gary Thomas and colleagues (66). The group performed a yeast-two hybrid 
screen to identify protein binding partners of the endopeptidase furin, a key molecule 
implicated in regulated secretion (66). These seminal studies demonstrated that PACS-1 
acts as a cytosolic molecular trafficking regulator that targets furin to the TGN (66). 
PACS-2 was subsequently discovered in 2005, as a membrane trafficking regulator 
protein that mediates cell death pathways (86). Together, these proteins have been studied 
for the last two decades and have been ascribed multiple roles in cellular homeostasis 
(88, 89). Unsurprisingly, the degree of homology between the two proteins is quite high 
(54%). The most significant of these homologies lies within the Furin Binding Region 
(FBR; 75% homology) of both PACS-1 and PACS-2, as this region has been repeatedly 
demonstrated to interact with client cargo molecules (91). Indeed, as the name suggests, it 
is the FBR region of PACS-1 that mediates the interaction with furin. 
Functionally, the PACS proteins serve as connector molecules between the coat proteins 
clathrin or COP-I, and the specific cargo proteins that are being transported within the 
cell. Interestingly, the PACS proteins have also evolved a degree of specificity in their 
interactions with cargo molecules. PACS-1 and PACS-2 both predominantly recognize 
cargo molecules that contain stretches of acidic amino acids, often referred to as “acidic 
clusters” (87, 92-95). The original acidic cluster binding motif was defined in the 
cytoplasmic tail of furin which is phosphorylated by Casein Kinase 2 (CK2) in order to 
bind PACS-1 (66). It is the latter mechanism which gave rise to the PACS name.  
In certain instances, the trafficking of cargo molecules is governed by both PACS-1 and 
PACS-2. For example, trafficking of the cation-independent mannose-6-phosphate 
receptor (CI-MPR) requires PACS-1 to mediate its shuttling from the cell surface in 
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addition to requiring PACS-2 to sort CI-MPR to additional endosomal locations (95). CI-
MPR trafficking demonstrates the potential interplay between PACS-1 and PACS-2 
needed to traffic certain cargo (96). Despite this interplay, my thesis will primarily focus 
on specific PACS-1-dependent trafficking steps.  
1.5.1 Regulation of PACS-1 sorting 
PACS-1 is a central membrane trafficking regulator protein that mediates the trafficking 
of multiple different proteins. A sampling of these receptors include: furin (66), CI-MPR 
(95), vesicular membrane associated protein-4 (VAMP4)(94), and the pro-hormone 
convertase 6B (97). The primary role of PACS-1 is to link acidic cluster containing cargo 
to a clathrin adaptor protein and induce their transport from an endosomal compartment 
to the TGN (Fig. 2.1A)(66). However, not all PACS-1-dependent trafficking is clathrin-
dependent. PACS-1 also utilizes the ADP ribosylation factor family of GTP binding 
protein 6 (ARF6), a protein which localizes to the plasma membrane, alters membrane 
lipid composition, and induces actin remodeling (98, 99). For example, the HIV-1 viral 
protein Nef commandeers both Arf6 and PACS-1 to induce the endocytosis of the MHC-I 
receptor from the surface of infected cells. 
During transcription PACS-1 is differentially spliced into two isoforms, a 104 KDa 
protein termed PACS-1a and a 97 KDa protein termed PACS-1b (100). The entire 
scientific literature on PACS-1 has been described using the 104 KDa isoform, PACS-1a, 
which is ubiquitously expressed and will be referred to as PACS-1 in this thesis for 
simplicity. PACS-1 possesses four domains (Figure 1.2B); the atrophin-1 related region 
(ARR), the furin binding region (FBR), the middle region (MR), and the C-terminal 
region (CTR)(65, 66). The roles of these domains have been described to varying 
degrees.  Both the FBR and MR have designated roles in receptor trafficking by directly 
binding client proteins. These domains also mediate the phosphorylation-dependent auto-
regulation of PACS-1 (101). In addition, the MR domain contains a predicted poly-basic 
nuclear localization signal (NLS), however, whether this latter domain functions as a true 
NLS remains to be seen (88). As studies of both the ARR and CTR are limited, these 
domains currently have unknown functions (88).  
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In vitro and cell-based assays have demonstrated that the FBR contains motifs that 
directly link it to the adaptor coat proteins. Specifically, PACS-1 ETELQLTF175 is 
required for binding to AP-1 and AP-3 (65, 66). Furthermore, the PACS-1 MR region 
contains an auto-regulatory region, which mediates PACS-1’s ability to bind cargo. 
Obtaining additional details on PACS-1 regulation and on the role of the various PACS-1 
domains have been partially hampered by the intrinsically disordered nature of PACS-1. 
Indeed, over half of PACS-1 is predicted to lack tertiary structure (Figure 1-2C). Despite 
this, details on the regulation of PACS-1 via phosphorylation emerged in the early 2000s.  
1.5.2 Receptor trafficking by PACS-1 
The initial description of PACS-1 regulation was described in relation to the 
phosphorylation of PACS-1 S278 located in the MR region. This phosphorylation is 
achieved by CK2, a ubiquitous serine/threonine kinase (102). In its dephosphorylated 
form, the PACS-1 MR adopts a conformation which blocks receptor binding due to the 
folding of the MR domain onto the FBR (95). However, CK2 phosphorylation at PACS-1 
S278 enables receptor binding (67, 94, 95). This process is inhibited by PACS-1 S278 
dephosphorylation by the protein phosphatase 2A (PP2A)(96). These elegant regulatory 
steps controlling PACS-1, were highlighted during studies of CI-MPR trafficking. CI-
MPR is a receptor that acts a chaperone protein that interacts with lysosomal hydrolases 
and cathepsins, to permit their trafficking to a pre-lysosomal compartment (103, 104). 
The retrieval of CI-MPR back to the Golgi is necessary to ensure the receptor is not 
degraded within the lysosome (95). This represents a model in which cells can maximize 
their energy by not degrading cellular proteins which can be used again. Additional 
studies are needed to fully grasp the extent of PACS-1 in preventing lysosomal 
degradation of receptors, and whether additional receptors follow the same pathway.  
The best-documented PACS-1 cargo is the cellular endopeptidase furin (105). Furin 
cleaves and activates multiple proteins to ensure they are in an active state. Furin 
substrates are numbered in the thousands and are implicated in diverse roles such as 
embryogenesis and bone development (106). These activities occur within the secretory 
pathway which ensures protein localization to the cell surface and/or extracellular protein 
secretion. Within the endomembrane system, furin localization is tightly regulated by 
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PACS-1 to ensure furin substrates are cleaved and activated (73, 107). This sorting 
activity is dependent on the phosphorylation by CK2 of both serines within the furin 
acidic cluster motif S773DS775EEDE (51), and the S278 within the PACS-1 autoregulatory 
region. The phosphorylation of furin promotes its recycling back to the plasma 
membrane, whereas, dephosphorylation by PP2A favors its progression to the late 
endosome (51).  Within the late endosomal compartment, PACS-1 can then interact with 
furin to facilitate its retrograde transport to the Golgi (51, 107).  Both recycling back to 
the plasma membrane, and transport to the TGN require the interaction of PACS-1 with 
the phosphorylated tail of furin (51, 73). However, it remains unclear how PACS-1 
distinguishes between furin returning back to the cell surface and furin transiting to the 
TGN. Ultimately, this elegant regulation of furin trafficking by PACS-1 highlights the 






Figure 1.2: PACS-1 structure and function 
(A) Within the cell, PACS-1 acts a connector which interacts with the acidic clusters 
(green) adjacent to phosphorylated serine/threonine residues (red), to recruit the clathrin 
adaptor proteins (purple), and subsequently clathrin (black) to induce vesicle formation, 
and retrograde transport to the TGN. (B) Shown is a diagram depicting the 4 domains of 
PACS-1: Atrophin related region (ARR), furin binding region (FBR), middle region 
(MR), and the C-terminal region (CTR). Indicated above are the various motifs which 
engage in specific interactions with the indicated proteins. (C) A graphical depiction of 
the PACS-1 disordered regions as determined by PSIPRED secondary structure predictor 
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1.6 The secretory pathway 
As was briefly introduced in Section 1.1, proteins that localize to the plasma membrane 
or that will be secreted, traffic within the secretory pathway and in particular via the 
constitutive secretion pathway. These events are due to the presence of signal peptides 
that are expressed at the amino terminus of proteins and are subsequently recognized by 
the ER secretory complex; Sec61 translocon, which marks the gateway to the secretory 
pathway (109, 110). This intralumenal trafficking pathway transports proteins through the 
various compartments of the ER and Golgi. Specifically, coat proteins such as COP-II 
will mediate the trafficking of vesicles within the Golgi complex where secretory 
pathway proteins can be subjected to post-translational modifications such as 
glycosylation (81). A critical sorting station within the secretory pathway is the TGN, 
which is also the ultimate trafficking locale within the Golgi apparatus (7). As noted 
earlier, secretory pathway cargo proteins such as the PACS-1-trafficked furin are shuttled 
to and from the TGN (65, 66). Further trafficking of proteins within the secretory 
pathway occurs upon the recognition of sorting motifs within these proteins by connector 
and adaptor proteins which include AP-1 and clathrin (49). As these two proteins are 
often found in the same location as PACS-1, it is not surprising that PACS-1 itself plays 
distinct roles in secretory pathway trafficking that have yet to be fully explored in this 
thesis. To fully appreciate these events, a specialized organelle, the dense core secretory 
granule (DCSG) will be introduced as it is a vesicle that buds from the TGN and is 
exclusively present within endocrine and neuroendocrine cells (111). Taken together, the 
TGN and DCSG trafficking events that involve PACS-1 comprise key elements of the 
regulated secretory pathway.  
1.6.1  Regulated secretory pathway 
Whereas most eukaryotic cell types contain a constitutive secretory pathway which 
traffics proteins to the cell surface, endocrine and neuroendocrine cells contain a 
regulated secretory pathway. This specialized form of secretion is characterized by the 
presence of a unique organelle termed the DCSG (112). DCSGs are dense vesicles that 
concentrate their contents, typically peptide hormones, and only release their contents 
upon receiving a physiological stimulus (113, 114). Thus, the specific cargo that are 
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trafficked from the TGN to the DCSGs are often peptide hormones that are released via 
exocytosis in a regulated fashion in order to avoid excessive secretion (114).  
An example of a cargo molecule that traffics through the regulated secretory pathway and 
that will be further explored in Chapter 4 is the pro-opiomelanocortin hormone (POMC) 
(115). Primarily synthesized in the anterior pituitary gland, POMC is the precursor 
peptide to multiple biologically active peptide hormones (116, 117). Specifically, POMC 
is processed into these active peptide hormones within DCSGs and the latter active 
hormones are only released upon the appropriate stimulus. Examples of the diverse 
hormones that are generated from POMC within DCSGs include α-melanin stimulating 
hormone (MSH), which controls critical functions such as sex behavior, appetite, and 
melanin production(118). Furthermore, the adrenocorticotropic hormone (ACTH) is also 
produced from POMC and controls the hypothalamic-pituitary-adrenal signaling 
axis(119). ACTH is also a potent stimulator of cortisol from the adrenal gland (119).  
Multiple proposed models exist to distinguish the trafficking of cargo between the 
regulated and constitutive pathways. Two models however, predominate; the “sorting by 
entry model” (120), and the “sorting by retention model” (120, 121). Both models imply 
that cargo traversing the secretory pathway will transit from the ER, through the Golgi 
apparatus and subsequently make a fate decision between the constitutive and regulated 
sorting pathways (120). In the sorting by entry model, cargo destined for DCSGs would 
contain appropriate sorting signals and be targeted to DCSGs (122). Examples of these 
sorting signals include recognition of receptor sequences, secondary structural elements 
and cleavage sites that serve as the very bait that cleaves precursor molecules into smaller 
molecules within DCSGs (123, 124). Conversely, in the “sorting by retention model”, all 
cargo, irrespective of whether they reside or not in DCSGs, will enter the regulated 
secretory pathway. Subsequent to this initial sorting event, cargo that is not a resident 
DCSGs protein will be removed or extruded from these vesicles and diverted to the 
constitutive secretory pathway (125). The remaining cargo located within DCSGs will 
thus have been sorted “by retention” to DCSGs and consequentially to the regulated 
secretory pathway. While both models are not mutually exclusive, PACS-1 has been 
defined as a key component of the sort by retention pathway.PACS-1 is capable of 
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removing the SNARE protein VAMP4 from the regulated secretory pathway and traffic it 
to the TGN (94). This PACS-1 dependent retrieval of VAMP4 from the regulated 
secretory pathway is dependent on VAMP4’s interaction with AP-1, PACS-1, and is 
regulated by the phosphorylation of S30 within the VAMP4 cytoplasmic tail 
(E27DDSDEEED) by CK2 (94). PACS-1- and AP-1 also mediate the retrieval of both 
furin and CI-MPR from the regulated secretory pathway (95).  
As highlighted in the previous sections, PACS-1 is a critical trafficking regulator that 
enables the trafficking of multiple cargo protein to various subcellular locales. It is thus 
unsurprising to discover that pathogens have subverted this protein to ensure their 
specific components are targeted to the correct subcellular locale often at the expense of 
deleterious effects on the host. The function of PACS-1 is subverted by viruses such as 
the human cytomegalovirus (hCMV) and HIV-1 (126, 127). The following sections will 
highlight this subversion of PACS-1 by viruses by emphasizing the example of the HIV-1 
Nef protein (92, 93, 126, 128). 
1.7 Introduction to viruses 
When compared to the human genome, viruses have on average a 100-1000 fold decrease 
in their genome’s coding capacity (129). This limited coding capacity results in a 
perceived deficiency in the diversity of viral proteins that would be required for the virus 
to complete its replication cycle. To overcome this, viral proteins seek and subsequently 
interact with host proteins located within the very cells they infect. The resulting viral-
host protein-protein interactions represent key events that the virus uses to complete its 
replication cycle often by fending off the host immune response. Indeed, viruses 
modulate the host cell to evade immune surveillance. Consequently, viruses encode 
proteins aimed at modulating the host cell trafficking machinery thereby evading the 
immune response and consequentially optimizing viral replication (130). An example 
where key viral-host protein interactions mediate the immune response include the 
modulation of the presence of host receptors on the cell surface (130-135). This virus-
dependent receptor modulation can occur due to multiple trafficking mechanisms such as 
preventing receptors from exiting the ER, blocking receptor transport through the Golgi 
apparatus or their sequestration within cellular compartments due to endocytosis or 
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degradation (93, 136-139). Specifically, controlling the ability of infected cells to traffic 
the MHC-I receptor to the cell surface where it would normally present viral antigens to 
cytotoxic T cells represents a mechanism by which viral proteins interact with host 
proteins to ensure viral persistence (140-145).  
1.8 Strategies for viral immune evasion: The MHC-I 
receptor 
The type I major histocompatibility complex (MHC-I) receptor is encoded by the human 
leukocyte antigen (HLA) allele and represents a primary antiviral signaling molecule that 
is ultimately trafficked to the cell surface of all nucleated cells (29, 146). The HLA locus 
is highly polymorphic and gives rise to thousands of unique HLA alleles (147, 148). The 
diversity of peptides loaded within the MHC-I cleft is determined by the variable α1 and 
α2 domains of the trans-membrane spanning alpha chain (Fig. 1.3) (149). Classically, the 
peptide-binding cleft can accommodate peptides ranging from 8-10 amino acids in 
length, which are anchored between tyrosine resides on the α1 or α2 domains (150). 
There are three classical MHC-I types termed HLA-A, HLA-B, and HLA-C, and four 
non-classical types termed HLA-E, HLA-F, HLA-G and HLA-H (151). HLA-A and 
HLA-B are primarily loaded with endogenous or exogenous antigens and interact directly 
with the CD8+ T cells via their T cell receptor (TCR) which recognizes presented 
antigens on MHC-I. The latter interaction has been termed the immunological synapse 
(151, 152).  
Within the immunological synapse, additional proteins also play important physiological 
roles (Fig. 1.3). CD3 is in complex with the TCR, and upon receptor binding, can engage 
in a phosphorylation dependent interaction with the Zeta-chain associated protein kinase 
70 kinase (ZAP-70), resulting in cellular activation (153). CD8 acts as a co-receptor for 
the TCR, and is specific for the binding of MHC-I (154). Upon receptor engagement with 
MHC-I, CD8 initiates downstream signaling cascades for activation involving the Src-
Family kinase (SFK) Lck (155). The presence of additional co-stimulatory molecules 
such as CD28 ensures the immune response occurs only when required (156). CD28 
interacts with CD80/86 on the antigen-presenting cell to promote downstream activation 
of the SFK, Lck, similar to CD8 (156). Ultimately, the plethora of interactions within the 
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immunological synapse trigger cytoskeleton remodeling, and activation of genes and 
kinases required for cytolysis of the infected cell (156-158). Coincidentally, viruses have 
targeted many steps along the viral antigen processing and presentation of MHC-I (135, 
136, 142).  
 
Figure 1.3: Interactions at the immunological synapse. 
Infected cells display viral peptides (red) within the α1 and α2 cleft of MHC-I heavy 
chain. Engagement of MHC-I by the TCR and CD8 mark the initiation of the 
immunological synapse. Key interactions between the co-stimulatory receptor CD86 and 
CD80 ensure that immune responses are appropriately directed at the infected cell. The 
numerous contact points between the infected cell and cytotoxic T cell initiate a signaling 

















kinases ZAP70 and Lck. (MHC-I: type 1 major histocompatibility complex 1, B2M; 
Beta-2-microglobulin, TCR; T cell receptor, ZAP70; zeta-chain associated protein kinase 




1.8.1 Targeting MHC-I peptide loading and trafficking 
First, viruses can mediate the localization of MHC-I on the cell surface by interfering 
with viral peptide loading at the ER. Targeting the early stages of MHC-I peptide 
loading, represents a mechanism that interferes with viral antigen presentation. Multiple 
viruses have evolved mechanisms to target this stage of peptide loading (Fig. 1.4). Herpes 
simplex virus (HSV) encodes the viral protein ICP47 which targets early peptide loading 
to the transporter associated with antigen presentation (TAP) (159, 160). Specifically, 
ICP47 binds TAP directly preventing peptide translocation (160). The human 
cytomegalovirus US6 protein can also prevent peptide loading by preventing TAP ATP 
hydrolysis (161). Normally, TAP ensures the proper loading of peptides into the MHC-I 
alpha cleft, and the proper addition of β2-microglobulin to the MHC-I complex in an 
ATP-dependent manner (162). Similarly, the US3 protein from hCMV binds to the TAP 
complex and interferes with peptide loading (139, 163). Targeting TAP is not only 
limited to the Herpesvirus family. Other diverse viruses also target this assembly 
complex. The cowpox virus protein CPXV012 prevents ATP binding to the TAP 
complex, (164) whereas the adenovirus E3-19K protein competes for TAP binding, and 
prevents MHC-I recruitment and subsequent peptide loading. Adenovirus E3-19K can 
also directly bind MHC-I to prevent peptide loading (145, 165, 166).  
Once MHC-I complexes have been successfully loaded in the ER, they transit through the 
Golgi apparatus, where post-translational modifications such as glycosylation occur (Fig. 
1.4) (167, 168).The MHC-I ER-to-Golgi transit step represents an attractive viral protein 
target. One such viral mechanism is dictated by the endoplasmic reticulum associated 
degradation pathway (ERAD) (169, 170). Under physiological conditions, the ERAD 
pathway degrades MHC-I heavy chains lacking associated β2-microglobulin, or 
improperly folded proteins (170, 171). Normally, only a small fraction of MHC-I 
undergoes ERAD (172). However, specific viral proteins can induce ERAD targeting of 
functional MHC-I as the receptor exits the ER. Viral proteins such as hCMV US2 and 
US11 translocate MHC-I into the cytosol for ERAD proteasomal degradation (173, 174). 
Specific mechanisms that mediate these translocation events are not yet fully understood, 
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but are believed to involve the recruitment of the dissociation complex Sec61b and 
ubiquitination of the cytoplasmic tail of MHC-I to facilitate its premature ER exit (173).  
Additional viral mechanisms that occur outside of the ER also prevent MHC-I Golgi 
trafficking. For example, poxviruses usurp the retrograde transport machinery between 
the Golgi and ER. To accomplish this, the poxvirus protein CPXV203 hijacks the COP-I 
ER retention pathway to induce the retrograde transport of MHC-I from the cis-Golgi 
back to the ER by binding to the MHC-I cytoplasmic tail (175).  
Other viruses have evolved alternative mechanisms that target cell surface MHC-I. 
Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins redirect MHC-I to the 
endolysosomal pathway for degradation within lysosomes (Fig. 1.4) (136, 137). This 
activity is ensured by the homology between both K3 and K5 and the host ubiquitin 
ligase machinery (137). The latter host machinery can post-translationally add ubiquitin 
to cellular proteins to ensure their degradation (176). In the context of K3 and K5, 
ubiquitination of MHC-I leads to the recruitment of the tumor susceptibility gene 101 
(TSG101), which targets MHC-I to lysosomal compartments of the endolysosomal 
network (177). 
The HIV-1 Nef protein also modulates cell surface MHC-I levels. Much like K3 and K5, 
Nef primarily targets cell surface MHC-I for rapid endocytosis (Fig. 1.4) (178). In the 
next section, I will review the ability of the HIV-1 Nef protein to modulate the cell 
surface levels of MHC-I. This activity is also dependent on key viral host interactions 
that subvert the membrane trafficking machinery including a critical interaction with 





(1) MHC-I heavy chain associates with the tapasin peptide loading complex to allow 
processed viral antigens to fill the alpha cleft, a process inhibited by Adenovirus E3-19K 
protein. Additionally, hCMV US2 and US11 can translocate the MHC-I heavy chain into 
the cytosol for proteasomal degradation.  Once MHC-I is fully associated with the 
peptide loading complex, peptides are translocated into the ER lumen through the ATP-
dependent transporter associated with antigen presentation (TAP1/2); Herpes simplex 
virus proteins ICP47, human cytomegalovirus US3 and U6, and cowpox virus protein 
CPX012 all inhibit efficient peptide translocation. (2) Once loaded, MHC-I transits 











































Figure 1.4: Viral targeting of MHC-I antigen presentation 
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linked glycosylation, which can be inhibited by the Cowpox virus CPXV203 protein. (3) 
MHC-I can either transit to the cell surface directly from the Golgi, or through an 
intermediate recycling endosome. (4) Cell surface MHC-I levels are maintained though a 
homeostatic recycling loop; a process which can be hijacked by the HIV-1 Nef protein. 
(5) Improperly loaded MHC-I is directed for lysosomal degradation, a process similar to 

















1.9 The human immunodeficiency virus (HIV-1) 
Human immunodeficiency virus type 1 (HIV-1) is a member of the Retroviridae family 
that belongs to the lentivirus subfamily (182). Retroviruses are characterized by their 
ability to reverse transcribe a positive sense strand of RNA into DNA due to the presence 
of the viral RNA-dependent DNA polymerase, also known as reverse transcriptase(182). 
In the early 1980’s, otherwise healthy individuals became susceptible to opportunistic 
infections. This condition was subsequently termed Acquired Immunodeficiency 
Syndrome (183, 184). Shortly there after, the causative agent was determined to be HIV-
1 (183, 184). Ever since that initial recognition, HIV-1 has become one of the most 
destructive infectious diseases in modern times, infecting over 76 million people, and, so 
far, claiming the lives of over half of these infected individuals (185). Currently, infected 
patients who can access treatment can benefit from anti-retroviral therapy which 
effectively controls viral replication and prolongs a patient’s lifespan when compared to 
untreated patients (186-188). Despite this, there are currently nearly 2 million new 
infections per year globally (185, 189). With no prophylactic vaccine available, 
understanding the HIV-1 lifecycle to generate new, more effective anti-retrovirals is a top 
priority. Therefore, determining the mechanisms and cellular factors governing viral 
persistence within the cell is of critical importance. 
1.10 A key pathogenic mediator of HIV-1 disease: Nef 
A mechanism that HIV-1 uses to thwart the immune system is its ability to hijack 
membrane trafficking pathways for the purposes of viral immune evasion. One such 
pathway is the retrograde transport of MHC-I from the cell surface to an intracellular 
location (141, 142, 144, 145, 175, 177). Whereas MHC-I down-regulation by DNA 
viruses often requires multiple proteins, HIV can use a single protein, Nef, to facilitate 
this form of immune evasion (143, 190). More recently, MHC-I downregulation during 
HIV-1 infection has expanded to include the viral protein Vpu (191). Both, Nef and Vpu 
alter host membrane trafficking and signaling pathways to disrupt immune cell signaling. 
Moreover, their importance to viral pathogenesis has been well documented (192, 193). 
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The importance of Nef during HIV-1 pathogenesis has been demonstrated in both 
patients and in animal models (194-198). Nef has been described as critical for HIV-1 
pathogenesis and disease progression to AIDS (199-201). Indeed, individuals infected 
with an HIV-1 deleted for the nef gene displayed a delayed progression to AIDS (202). 
Moreover, a transgenic Nef mouse model was previously developed to highlight the 
importance of Nef in disease progression. In these studies pioneered by Paul Jolicoeur, 
1998, Nef was expressed under the control of the CD4 promoter, thereby allowing all 
CD4-positive cells within a transgenic mouse line to express the Nef protein (196). 
Transgenic mice expressing Nef exhibited a rapid CD4 T cell decline, significant weight 
loss, and overall a phenotype that resembled AIDS when compared to their littermates 
that did not express Nef (196, 197). Overall, this animal model highlighted the 
pathogenic nature of Nef protein even in the absence of any viral replication. Importantly, 
the importance of Nef could also be recapitulated in a simian model of disease during 
infection by simian immunodeficiency virus (SIV)(194, 195, 203). These studies 
illustrated not only that Nef was important for pathogenesis, but also that SIV harboring a 
mutated Nef sequence could revert back to its wildtype sequence, ultimately resulting the 
infected macaque to develop simian AIDS (194).  
Nef is a 27-34 kDa protein which is myristoylated at its amino terminus. This co-
translational modification is key as it enables Nef to associate with membranes, thereby 
permitting the protein to traffic to various membrane subcellular locations (204). Nef has 
no known enzymatic functions, and therefore must interact with numerous host cell 
proteins to benefit viral persistence (205). These viral-host protein interactions result in 
Nef mediating pathways implicated in programmed cell death, T-cell activation, B-cell 
immunoglobulin class switching, and the down-regulation of many host cell receptors 
(206-211). 
Perhaps the most profound consequence of Nef expression in cells during infection is its 
ability to modify the cellular localization of over 35 different host receptors. Most 
notably, cell surface receptor CD4 (212), MHC-I (213), and more recently, host 
restriction factor serine incorporator 5 (SERINC5) (214, 215), have been extensively 
studied. The down regulation of CD4 from the cell surface prevents HIV-1 superinfection 
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(216) and decreases antibody-dependent cellular cytotoxicity (ADCC)(217, 218). To 
achieve this, Nef interacts with the cytoplasmic tail of CD4 to recruit AP-2 via the Nef 
LL64-65 motif (209, 212, 219). Nef and CD4 subsequently traffic to the acidified 
lysosomal compartment for degradation, further requiring the interaction of Nef (DE178-
179) with the vacuolar ATPase (vATPase), which aids in lysosomal acidification (220). 
The apparent downregulation of CD4 allows the HIV-1 envelope glycoprotein gp120 to 
be present on the cell surface in a closed confirmation. Adopting this confirmation 
prevents high affinity antibody binding and associated effector cell recruitment (218).  
Recently however, these and other Nef functions were reevaluated in the context of a 
newly discovered cellular restriction factor that restricts HIV infectivity. As such, 
SERINC5 was identified as a potent inhibitor of viral particle infectivity (214, 215).  
However, once again, HIV-1 has developed a mechanism to negate SERINC5 effects by 
downregulating this receptor from the cell surface and thereby inhibiting the 
incorporation of this restriction factor in newly formed virions (215, 221). Trafficking of 
SERINC5 away from the budding virion seems to follow a similar trafficking pathway to 
CD4 downregulation by Nef (222). To this end, SERINC5 downregulation is dependent 
on the Nef dileucine motif (LL164-165)(222). Microscopy studies have examined the 
interaction between Nef and SERINC5, and identified that it accumulates within a late 
endosome or lysosome(222). Importantly, knockdown of AP-2 partially restored the 
restrictive abilities of SERINC5 in the presence of Nef, further highlighting similarities 
between CD4 and SERINC5 downregulation (223).   
In contrast to the downregulation of CD4 and SERINC5, the Nef-dependent 
downregulation of MHC-I follows a distinct pathway, requiring a different set of viral-
host interactions. Two primary models exist to explain how Nef down-regulates MHC-I 
(Fig. 1.5). The first is termed the ‘signaling model’ and indicates that Nef affects the 
retrograde transport of cell surface MHC-I(180). The signaling model further proposes 
that Nef interacts with PACS-1 and PACS-2 to facilitate MHC-I endocytosis (128). 
Specifically, Nef’s interaction with PACS-2, localizes Nef to the TGN where it interacts 
and activates the Src family kinases (SFKs) Hck, Lyn, Syk or c-Src (92). In turn, 
activated SFKs activate ZAP-70, followed by the phosphorylation of phosphoinositide-3-
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kinase (PI3K) (92). Upon PI3K activation, the incorporation of PIP3 into the membrane 
permits the clathrin-independent endocytosis of MHC-I from the cell surface (93). The 
mechanism by which this endocytosis takes place is not completely understood, however 
this process is thought to be partly regulated by the small guanine nucleotide exchange 
factors Arf6 and Arf1(93). Subsequent to MHC-I endocytosis, AP-1 interacts with Nef 
via its μ1 subunit and targets the MHC-I cytoplasmic tail through the tyrosine motif 
(Y320SQA) (224, 225). It is hypothesized that a ternary complex between Nef/MHC-
I/AP-1 prevents MHC-I from recycling back to the cell surface; however, visualization of 
this ternary complex within a defined cellular compartment has yet to be conducted 
(225). In addition, the “signaling model” demonstrated that MHC-I ultimately 
accumulates in a para-nuclear region, characteristic of the TGN (226). In this case, MHC-
I would be sequestered at TGN and away from the cell surface where it would fail to 
present viral antigens to anti-HIV CTLs (127, 190). This sequestration of MHC-I within 
the cell is PACS-1 dependent and is believed to involve AP-1 as well (127). However, 






Figure 1.5: Dual mechanisms of Nef-mediated MHC-I downregulation.  
Within the signaling mode (left) of MHC-I downregulation, (1) Nef is localized from the 
early endosome to the TGN through its interaction with PACS-2. (2) Nef interacts, and 
activates Golgi-resident Src-Family kinases to initiate a signaling cascade involving 
ZAP-70, PI3K, and SYK (a Src-Family Kinase). (3) Arf6/Arf1 becomes activated to 
induce the endocytosis of MHC-I from the cell surface. (4) Once within the cell, MHC-I 
is targeted by both Nef and AP-1, and through a PACS-1-dependent trafficking step, 
becomes localized to a paranuclear compartment. The stoichiometric mode (right) 
involves the targeting of newly synthesized MHC-I at the Golgi, and its rapid trafficking 







































A contrasting model of Nef-dependent MHC-I downregulation occurs during the latter 
stages of infection and involves the inhibition of newly synthesized MHC-I trafficking to 
the cell surface (180). This model, termed the “stoichiometric mode” involves Nef 
binding to the MHC-I cytosolic tail during transport through the Golgi by an undefined 
mechanism. As with the signaling mode, a MHC-I/Nef/AP-1 ternary complex is formed, 
thus preventing MHC-I from trafficking to the cell surface (224). In contrast, this model 
proposes that MHC-I is routed toward the degradative lysosomal compartment where 
MHC-I is degraded (225, 227, 228). 
It is likely these mechanisms of MHC-I downregulation are not mutually exclusive, and 
in fact, represent redundant approaches to evade the cytotoxic T cell responses (130, 
180). In fact, studies identified that Nef can downregulate MHC-I by both the signaling 
mode, and the stoichiometric mode (180). However, the mechanism by which this mode 
switch occurs remains elusive. Moreover, the precise contribution of PACS-1 in the 
intracellular trafficking of MHC-I has yet to be defined.  
1.11 Thesis overview 
Throughout this thesis, I will outline the role of PACS-1 in the sorting of cellular proteins 
in two contexts. First, I will explore the role of PACS-1 in Nef-mediated MHC-I 
downregulation. This function of Nef has been described in some detail, yet, many of the 
specific cellular trafficking steps have not yet been elucidated. It is known that the rate of 
MHC-I endocytosis is increased in the presence of Nef, and that this is dependent on the 
PACS proteins. Moreover, we know that once internalized, MHC-I is trafficked to a para-
nuclear compartment, however, the exact subcellular location remains elusive (179, 181). 
Structural studies have proposed a ternary complex model by which both Nef and AP-1 
cooperatively bind the cytoplasmic tail of MHC-I to alter its cellular location (205). This 
model is attractive, but has not been completely confirmed within cell, nor does it fully 
integrate PACS-1 in the cellular sorting of MHC-I. Importantly, Nef and PACS-1 have 
been shown to interact directly through multiple interaction assays, and its importance to 
Nef function has been well documented (92, 127, 128, 181, 226). The role of PACS-1 in 
the cellular receptor sorting is based on the premise that PACS-1 connects acidic cluster 
containing cargo to the clathrin adaptor protein machinery (66, 95). Thus, I hypothesize 
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that Nef and PACS-1 interact, and facilitates the recruitment of AP-1 to the cytoplasmic 
tail of MHC-I to induce its retrograde transport to the TGN.  
My second objective revolves around examining the role of PACS-1 in the uninfected 
cell. Specifically, I explored how PACS-1 controls the localization and secretion of the 
small peptide hormone ACTH. PACS-1 has been implicated in the routing of cellular 
receptors within the regulated secretory network of neuroendocrine cells (65, 66, 94). 
However, the role of PACS-1 in controlling the trafficking of small peptides within the 
lumen of vesicles has yet to be defined. Thus, I hypothesize that PACS-1 and AP-1 are 
integral trafficking proteins which regulate the localization of ACTH within 
neuroendocrine cells.  
Overall, defining the PACS-1-dependent trafficking steps in homeostasis and disease will 
aid in the understanding of the regulation of AP recruitment to mediate the movement of 
a diverse array of receptors and cargo. Importantly, this will define the cellular 
compartments important for MHC-I downregulation by Nef, as well as identify the role 
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2 Viral Bimolecular Fluorescence Complementation: A 
Novel Tool to Study Intracellular Vesicular Trafficking 
Pathways 
2.1 Introduction 
The sub-cellular localization of mammalian proteins is coordinated by the membrane 
trafficking machinery, including a vast network of membrane-bound vesicles and adaptor 
molecules (1, 2). Viruses, such as Human Immunodeficiency Virus type 1 (HIV-1), are 
able to exploit the host membrane trafficking machinery and key cellular components to 
favour viral replication. HIV-1 produces 15 viral proteins (3, 4), including a 27 kDa 
accessory protein termed Nef, which lacks any known enzymatic activity, but is essential 
for viral pathogenesis (5, 6). Nef mediates its pathogenic effects by modulating 
membrane trafficking in infected cells. Notably, Nef facilitates downregulation of various 
cell surface molecules, including major histocompatibility complex-I (MHC-I), which 
results in attenuation of the immune response by impairing the presentation of viral 
antigens to cytotoxic T-lymphocytes (CTLs) (7, 8).  
Nef-mediated MHC-I downregulation is primarily orchestrated by protein-protein 
interactions between Nef and various host cellular proteins (7, 9-12). This includes the 
membrane trafficking regulators phosphofurin acidic cluster sorting proteins 1 and 2 
(PACS-1 and PACS-2), which form specific protein complexes with Nef at distinct sub-
cellular locations in order to downregulate MHC-I (7, 9, 12, 13). In turn, PACS-1 can 
specifically interact with the clathrin adaptor protein-1 (AP-1) to facilitate Nef mediated 
sequestration of MHC-I away from the cell surface (7, 13, 14). The PACS-1/AP-1 
interaction, as well as the crystal structure of Nef in complex with AP-1 and MHC-I, 
demonstrate that host membrane trafficking regulator proteins, such as AP-1 and PACS-
1, are key for HIV-1 immune evasion (14). Recently, the interactions between Nef and 
PACS proteins have been visualized using bimolecular fluorescence complementation 
(BiFC). BiFC is a microscopy technique that localizes protein interactions through the 
reconstitution of a functional fluorophore upon the interaction of two protein-binding 
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partners each fused to a non-fluorescent fragment of a fluorophore (15-17). Although 
BiFC has demonstrated that PACS-1 or PACS-2 and Nef interact at distinct sub-cellular 
compartments, it has not been shown with concurrent expression from a single plasmid or 
in the context of viral infection with other HIV-1 proteins present (9).  
This study addresses the current limitations of using BiFC to investigate viral protein 
interactions through the development of a lentiviral vector that enables simultaneous 
expression of Nef with various binding partners from the same vector in the context of a 
viral infection. To accomplish this, we utilized a lentiviral expression system yielding 
pseudovirions modified such that they only undergo a single round of replication, but are 
still capable of genomic integration (18). The co-expression of transgenes of interest was 
achieved by inserting the autocleavable 2a (F2A) coding sequence from the foot and 
mouth disease virus into the previously described HIV-1 based vector pNL4-3 Δgag/pol 
eGFP (19-22). Previous reports have demonstrated that insertion of an F2A site stalls 
translation, resulting in the production of cleaved polyproteins containing a 21 residue 
carboxy terminal F2A tag and a single proline addition at the amino terminus (23). We 
have used this unique system to express multiple transgenes fused to split fluorophores, 
thereby permitting analysis of protein-protein interactions using BiFC. Our results 
demonstrate that viral BiFC can be used to study the interaction between HIV-1 Nef and 
PACS-1 at both early and late endosomal compartments. The utility of viral BiFC is 
highlighted by its ability to provide the distinct sub-cellular localization of the interaction 
between Nef and MHC-I. In addition, viral BiFC can be used to study novel interactions 
between Nef and host membrane trafficking regulators. Indeed, using viral BiFC we 
demonstrate for the first time an interaction between Nef and the sorting nexin 18 
(SNX18) protein. Viral BiFC represents a unique tool enabling the visualization of Nef 




2.2.1 Designing a lentiviral vector enabling dual transgene 
expression 
Multiple Nef-interacting proteins have been identified using in vitro interaction assays, 
cellular co-immunoprecipitation analyses, and more recently by fluorescence resonance 
energy transfer and mass spectrometry (7, 9, 10, 13, 24-31). However, the Nef protein-
protein interaction network has never been defined in the context of expression from a 
single vector that mimics the conditions present during a viral infection. To address this, 
we constructed a lentiviral vector containing an F2A cleavage site or the non-functional 
mutant, F2A (null), as a control, thereby facilitating concurrent expression of Nef and a 
potential Nef-interacting partner (Fig. 2.1). Vector assembly was initiated using the 
previously described pNL4-3 Δgag/pol eGFP vector as a base (Fig. 2.1; top panel) (19, 
20). This base vector contains intact 5’ and 3’ long terminal repeat (LTR) regions and 
expresses all HIV-1 viral proteins except full-length Gag and Pol. These genes are 
mutated in the base vector to generate truncated proteins and must be supplied in trans for 
productive pseudovirion synthesis (Fig. 2.1; top panel) (20, 32). To facilitate gene 
insertion, two multiple cloning sites (MCSs) were introduced into the base vector: a 3’ 
MCS containing the XmaI, AgeI and NotI restriction sites and a 5’ MCS containing the 
ApaI, SphI and SpeI restriction sites (Fig. 2.1; bottom panel). We inserted HIV-1 Nef 
fused with the eGFP fluorescent tag into the 3’ MCS whereas the 5’ MCS was used to 





Figure 2.1: Construction of an HIV-1 derived lentiviral expression system harboring 
an F2A peptide and two multiple cloning sites. 
The pNL4-3 Δgag/pol eGFP vector (top) was engineered to contain the self-cleaving F2A 
peptide followed by a 5’ MCS (ApaI, SphI and SpeI), to introduce various transgene 
fusion proteins of interest. A MCS was introduced at the 3’ end in order to insert various 
Nef fusion proteins (XmaI, AgeI and NotI). (MCS: multiple cloning site; FL1: 
fluorophore fused to transgene of interest in the 5’ MCS; FL2: fluorophore fused to Nef 








































2.2.2 Insertion of an F2A site into a lentiviral vector allows concurrent 
protein production  
To avoid the production of proteins fused to truncated Gag/Pol proteins from the 5’ MCS, 
we exploited the self-cleaving property of the 2A peptide (F2A) derived from the foot 
and mouth disease virus by inserting the 21 amino acid F2A site between the Gag/Pol 
fusion protein and the 5’ MCS (Fig. 2.1; bottom panel). The resulting vector, pNL4-3 
F2A-X Nef-eGFP (Fig. 2.2A) has an empty 5’ MCS in order to accommodate future gene 
insertions. To test the cleavage efficiency of the F2A site, we constructed a lentiviral 
vector containing a Flag-tagged mStrawberry (mSB) fluorophore in the 5’ MCS (Fig. 
2.2A). Pseudovirus from the resulting pNL4-3 F2A-mSB-Flag Nef-eGFP construct was 
then used to infect Jurkat E6.1 T-cells. In order to directly quantitate the cleavage 
efficiency, a control vector with an inactive F2A site was constructed (Fig. 2.1 & 2.2; 
F2A (null)). Site-directed mutagenesis of the penultimate proline residue to alanine has 
been demonstrated to render the F2A site inactive (33). In agreement with cleavage 
mediated at the F2A site, western blot analysis demonstrated the production of a cleaved 
Flag-tagged mStrawberry protein that migrated just below the 35 kDa molecular weight 
marker (Fig. 2.2B; ++ Flag blot). Consistent with mutation of the penultimate proline in 
the F2A site to produce a defective cleavage site (22, 33, 34), cells infected with pNL4-3 
F2A (null)-mSB-Flag Nef-eGFP pseudovirus produced a Flag-tagged mStrawberry 
protein fused to the HIV-1 Gag/Pol protein that migrated above the 48 kDa molecular 
weight marker (Fig. 2.2B; + Flag blot). Quantification of the cleavage efficiency between 
the F2A and the F2A (null) site was determined by dividing the densitometry 
measurement of the cleaved product by the sum of both the cleaved and uncleaved 
products. We observed a 6-fold increase in cleavage efficiency in the presence of a 
functional F2A site, confirming that the cleavage is F2A-dependent (Fig. 2.2C). 
Moreover, the pNL4-3 F2A-mSB-Flag Nef-eGFP construct efficiently produced Nef-
eGFP, confirming that the 3’ MCS can also produce a fluorophore-tagged protein of 
interest (Fig. 2.2B; lane 3 GFP blot). Overall, these results demonstrate the 3’ and 5’ 
MCSs can be used to produce conjugated proteins and the proteins expressed from the 5’ 
MCS are cleaved from truncated Gag/Pol. 
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Figure 2.2: Functional cleavage at the engineered F2A site. 
Viruses were engineered with various proteins within the 5’ MCS and/or the 3’ MCS and 
Jurkat E6.1 T-cells were infected with the resulting pseudoviruses. Flag and GFP specific 
western blots were performed on lysates collected 48 hours post infection to verify 
protein expression levels. (A) Schematic representation of proteins produced from 
lentiviral expression system. (B) A Flag specific western blot was used to quantitate the 
cleavage efficiency at the F2A site in the F2A-mSB-Flag Nef-eGFP virus, compared to 
the F2A mutant, F2A (null)-mSB-Flag Nef-eGFP, which lacks cleavage activity (+ 
uncleaved product, ++ cleaved product). GFP specific western blots confirmed the 
presence of the Gag-eGFP fusion protein (lane 1) or Nef-eGFP fusion proteins (lanes 2-
4). (C) Cleavage efficiency at the F2A site was 6-fold higher compared to the F2A (null) 
virus (* indicates p-value < 0.05). Details n how the cleavage efficiency was calculated 
are included in Materials and Methods. Error bars calculated from 3 independent 


























































































































































































2.2.3 Nef and Nef-interacting partners are simultaneously 
expressed in a lentiviral vector  
The Nef-dependent endocytosis of cell surface MHC-I during an HIV-1 infection leads to 
evasion of CTL killing, thereby contributing to continued viral replication (35). Nef-
mediated MHC-I downregulation requires subversion of multiple membrane trafficking 
regulators, including binding to PACS-1 (7, 9, 10, 12, 13, 36). Therefore, to evaluate the 
simultaneous expression of Nef with PACS-1 or MHC-I, specifically the HLA-A2 allele, 
we engineered constructs containing different fluorophores for all genes inserted in the 5’ 
or 3’ MCS, respectively (Fig. 2.3A). The resulting vectors (pNL4-3 F2A-MHC-I-
mCherry Nef-eGFP and pNL4-3 F2A-PACS-1-mCherry Nef-eGFP) were designed to 
include an mCherry tag at the 5’ site and an eGFP tag at the 3’ site. To confirm the 
presence of the different fluorophores fused to proteins of interest, we infected HeLa cells 
with pseudovirions encoding the MHC-I or PACS-1 genes and visualized cells by 
widefield fluorescence microscopy.  This demonstrated simultaneous expression of both 
mCherry-tagged MHC-I or PACS-1 and eGFP tagged Nef (Fig. 2.3B, column 2 and 3). 
Similar infection of Jurkat E6.1 T-cells with pseudovirions generated from the respective 
vectors confirmed their simultaneous expression by western blot (Fig. 2.3C, lane 4 and 
5). Importantly, the conjugation of mCherry to MHC-I did not alter its localization within 
the cell as flow cytometry measurements indicated that mCherry-tagged MHC-I 
expressed in Jurkat E6.1 T-cells infected with the pNL4-3 F2A-MHC-I-mCherry ΔNef 
pseudovirus, was correctly routed to the cell surface (Fig. 2.3D & 2.4). Moreover, MHC-
I-mCherry was sensitive to Nef activity as Jurkat E6.1 T-cells infected with pNL4-3 F2A-
MHC-I-mCherry Nef-eGFP resulted in less MHC-I-mCherry on the cell surface 
compared to cells infected with pNL4-3 F2A-MHC-I-mCherry ΔNef (Fig. 2.3D and 2.4). 
These results indicate that co-expression of PACS-1-mCherry or MHC-I-mCherry and 
Nef-eGFP is achievable. Moreover, using different fluorophores for Nef and its binding 
partners allows for simultaneous observation of both proteins in infected cells without 





Figure 2.3: Fluorescence microscopy confirms expression of proteins from the 5’ 
and 3’ MCS.  
Viruses were engineered to produce MHC-I-mCherry or PACS-1-mCherry from the 5’ 
MCS in combination with Nef-eGFP from the 3’ MCS. (A) Schematic representation of 
proteins produced from lentiviral expression system. (B) To detect the fluorescent fusion 
proteins, HeLa cells were infected and visualized 48 hours post infection by widefield 
fluorescence microscopy. Expression of the Nef-mSB fusion protein was confirmed 
(column 1), along with concurrent expression of MHC-I or PACS-1-mCherry fusions 
with Nef-eGFP (columns 2 and 3). Cell nuclei were stained using Hoescht nuclear stain 
(blue). Scale bars represent 15μm. (C) mCherry and Nef specific western blots were 
performed to confirm the expression of the fusion proteins. (D) Jurkat E6.1 T-cells were 
infected with pNL4-3 F2A-MHC-I-mCherry Nef-eGFP (Nef-eGFP) or pNL4-3 F2A-

















































































































MHC-I-mCherry (BB7.2 antibody), fixed, permeabilized and stained for intracellular p24 
(KC57-RD1 antibody). Columns represent relative MHC-I-mCherry surface expression 
calculated from the geometric mean fluorescent intensity (gMFI) of surface MHC-I-
mCherry on infected cells and normalized to the cell surface MHC-I-mCherry levels of 
ΔNef-infected cells. Error bars were calculated from four independent repeats. (* 











Figure 2.4: MHC-I-mCherry produced from the F2A site reaches the cell surface 
and is sensitive to Nef. 
Jurkat E6.1 T-cells were infected with a virus expressing MHC-I-mCherry in the 
presence (F2A-MHC-I-mCherry Nef-eGFP) or absence (F2A MHC-I mCherry ΔNef) of 
eGFP-tagged Nef. At 48 hours post infection cells were washed and stained for surface 
HLA-A2 using APC/Cy7 conjugated BB7.2 monoclonal antibody. Cells were then 
washed, fixed, and permeabilized to allow for intracellular staining of p24 (using a PE 
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2.2.4 Viral BiFC demonstrates that Nef interacts with PACS-1 in 
specific endosomal compartments 
To investigate the utility of our lentiviral vector system for studying protein-protein 
interactions, we constructed lentiviral BiFC vectors (Fig. 2.5A). These were designed 
such that a functional Venus fluorophore was reconstituted when proteins fused to the 
amino (VN [1-173]) and carboxy (VC [155-238]) fragments of Venus were in close 
proximity. Indeed, vectors were designed to contain PACS-1-VN in the 5’ MCS and Nef-
VC in the 3’ MCS (pNL4-3 F2A-PACS-1-VN Nef-VC). Strikingly, infection of HeLa cells 
revealed that PACS-1 and Nef reconstitute a functional fluorophore when expressed from 
the pNL4-3 F2A-PACS-1-VN Nef-VC vector, indicating that PACS-1 and Nef are 
expressed and are in close proximity (Fig. 2.5B, column 3). Analysis at the protein level 
revealed PACS-1-VN and Nef-VC are both expressed (Fig. 2.5C). To rule out possible 
auto-fluorescence of the individual split fluorophores, we also infected HeLa cells with 
viruses expressing the individual split fluorophores (Nef-VC or PACS-1-VN; Fig. 2.5B), 
in combination with either PACS-1-mCherry or Nef-mSB (Fig. 2.5A). Indeed, sole 
expression of PACS-1-VN or Nef-VC did not result in fluorescence (Fig. 2.5B; column 1, 
2), even though these proteins were efficiently produced (Fig. 2.5C) and red fluorescence 
was observed indicating protein expression from the other MCS (Fig. 2.5B; column 1, 2). 
Moreover, to determine if the Nef protein produced from our viral BiFC vector system 
was functional, we used flow cytometry to test the ability of Nef produced from pNL4-3 
F2A-PACS-1-VN Nef-VC to downregulate endogenous MHC-I in Jurkat E6.1 T-cells. 
Our analysis demonstrated that Nef-VC downregulated MHC-I efficiently when 
compared to Jurkat E6.1 T-cells infected with a virus lacking Nef (pNL4-3 F2A-PACS-1-







Figure 2.5: Visualizing the Nef/PACS-1 interaction using viral Bimolecular 
Fluorescence Complementation. (A)  
Schematic representation of proteins produced from lentiviral expression system. (B) 
HeLa cells were infected with various viruses encoding different fusion proteins and 
visualized using widefield fluorescence microscopy. BiFC (green, column 3) was 
visualized in the F2A-PACS-1-VN Nef-VC infected HeLa cells and not the control BiFC 
viral infections (columns 1 and 2). Cells were mounted in DAPI Fluoromount G media 
for nuclear staining (blue). Scale bars represent 15μm. (C) Expression of the VN or VC 
fragment was detected by a GFP specific Western blot, whereas the mCherry and mSB 








































































































Densitometry measurements for PACS-1-VN and Nef-VC were 10,500 and 29,200 
arbitrary units, respectively, as determined by Licor C-Digit. (D) Jurkat E6.1 T-cells were 
infected with F2A-PACS-1-VN Nef-VC and the corresponding non-functional Nef mutant 
(F2A-PACS-1-VN ΔNef). At 72 hours post infection, cells were surface stained for 
MHC-I (W6/32 antibody), fixed, permeabilized and stained for intracellular p24 (KC57-
RD1 antibody). Columns represent relative MHC-I surface expression calculated from 
the geometric mean fluorescent intensity (gMFI) of surface MHC-I on infected cells and 
normalized to cell surface MHC-I levels of ΔNef-infected cells. Error bars were 



















Figure 2.6: Nef-VC expressed from a viral BiFC vector expressing PACS-1-VN is 
able to downregulate MHC-I 
Jurkat E6.1 T-cells infected with a virus expressing PACS-1-VN in the presence (F2A-
PACS-1-VN Nef-VC) or absence (F2A-PACS-1-VN ΔNef) of Nef-VC. At 72 hours post-
infection cells were washed and stained for surface MHC-I (using an APC/Cy7 
conjugated pan-selective monoclonal antibody). Cells were then washed, fixed, 
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To test if the viral BiFC signal between PACS-1-VN and Nef-VC was localized to a 
specific sub-cellular compartment, we performed an immunofluorescence analysis (Fig. 
2.7A) using markers of the endocytic pathway previously identified as co-localizing with 
Nef/PACS-1 complexes (9). HeLa cells infected with pNL4-3 F2A-PACS-1-VN Nef-VC 
and exhibiting viral BiFC were stained with markers for late or early endosomes. We 
observed 21% and 34% co-localization with makers for Rab5 and LAMP-1, consistent 
with a Nef/PACS-1 interaction on early and late endosomes, respectively (Fig. 2.7B). 
Together these experiments indicate that viral BiFC can be applied to study protein-
protein interactions between Nef and host cellular binding partners, and is particularly 
effective for mapping the sub-cellular locations of their interactions during viral 
















Figure 2.7: Nef/PACS-1 viral BiFC signal is localized to specific Rab5 and LAMP-1 
positive endosomes.  
(A) HeLa cells were infected with the F2A-PACS-1-VN Nef-VC virus and immunostained 
for Rab5 or LAMP-1. Cells were fixed, permeablized and stained using Rab5 or LAMP-1 
specific primary antibodies. Viral BiFC (green) was observed under the FITC channels 
and Rab5/LAMP-1 (red) fluorescence was observed under the Far-Red channel. Cells 
were mounted in DAPI Fluoromount G media for nuclear staining (blue). Scale bars 
represent 10μm.  Panels on the right represent a magnification of the boxed region from 
the left panel. (B) Twenty-one percent of the viral BiFC signal co-localized with Rab5, 
whereas 34% co-localized with LAMP-1. Co-localization was determined by the 
Manders Coefficient. Pearson’s correlation values were determined to be 0.36 and 0.42 



































































































independent experiments and quantification of at least 25 different cells. (* indicates p 







2.2.5 Viral BiFC can be used the study novel interactions between 
Nef and host cellular proteins in the endocytic network 
We demonstrated that viral BiFC can recapitulate previously characterized interactions 
between Nef and host cellular proteins, such as the Nef/PACS-1 interactions, and can be 
used to examine the sub-cellular localization of such interactions (Fig. 2.7). Therefore, 
we decided to test if viral BiFC can spatially define the interaction between Nef and 
additional interacting partners. We first tested the ability of Nef to interact with the cell 
surface receptor MHC-I. Indeed, the Nef/MHC-I interaction has been demonstrated both 
in vitro and by crystallography, but this complex has never been demonstrated within 
cells.  Thus, we inserted the MHC-I allele HLA-A2 into the 5’ MCS of our viral BiFC 
vector to generate the vector pNL4-3 F2A-MHC-I-VN Nef-VC. To test for an interaction 
between MHC-I-VN and Nef-VC, HeLa cells were infected and observed under widefield 
fluorescence microscopy. Interestingly, BiFC was observed, demonstrating an interaction 
between Nef and MHC-I in cells (Fig. 2.8A). Furthermore, we co-localized this 
interaction to vesicles that are positive for AP-1 (Fig. 2.8B) consistent with the in vitro 
Nef/MHC-I/AP-1 crystal structure (14). 
Since both PACS-1 and AP-1 are implicated in the Nef mediated downregulation of 
MHC-I, we explored the possibility that Nef associates with another host cellular 
membrane trafficking regulator, sorting nexin 18 (SNX18). We pursued SNX18 since 
this protein co-localizes with both PACS-1 and AP-1 within the endocytic network (37). 
To test if there is an association between Nef and SNX18, we inserted the SNX18 gene in 
the 5’ MCS of our viral BiFC vector to produce pNL4-3 F2A-SNX18-VN Nef-VC. We 
then infected HeLa cells with pNL4-3 F2A-SNX18-VN Nef-VC and tested for BiFC. As 
for our previously tested interactions, BiFC was observed between SNX18 and Nef 
demonstrating for the first time the close proximity between Nef and SNX18 (Fig. 2.8A; 
bottom panels). Furthermore, this association co-localized with AP-1, consistent with 
SNX18’s localization in the endosomal network (Fig. 2.8A) (37). Importantly, infection 
with a vector harboring an empty 5’ MCS (pNL4-3 F2A-X Nef-VC) demonstrated that 
Nef-VC expressed from this vector can downregulate endogenous MHC-I in Jurkat E6.1 
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T-cells (Fig. 2.8C and 2.9). This indicates that Nef fused to a split fluorophore is 
functional. Overall, viral BiFC can be used to further study previously described 
interactions as well as identify novel interactions between Nef and host cellular partners, 





Figure 2.8: Viral BiFC signals of MHC-I/Nef and SNX18/Nef are localized to AP-1 
positive endosomes.  
(Α) HeLa cells were infected with either the F2A-MHC-I-VN Nef-VC virus (top) or the 
F2A-SNX18-VN Nef-VC virus (bottom) and immunostained for AP-1. Cells were fixed, 
permeabilized and stained using an AP-1 specific primary antibody. Viral BiFC 



























































































































was observed under the Far-Red channel. Cells were mounted in DAPI Fluoromount G 
media for nuclear staining (blue).  Scale bars represent 10μm. Panels on the right 
represent a magnification of the boxed region from the left panel. (B) 78% percent of the 
Nef/MHC-I BiFC signal co-localized with AP-1, whereas 37% of the Nef/SNX18 BiFC 
signal co-localized with AP-1. Co-localization was determined by the Manders 
Coefficient, and mean Pearson’s correlation was determined to be 0.74 and 0.40 for 
Nef/MHC-I and Nef/SNX18, respectively. Error bars were calculated by 3 independent 
experiments and quantification of at least 25 different cells. (C) Jurkat E6.1 T-cells were 
infected with F2A-X Nef-VC virus and the corresponding non-functional Nef mutant 
(F2A-X ΔNef). At 72 hours post infection, cells were surface stained for MHC-I (W6/32 
antibody), fixed, permeabilized and stained for intracellular p24 (KC57-RD1 antibody). 
Columns represent relative MHC-I surface expression calculated from the geometric 
mean fluorescent intensity (gMFI) of surface MHC-I on infected cells and normalized to 
the cell surface MHC-I levels of ΔNef-infected cells. Error bars were calculated from 












Figure 2.9: Nef-VC expressed from a base viral BiFC vector is able to downregulate 
MHC-I.  
Jurkat E6.1 T-cells were infected with a base viral BiFC virus containing Nef-Vc (F2A-X 
Nef-VC) or a virus that does not produce Nef (F2A-X ΔNef). At 72 hours post-infection 
cells were washed and stained for surface MHC-I (using an APC/Cy7 conjugated pan-
selective monoclonal antibody). Cells were then washed, fixed, permeabilized and 
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This study describes viral BiFC, a novel lentiviral expression system designed for 
studying protein-protein interactions and mapping their sub-cellular locations. This vector 
has the unique capability of enabling the use of bimolecular fluorescence 
complementation from a single vector in the context of a viral infection. We demonstrate 
the application and utility of viral BiFC for understanding the membrane trafficking 
pathways of cellular proteins interacting with the HIV-1 protein Nef (Fig. 2.7 and 2.8). 
This is of utmost importance as Nef is considered the pathogenic factor responsible for 
the progression to AIDS (38). Moreover, since Nef lacks any enzymatic activity its 
ability to interact with cellular partners is key to define its pathogenic nature.   
Lentiviral vectors are ideal vehicles for introducing genes at high expression levels inside 
a heterologous cell {for review see (18, 39, 40)}. However, the study of protein 
interactions often requires gene expression from multiple vectors, which may result in 
suboptimal or differential expression of the proteins of interest. One approach to express 
multiple genes with lentiviral vectors involves using an internal ribosome entry site 
(IRES) (41). However, significant differences in IRES activity have been reported in 
different cell types, thereby decreasing the utility of these vectors (42, 43). Moreover, the 
use of an IRES is limited, as there are significant restrictions imposed when cloning due 
to the substantial size of IRES sequences (23) and multiple reports suggest certain 
cistrons inhibit IRES element activity (44, 45).  
In contrast, effective protein expression from polycistronic RNA can be achieved using 
plasmids harboring the 2A peptide sequence, such as in this study, which permits 
independent translation of coding sequences from a single transcript (23, 46, 47). This 
approach allowed for co-expression of PACS-1-mCherry or MHC-I-mCherry and Nef-
eGFP, demonstrating that Nef and host cell proteins can be efficiently expressed from a 
single integrating vector (Fig. 2.3). We validated the cleavage efficiency of the 2A site by 
constructing a modified vector with a mutated F2A site (Fig. 2.2). Production of cleaved 
mStrawberry-Flag was significantly reduced (a six-fold decrease; p<0.05) in the vector 
encoding the mutated F2A site (Fig. 2.2B, C), directly confirming the efficiency of 
cleavage mediated by the F2A site.  
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BiFC is a valuable tool for visualizing protein-protein interactions within a cell {for 
review see (15, 16)}. This powerful technique can be used to identify the specific sub-
cellular locations where protein interactions occur, and to define protein interaction 
interfaces by elucidating the residues critical for a protein interaction to occur (9, 15, 16, 
48). In the case of Nef, previous reports have utilized BiFC to demonstrate the 
dimerization of Nef and to study the interaction between Nef and the host cellular 
proteins PACS-1 and PACS-2 (9, 48-50). However, these studies utilized a dual vector 
expression system, which may result in the need to laboriously optimize the expression 
levels of two different plasmids in order to observe BiFC (48, 50). This fine-tuning of 
plasmid levels is effectively removed in our system, which relies on protein expression 
from a single vector. In addition, previous studies were not conducted under the 
conditions of viral infection, precluding generalizability of these studies to the nature of 
HIV-1 infection. Our single vector expression system has the added advantage that all 
infected cells express both proteins of interest concomitantly within the context of a viral 
infection (Fig. 2.3, 2.5, 2.8). This is of particular interest when studying interactions 
between Nef and PACS-1. Indeed, the Nef/PACS-1 interaction modulates the 
downregulation of cell surface MHC-I via a mechanism that depends on the length of 
infection (13). Our viral BiFC system will facilitate full elucidation of the mechanisms 
governing the influence of the HIV-1 genome on the time-dependent action of the 
Nef/PACS-1 interaction through deletion of specific HIV-1 proteins within our viral 
vector. This molecular dissection will be possible using a single vector system that 
detects Nef interactions (Fig. 2.7A, 2.8) and is functionally capable of downregulating 
MHC-I (Fig. 2.3D, 2.5C). 
Interestingly, our observation of the Nef/PACS-1 interaction at distinct endosomal 
compartments (Fig. 2.7) is in accordance with the previously defined sub-cellular 
localization of this interaction (9), thereby validating that viral BiFC demonstrates protein 
interactions between Nef and host proteins at bone fide cellular compartments. Indeed, 
this system can define the interacting interfaces between Nef and multiple Nef-binding 
partners as well as map the sub-cellular location of their interactions. Specifically, the 
interaction between Nef, MHC-I, and the membrane adaptor protein-1 (AP-1) is critical 
in orchestrating the downregulation of MHC-I to evade immune detection and this 
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interaction has been studied in vitro (36, 51, 52). However, the exact sub-cellular 
localization of these interactions currently remains unknown. By inserting the MHC-I 
gene into our viral BiFC system and co-localizing the Nef/MHC-I interaction to AP-1 
positive endosomes we effectively recapitulated the Nef/MHC-I/AP-1 interaction in HIV-
1 infected cells (Fig. 2.8). This information is critical to understand the exact molecular 
players that are subverted by Nef in order to traffic MHC-I molecules from the plasma 
membrane. A novel membrane trafficking regulator that may play a role in this process is 
SNX18. Our analysis is the first to demonstrate that SNX18 associates with Nef in an 
AP-1 positive compartment (Fig. 2.8). This is consistent with the reported presence of 
SNX18 in compartments that are PACS-1 and AP-1 positive (37). Future studies will be 
required to correctly decipher the role of SNX18 in Nef mediated MHC-I downregulation 
and to confirm if the Nef/SNX18 interaction is direct. An attractive hypothesis is a 
required role for SNX18 in biogenerating specific vesicles required for Nef to correctly 
remove MHC-I from the cell surface. This implies that Nef may require the fissiogenic 
ability of proteins such dynamin, which is recruited by SNX18 to correctly shuttle host 
proteins such as MHC-I to sub-cellular locales (37). 
Although constructed as a robust tool to decipher membrane trafficking networks in HIV-
1 infected cells, our vector system also has potential as a drug discovery tool. Recently, 
Poe et al. elegantly demonstrated that BiFC can be utilized for high-throughput screening 
of small molecule inhibitor libraries for molecules that block specific protein-protein 
interactions (49). By performing small-molecule screens of compound libraries in cells 
infected with our viral BiFC system we will be able to identify compounds that disrupt 
the interactions between Nef and Nef-binding partners such as PACS-1 or the Nef/MHC-
I/AP-1 complex. Our system will allow for identification of novel inhibitors of these 
interactions in a model of infection, thereby affording us key information about the Nef 
interaction interfaces that mediate immune evasion during HIV-1 infection.  
Due to the essential role Nef plays in HIV-1 pathogenesis, our viral BiFC system was 
designed to study the many interactions Nef must make to modulate infected cells. 
However, it will be interesting to determine in future studies if removal of Nef from the 
3’ MCS will allow viral BiFC to be applicable to any protein-protein interaction analysis. 
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Given that Nef itself has been determined to play a role in viral replication (53), 
additional studies are required to determine if Nef can be replaced by a heterologous 
sequence. Previous studies suggest that viruses harboring a Nef gene deletion could still 
efficiently replicate suggesting that heterologous sequences can be placed in the 3’ MCS 
(53). Moreover, the MCSs in our lentiviral system will not only enable insertion of genes 
of interest, but also sequences capable of silencing host genes, such as short hairpin RNA 
sequences (54, 55). 
In summary, viral BiFC is a powerful tool that enables the study of vesicular trafficking 
in the context of HIV-1 infection and provides an efficient method to introduce 
transgenes directly into a lentiviral vector. Viral BiFC will enable researchers to study 
Nef interactions at specific sub-cellular locales, thereby elucidating key cellular events 
that mediate HIV-1 pathogenesis.   
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2.4 Materials and Methods 
2.4.1 Cell Culture  
HeLa (ATCC, Manassas, VA) and HEK 293T cells (Life Technologies, Carlsbad, CA) 
were grown in complete DMEM containing 10% fetal bovine serum (Life Technologies, 
Waltham, WA), 100μg/ml penicillin-streptomycin (Hyclone, Logan, UT), 1% sodium 
pyruvate, 1% non-essential amino acids and 2mM L-glutamine (Hyclone). Jurkat E6.1 T-
cells (Catalog number 177; National Institutes of Health, AIDS Research and Reference 
Reagent Program) were cultured in RPMI 1640 with supplements as mentioned above. 
All cell lines were grown at 37°C in the presence of 5% CO2 and sub-cultured in 
accordance with supplier’s recommendations. 
2.4.2 Proviral plasmids and cloning strategy 
3’ cloning site for Nef fusion proteins: The previously described pNL4-3 Δgag/pol eGFP 
replication incompetent HIV-1 proviral vector (19, 20) was used as the base template for 
modification into our final expression vector system. First, primer overlap extension 
mutagenesis (56) was used to amplify two fragments flanking the Nef coding sequence in 
order to remove Nef and insert XmaI, AgeI and NotI restriction sites, termed the 3’ 
multiple cloning site (MCS). Specifically, an initial PCR reaction (Reaction I) was 
performed with primers JD 14 and JD 37 (Table 2) in order to amplify a 316 bp fragment 
upstream of Nef, containing the 3’ MCS restriction sites. A subsequent PCR reaction 
(Reaction II) amplified a 1157 bp fragment immediately after the Nef stop codon using 
primers JD 38 and JD 15 (Table 2). The forward primer in Reaction II contained 
complementary nucleotides to the 3’ MCS restriction sites in JD 37. Products from 
Reaction I and II were purified, mixed and amplified (Reaction III) using the flanking JD 
14 and JD 15 primers (Table 2). The Reaction III product was inserted into the pNL4-3 
Δgag/pol eGFP base vector using BamHI and NcoI restriction sites in order to generate a 
pNL4-3 Δgag/pol eGFP with the 3’ MCS in lieu of Nef (Fig. 2.1). This 3’ MCS is 
capable of accepting Nef fusion proteins with various fluorophores. The mStrawberry 
(mSB) fragment was amplified from Addgene plasmid 20970 (57). For the BiFC 
experiments regions expressing the amino portion of the Venus fluorophore (VN; amino 
74 
 
acids 1-173) or the carboxy portion of the Venus fluorophore (VC; amino acids 155-238) 
(15) were inserted in either MCS. 
Table 2: Primers used for cloning viral-BiFC vectors 
Primer Sequence 
JD 14 GTGAACGGATCCTTAGCAC  
JD 15 CCTGCACTCCATGGATCA 
JD 37 CCTTGGGCGGCCGCATATACCGGTAAATTTCCCGGGCTTATAGCAAAATCCTTTCCAAGCCCT 
JD 38 CCTTGGCCCGGGAAATTTACCGGTATATGCGGCCGCCATCGAGCTTGCTACAAGGGAC 
JD 42 GTTGTTGCAGAATTCTTATTATGGCTTCCAC 









JD 132 GGTTGGGCATGCATGGCGCTGCGCGCCCGG 
JD 142 GCAGCAACTAGTTTACTTATCGTCGTCATCCTTGTAATCTCCGTCCTCGATGTTGTGGCGGATC 
JD 144 GCTGCTGCATGCATGGCCGTZATGGCGCCC 
JD 165 TGAAGCGCGCACGGCAAG 











2.4.3 Generation of the F2A cleavage site and 5’ MCS 
An ApaI site was inserted directly after eGFP in the pNL4-3 Δgag/pol eGFP plasmid (JD 
43 and JD 42). Briefly, a PCR reaction was conducted to produce the desired ApaI 
restriction site directly adjacent to the MscI restriction site already present in the proviral 
vector. The product was then digested with MscI and EcoRI and cloned into the parent 
vector. Subsequently, to insert the F2A sequences and the 5’ MCS, two complementary 
primers (JD 106 and 107, Table 2) were engineered to contain the F2A sequence 
(VKQTLNFDLLKAGDVESNPGP) in addition to ApaI, SphI and SpeI restriction sites, 
termed the 5’ MCS, plus a 2 bp overhang that is complementary to the ApaI and SphI cut 
sites. These primers were annealed together and ligated into pNL4.3 ΔGag/pol eGFP with 
the inserted ApaI cut site (Fig. 2.1; bottom), which was cut with SphI and ApaI. The 
resulting plasmid contained unique 5’ restriction cut sites in order to permit insertion of 
foreign genes. To generate the F2A (null) control vector, primer overlap extension 
mutagenesis was performed to mutate the penultimate proline to an alanine. First, a 
forward primer was generated upstream of the F2A site containing a PauI restriction site 
(JD 165). Second, a reverse primer was engineered to contain the F2A mutation with an 
adjacent ApaI site (JD 166). A subsequent PCR was conducted using F2A mSB-Flag 
Nef-eGFP as a template, and the product was inserted into the F2A vector utilizing the 
PauI and ApaI restriction sites, thereby replacing the functionally active F2A with the 
non-functional mutant.  
To generate the MHC-I (HLA-A2 allele) and SNX18 BiFC constructs, products were 
amplified from expression plasmids containing cDNA sequences for MHC-I-VN  (JD 144 
and JD 142; Table 2) or SNX18-VN, (JD 132 and JD 142; Table 2, SNX18 cDNA was 
provided by Rytis Prekaris; University of Colorado Denver) then cloned into the viral 
vector using the SpeI and SphI cut sites. To engineer the F2A-MHC-I-mCherry ΔNef 
viral vector, we digested the parental backbone of F2A-MHC-I-mCherry Nef-GFP with 
PauI and EcoRI and cloned the product into a pNL4-3 ΔΝef construct generating an F2A-
MHC-I-mCherry ΔNef viral vector.  
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2.4.4 Pseudovirus production and processing 
Pseudovirions were produced in HEK 293T cells. Cells were triple transfected using 
PolyJet (FroggaBio, Toronto, ON) with pNL4-3 Δgag/pol eGFP or the modified variants, 
as well as pdR8.2 and pMD2.G as previously described (32). Pseudovirus was harvested 
48 hours post-transfection. Briefly, virus-containing media was first centrifuged at 
3000xg for 5 minutes and subsequently filtered. The filtered supernatant was 
supplemented with an additional 10% FBS prior to storage at -80°C.  
2.4.5 Western Blots, Antibodies and Infections 
Jurkat E6.1 T-cells or HeLa cells were infected with various pseudoviruses for 48 hours, 
at which point infected cells were washed once with phosphate buffered saline (PBS) and 
subsequently lysed in lysis buffer (0.5M HEPES, 1.25M NaCl, 1M MgCl2, 0.25M 
EDTA, 0.1% Triton X-100 and 1X complete Protease inhibitor Tablets (Roche, 
Indianapolis, IN). Cells were incubated on a rotator for 20 minutes at 4°C before 
removing insoluble cellular debris by centrifugation at 20,000xg for 20 minutes. Lysates 
were boiled at 98°C in 5X SDS-PAGE sample buffer (0.312M Tris pH 6.8, 25% 2-
Mercaptoethanol, 50% glycerol, 10% SDS) and proteins were separated on a 12% SDS-
PAGE gel and subsequently transferred to nitrocellulose membranes. Membranes were 
blocked in 5% non-fat skimmed milk (Bioshop, Burlington, ON) in TBST containing 
0.1% Triton X-100 for 1 hour, then incubated overnight at 4°C with various antibodies: 
rabbit anti-Nef polyclonal antibody (1:4000; catalog number 2949, NIH AIDS Research 
and Reference Reagent Program, USA), rabbit anti-GFP polyclonal antibody (1:2000; 
Clontech; Mountain View, CA), rat anti-DYKDDDK monoclonal IgG (1:2500; 
BioLegend, San Diego, CA), or rabbit anti-mCherry monoclonal IgG (1:2000; Thermo 
Scientific).  Membranes were then washed and incubated for two hours with the 
appropriate species-specific HRP-conjugated antibodies (1:5000; Thermo Scientific). All 
blots were developed and quantified using ECL substrates (Millipore Inc., Billerica, MA) 





Cleavage efficiency of the F2A site was calculated by dividing the signal intensity of the 
cleaved product by the sum of both the cleaved and un-cleaved product. Efficiencies were 
then normalized to the wildtype F2A cleavage. Subsequently, a ratio was obtained by 
comparing the wildtype functional F2A cleavage efficiency to the mutant. 
For flow cytometry the following antibodies were used: W6/32 (anti-MHC-I; pan-
selective, provided by D. Johnson, Oregon Health and Sciences University), antibody 
conjugated to APC/Cy7 (1:25, Biolegend, San Diego, CA), anti-p24 clone KC57 
conjugated to RD1 (phycoerythrin) (1:50, Beckman Coulter, Brea, CA), anti BB7.2 
conjugated to APC/Cy7 (1:25, Biolegend, San Diego, CA). 
For immunofluorescence, rabbit anti-Rab5 (clone C8B1; 1:200, Cell Signaling), mouse 
anti-LAMP-1 (clone H4A3, 1:100, obtained from the Developmental Studies Hybridoma 
Bank) and mouse anti-AP-1γ (Sigma Aldrich) antibodies were used.  
2.4.6 Microscopy 
HeLa cells were seeded onto sterile glass coverslips at 5x105 cells per coverslip for 16 
hours prior to infection. Cells were infected for 48 hours before processing for 
immunofluorescence. Briefly, cells were washed three times with PBS before fixation in 
4% paraformaldehyde for 20 minutes at room temperature. Cells were subsequently 
washed with PBS twice prior to nuclear staining. Immediately prior to imaging, Hoechst 
nuclear stain (1μg/ml; Thermo Scientific) was added to the coverslip and incubated for 10 
minutes. Cells were imaged on the Leica DMI6000 B on 63X objective using the FITC, 
CY3 and DAPI filter settings using the Hamamatsu Orca-flash 4.0 Camera.  
For BiFC experiments, infections were set as above. Prior to fixation, the cells were 
incubated at room temperature for 2 hours to allow the reconstituted fluorophore to 
mature. The fixation protocol was then carried out as described above. To visualize early 
or late endosomes, cells were stained with rabbit anti-Rab5 or mouse anti-LAMP-1 
antibodies, respectively. Samples were incubated in a permeabilization buffer containing 
1% BSA in PBS and 0.2% Triton X-100 for 5 minutes, then blocked in a buffer 
containing 5% BSA in PBS for 1 hour. Anti-Rab5 or LAMP-1 antibodies were then 
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diluted in 1% BSA and 0.2% Triton X-100 (1:200 and 1:100, Jackson ImmunoResearch). 
Cells were then washed three times in PBS (2 minutes each) before adding the secondary 
donkey anti-rabbit AlexaFluor 647 or donkey anti-mouse Alexafluor 647 (1:1000; 
Jackson ImmunoResearch) in the same manner as the primary antibody. AP-1 staining 
was carried out as mentioned above using mouse anti-AP-1γ (1:200; Sigma Aldrich) 
primary antibody and donkey anti-mouse Alexafluor 647 (1:1000; Jackson 
ImmunoResearch). Samples were washed three times in PBS (1 minute each) prior to 
imaging and mounted onto glass slides using DAPI Fluormount-G (Southern Biotech, 
Birmingham, AL). Cells were imaged on the Leica DMI6000 B on 100X objective using 
the FITC, CY5 and DAPI filter settings using the Hamamatsu Photometrics Delta Evolve 
camera. Images were subsequently deconvolved using the Advanced Fluorescence 
Deconvolution application on the Leica Application Suite software. Co-localization 
analysis was conducted using the Manders Coefficient and Pearson Correlation from the 
Image J plugin as described previously (58). 
2.4.7 Flow Cytometry 
To quantify the cell surface expression levels of MHC-I, Jurkat E6.1 T-cells were 
infected with the appropriate viruses and 72 hours post infection cells were surface 
stained for MHC-I using W6/32 antibody conjugated to APC/Cy7 (Biolegend, San 
Digego, CA). Following fixation in 1% paraformaldehyde, cells were permeabilized with 
cold methanol. Subsequently, intracellular staining with RD1 (phycoerythrin) conjugated 
anti-p24 (Beckman Coulter) was performed to gate for infected cells. Cell surface MHC-I 
expression was quantified by flow cytometry (BD FACS Canto II) and the data analyzed 
using FlowJo software (version 9.6.4, Treestar, Ashland, OR). 
The ability of the MHC-I-mCherry fusion protein to be trafficked to the membrane was 
tested using an allele specific antibody. Jurkat E6.1 T-cells were infected with the 
appropriate virus and 48 hours post-infection, cell surface staining was performed using 
the BB7.2 antibody (Biolegend) which recognizes only MHC-I molecules encoded by 
A*02 alleles. Cells were then fixed in 1% paraformaldehyde and permeabilized with cold 
methanol and intracellularly stained with RD1 (phycoerythrin) conjugated anti-p24 to 
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gate for infected cells. MHC-I-mCherry cell surface expression was quantified by flow 
cytometry (BD FACS Canto II) and the data analyzed using FlowJo software (version 
9.6.4) 
2.4.8 Statistics 
All statistics were conducted using a paired T-test on Graph Pad Prism (Graph Pad 
Sofware Inc., La Jolla, CA) 
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3 HIV-1 Nef sequesters MHC-I intracellularly by targeting 
early stages of endocytosis and recycling 
3.1 Introduction 
The human immunodeficiency virus type 1 (HIV-1) encodes a class of proteins that lack 
any known enzymatic activity. These proteins, termed “accessory proteins”, include Nef, 
Vpr, Vpu and Vif. Accessory proteins can promote viral fitness by allowing infected cells 
to evade the host immune response (1). The ability of Nef to promote HIV-1 immune 
evasion has been ascribed to its extensive interaction network with host proteins (2-4). 
Indeed, Nef interacts with multiple proteins implicated in membrane trafficking in order 
to downregulate cell surface levels of major histocompatibility complex class I (MHC-I), 
resulting in a decreased ability of infected CD4+ T-cells to be detected and killed by 
CD8+ cytotoxic T lymphocytes (CTLs)(5). This rerouting of MHC-I away from the cell 
surface is an example of a viral protein usurping host cell functions to ensure viral 
replication. 
Currently, two models explain how Nef orchestrates the re-localization of MHC-I away 
from the cell surface (reviewed in (6)). The first model, termed the signaling model of 
downregulation, is activated early during infection and involves the targeting of Nef to 
the trans-Golgi network (TGN) by the host membrane trafficking regulator protein 
phosphofurin acidic cluster sorting protein 2 (PACS-2)(2, 7). Once at the TGN, Nef binds 
and activates specific Src-family kinases (SFKs), which subsequently trigger the 
phosphoinositide 3-kinase (PI3K)-dependent endocytosis of cell surface MHC-I (3). 
Internalized MHC-I is then sequestered in an intracellular compartment by a process 
involving the cytoplasmic tail of MHC-I (8) and the membrane trafficking regulator 
phosphofurin acidic cluster sorting protein 1 (PACS-1), which has previously been 
identified to interact with the membrane adaptor protein-1 (AP-1)(2, 3, 9). Interestingly, 
Nef, AP-1 and MHC-I have been described to form a ternary complex which depends on 
the cytoplasmic tail of MHC-I (10). Structural information obtained by Jia et al. revealed 
that residues Y320 and D327 in the cytoplasmic tail of MHC-I bridge key interactions with 
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Nef and AP-1, supporting Nef-dependent downregulation of MHC-I (10). The role of 
PACS-1, in Nef-mediated MHC-I downregulation has remained understudied. Indeed, 
knockdown of PACS-1, or inhibition of a PACS-1:AP-1 interaction hinders MHC-I 
downregulation. PACS-1 plays important roles in receptor trafficking in the uninfected 
cell. Classically, PACS-1 recognizes the presence of an acidic cluster motif in the 
cytoplasmic tail of cargo molecules and is able to connect the itinerant cargo to AP-1. 
The PACS-1:AP-1 interaction is required for proper regulation of the cellular protease 
furin in the Golgi, as well as the correct localization of the cation-independent mannose-
6-phosphate receptor in late endosomes (11, 12). Thus, recognition of cargo molecules by 
AP-1 is tightly regulated by PACS-1; however, the role of PACS-1 in the recruitment of 
AP-1 to the MHC-I cytoplasmic tale has yet to be defined. 
The second model of Nef-dependent MHC-I downregulation, termed the stoichiometric 
mode, occurs at later stages of infection (7). In this model, Nef interacts with the 
cytoplasmic tail of MHC-I and traffics the receptor to a degradative compartment in a 
process that also involves the membrane trafficking regulators AP-1 in addition to coat 
protein 1 (COPI) (13). The signaling and stoichiometric models are not mutually 
exclusive and appear to be temporally linked (7). Moreover, the signaling model may be 
more prominent in T-cells, as they have a relatively short half-life, whereas, the 
stoichiometric model may be more relevant in longer lived monocytes (7).  
Despite having identified multiple membrane trafficking regulator proteins implicated in 
the removal of MHC-I from the cell surface, it remains unknown what cellular 
compartments Nef uses during this process precluding our understanding of the pathway 
subverted by HIV-1 to evade immune surveillance. In addition, prior analysis of 
pathways implicated in Nef-dependent MHC-I downregulation have primarily relied on 
the co-localization of Nef or MHC-I with markers of the membrane trafficking apparatus 
without analyzing Nef and MHC-I in complex, which is essential for Nef’s ability to 
downregulate MHC-I (14, 15). Importantly, the various compartments implicated in the 
trafficking of receptors such as MHC-I play distinct functional roles within the 
endosomal trafficking system (2). Vesicles, such as early and late endosomes, are often 
implicated in the movement of cargo from the plasma membrane to distinct subcellular 
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locations (16, 17). Moreover, late endosomes can also facilitate trafficking of cargo to 
degradative lysosomal compartments (18). In parallel, recycling endosomes will 
continuously deplete proteins from the cell surface and return them to this location (19).   
Fortunately the identity of the various intracellular compartments that comprise the 
endosomal trafficking system can be distinguished by specific effector molecules that 
coat the cytosolic face of these vesicles (20). 
We have previously localized interactions at the subcellular level between Nef and 
membrane trafficking regulators PACS-1 and PACS-2 using bimolecular fluorescence 
complementation (BiFC) (2). This technique is used to study protein-protein interactions 
within cells and involves the reconstitution of a visible fluorophore from split fluorescent 
molecules expressed as fusion proteins on two distinct putative protein binding partners 
(21-23). BiFC has enabled us and others to identify locations inside the cell where Nef 
can interact with itself or cytosolic binding partners, such as the trafficking regulator 
sorting nexin 18 (SNX18) (23-25).  
In the current report, we sought to determine the trafficking route undertaken by MHC-I 
in complex with Nef, and determine the role of PACS-1 in the subversion of MHC-I, in 
order to determine the fate of MHC-I in Nef-expressing cells. Using BiFC, we 
demonstrate that the Nef:MHC-I interaction is dependent on key residues in the 
cytoplasmic tail of MHC-I and we localize the Nef:MHC-I interaction within cells. 
Specifically, we show that Nef interacts with MHC-I in both early and late endosomes, 
and at the TGN, but that the Nef:MHC-I interaction is not detectable in lysosomes. 
Interestingly, we show that Nef depletes the amount of MHC-I in Rab11-positive 
recycling endosomes, and that a functional early endosomal compartment is required for 
Nef-dependent MHC-I downregulation. This Nef-mediated rerouting eventually 
sequesters MHC-I at the TGN, which is dependent on presence of PACS-1 and AP-1. 
Taken together, these results, demonstrate for the first time, the specific endocytic 
compartments utilized by Nef to orchestrate MHC-I downregulation and support a model 




3.2.1 Bimolecular fluorescence complementation microscopy 
detects a Nef:MHC-I complex in cells 
The immunoevasive capabilities of HIV-1 are largely mediated by the ability of Nef to 
remove MHC-I from the cell surface (26). The crystal structure of a Nef:MHC-I complex 
revealed that this interaction is stabilized by AP-1, demonstrating that Nef, MHC-I and 
AP-1 are able to form a ternary complex (26). To validate the Nef:MHC-I interaction in 
cells, we performed a bimolecular fluorescence complementation (BiFC) assay. BiFC 
entails the expression of a split Venus fluorophore from two distinct plasmids in the form 
of fusion proteins, and results in a reconstituted, functional Venus fluorophore when the 
two fusion proteins are within 100 nm (22). Co-transfection of HeLa cells with plasmids 
encoding Nef-VC and MHC-I-VN-Flag, more specifically Nef and MHC-I fused to 
carboxy (VC) or amino (VN) fragments of Venus, respectively, revealed that Nef and 
MHC-I form a complex (Fig. 3.1A). In order to test for the requirement of AP-1 in the 
formation of the Nef:MHC-I complex in cells, we tested Nef:MHC-I BiFC with MHC-I 
encoding mutations in residues previously implicated in interacting with AP-1 when 
MHC-I is in complex with Nef (MHC-I Y320 or D327). Co-transfection of plasmids 
encoding MHC-I Y320A-VN or MHC-I D327N-VN and Nef-VC into HeLa cells revealed a 
decrease in the BiFC signal relative to wild type MHC-I (Fig. 3.1A), as measured by 
Venus mean fluorescence intensity in cells expressing both Nef and Flag tagged MHC-I 
(Fig. 3.1B). Similarly, co-expression of Nef-VC and a MHC-I double mutant (MHC-I 
Y320A/D327N) resulted in a 2-fold reduction in BiFC signal (Fig. 3.1A and 3.1B), 
indicating that interactions between MHC-I and AP-1 are critical to observe a Nef:MHC-
I BiFC signal, supporting the formation of a Nef:MHC-I:AP-1 ternary complex in cells. 
Importantly, the reductions in BiFC signal with the various MHC-I mutants were not due 
to differences in protein expression, as revealed by Western blot analysis (Fig. 3.1C). 
Furthermore, we demonstrate that the fusion of VN or VC to MHC-I or Nef respectively, 
did not alter protein function with respect to downregulation, as we previously 
demonstrated (24). Specifically, wildtype MHC-I-VN is downregulated by Nef (Fig. 3.2), 
unlike the double mutant (Y320A/D327N) (Fig. 3.2). Similarly, Nef-VC is able to efficiently 
downregulate cell surface MHC-I (Fig. 3.2). 
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Figure 3.1 Bimolecular fluorescence complementation is observed between Nef and 
MHC-I.  
(A) Left: Schematic representation of the BiFC reporter system. Right: Nef-VC and either 
wildtype MHC-I-VN-Flag or the indicated mutants were transfected into HeLa cells, 24 
hrs later cells were fixed, and BiFC fluorescence (green) was observed under the FITC 
channel. Scale bars represent 20μm. (B) Fluorescence intensities of Nef and MHC-I-VN-
Flag positive cells were quantified in ImageJ, minus the background signal, to observe a 
decrease in fluorescence in the presence of the MHC-I mutations (n = 100, * indicates p-
value < 0.05, ** indicates p-value < .01). (C) Flag and GFP specific Western blots were 
conducted to ensure equal expression of both the MHC-I-VN-Flag mutants and Nef-VC, 




























































































Figure 3.2: Functionality of MHC-I and Nef fusion proteins.  
(A and B) MHC-I-VN-Flag or MHC-I-Y320AD327N-VN-Flag and Nef-eGFP (blue line) or 
eGFP (red line) were co-transfected in HeLa cells and surface stained with BB7.2 (HLA-
A2 specific antibody) and surface levels of MHC-I were quantified by flow cytometry 
upon gating on eGFP positive cells. (C) Nef-VC or empty backbone (pcDNA3.1) and 
eGFP were co-transfected and surface stained with W6/32 MHC-I antibody and surface 
levels of MHC-I were quantified by flow cytometry after upon on GFP positive cells. 

















































































3.2.2 Nef targets recycling MHC-I prior to transit through a Rab11 
compartment  
An obligate step in cellular homeostasis involves the rapid recycling of MHC-I to and 
from the cell surface in Rab11-positive recycling endosomes (27). We first tested if Nef 
disrupts this rapid recycling step. To test this, we co-transfected HeLa cells with plasmids 
encoding MHC-I-eGFP and Rab11a-dsRed (Fig. 3.3A; panel 2), which labels recycling 
endosomes (28). We then compared this to cells expressing Nef:MHC-I BiFC and 
Rab11-dsRed, in order to focus specifically on the MHC-I molecules that are targeted by 
Nef (Fig. 3.3A: panel 1). Pearson’s correlation analysis revealed that there was ~1.6 fold 
less co-localization between Rab11-dsRed and Nef:MHC-I BiFC than between Rab11-
dsRed and MHC-I-eGFP, suggesting that Nef targets MHC-I prior to MHC-I entering a 
Rab11 dependent recycling route. Furthermore, an antibody uptake experiment confirmed 
that the majority of MHC-I that is being targeted by Nef originates from the cell surface 
(Fig. 3.3C), as the Nef-MHC-I BiFC signal originating from Nef-VC and MHC-I-VN-Flag 













Figure 3.3: Nef prevents MHC-I from entering into a Rab11 dependent recycling 
route. 
(A) Nef-VC and MHC-I-VN-Flag (panel 1) MHC-I-eGFP (panel 2) and dsRed-Rab11 
were co-transfected into HeLa cells. 24hrs post transfection, cells were fixed and 
mounted onto coverslips. GFP and BiFC fluorescence was observed under the FITC 
channel, and dsRed-Rab11a was observed under the Cy3 channel. (B) Co-localization 
was quantified by using the Pearson’s correlation through the JaCoP Plug-in on ImageJ. 
(C) MHC-I (BB7.2) uptake experiments were performed as described in the materials and 
methods. BiFC signal is visualized in green, and MHC-I uptake was pseudocolored in 





























































































bars), and Pearson’s correlation (right axis and grey bars) were determined using the 
Mander’s and Pearson’s correlation respectively through the JaCoP Plug-in on ImageJ. 
Error bars were calculated by quantification of at least 50 cells between 3 independent 
experiments. (** Indicates p-value < 0.01, *** indicates p-value < 0.001).  
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3.2.3 Nef interacts with MHC-I within an early endosomal 
compartment 
Since Nef reroutes cell surface MHC-I away from recycling endosomes (Fig. 3.3A and 
B), we next tested if a Nef:MHC-I complex would be located in early endosomes. Early 
endosomes constitute the initial compartment implicated in the endocytosis and sorting of 
cell surface cargo (17, 29). We co-transfected HeLa cells with plasmids encoding Nef-
VC, MHC-I-VN-Flag and the early endosomal effector molecule mCherry-Rab5. 
Fluorescence microscopy analysis revealed that the Nef:MHC-I interaction co-localized 
with mCherry-Rab5, suggesting that the complex is present in early endosomes (Fig. 
3.4A; Pearson’s = 0.612). Furthermore, in order to confirm that the Nef:MHC-I complex 
localizes to early endosomes, we co-expressed a constitutively active mCherry-tagged 
Rab5 molecule (mCherry-Rab5-CA; mCherry-Rab5 Q67L) with Nef-VC and MHC-I-VN-
Flag. Expression of Rab5-CA has previously been associated with a build-up of cargo 
molecules in early endosomes resulting in their subsequent enlargement (30). Rab5-CA 
expression modified the co-localization of the Nef:MHC-I BiFC signal, wherein the BiFC 
signal was more prominent within Rab5 positive early endosomes (Pearson’s = 0.89), 
confirming that these vesicles are indeed a transiting point for Nef:MHC-I complexes 
(Fig. 3.4A and B). Furthermore, expression of Rab5-CA reduced Nef’s ability to 
downregulate MHC-I, demonstrating that a functional early endosomal compartment 
through which Nef-MHC-I complexes can transit is required for optimal downregulation 





Figure 3.4: Nef:MHC-I interaction occurs within Rab5-positive early endosomes. 
(A) HeLa cells were co-transfected with plasmids encoding Nef-VC, MHC-I-VN-Flag and the 
indicated mCherry-tagged Rab5 constructs (wildtype and constitutively active (CA)). Twenty-
four hours post transfection cells were fixed and mounted with DAPI Fluoromount-G. BiFC 
fluorescence (green) was detected under the FITC channel, while the mCherry-tagged Rab5 


















































































































channel (scale bars represent 10μm). (B) Co-localization of Nef:MHC-I BiFC with the mCherry 
tagged Rab5 constructs was quantified by the Pearson’s correlation through the JaCoP Plug-in on 
ImageJ. Error bars were calculated by quantification of at least 25 cells between 3 independent 
experiments (* Indicates p-value < 0.05). Western blot analysis for mCherry to confirm 
expression levels of Rab5 and Rab5-CA, with actin as a loading control. (C) Cells were 
transfected with Nef-VC and MHC-I-VN-Flag and immunostained for Rab5 and subsequently 
imaged utilizing ground state depletion microscopy (GSDM). (D) A histogram plotting the 
intermolecular distances between the nearest neighbor, representing either BiFC:Rab5 (Solid line) 
or BiFC:Simulated random positions (Sim. Positions; Dashed line). (E) A graphical 
representation of the fraction of co-localized particles observed in (D) which were observed to be 
under the cut-off value of ~40nm. Error bars were calculated by quantification of 10 cells in 3 























Figure 3.5: Disruption of early endosomal regulation interferes with Nef-mediated 
MHC-I downregulation.  
HeLa cells were co-transfected with mCherry-tagged Rab5-constitutively active (CA) or Rab5 
and Nef-eGFP or empty eGFP encoding backbone. Twenty-four hours post transfection, cell 
surface levels of MHC-I were measured by flow cytometry by gating on GFP and mCherry 
positive cells. Downregulation efficiency was calculated relative to Rab5 (wt) using the following 




















































Current resolution limits of conventional widefield microscopy do not allow for the 
visualization of discrete vesicular structures. To determine whether the Nef:MHC-I 
complex is contained within Rab5 early endosomes, we imaged the Rab5-dependent 
sorting step using the super-resolution microscopy technique of ground-state depletion 
microscopy (GSDM). This technique allows for visualization of cellular compartments 
with a resolution 10X greater than conventional microscopy (31). To visualize early 
endosomes by GSDM, HeLa cells were transfected with the BiFC plasmids (Nef-VC and 
MHC-I-VN-Flag), and immunostained for Rab5. The 10.25 fold gain in resolution 
provided by GSDM allowed for the detection of single Nef:MHC-I positive vesicles 
coated with the early endosomal effector Rab5 (Fig. 3.4C). Quantification of the 
association between Nef:MHC-I and Rab5 using the spatial association algorithm (SAA), 
which calculates the distance between punctate structures of different acquisition 
channels to determine if they are co-localizing together (32). The SAA analysis revealed 
that the association of the Nef:MHC-I BiFC complex with Rab5 is significantly greater 
than that of randomly simulated positions in either acquisition channel (Fig. 3.4D and E). 
Taken together, multiple imaging techniques have demonstrated the close association of 
the Nef:MHC-I complex with early endosomes suggesting that this organelle plays a key 
role in the immunoevasive capabilities of HIV-1. 
3.2.4 Nef traffics MHC-I to a late endosomal compartment  
Early endosomes mature to form late endosomes within the endocytic network (16). In 
order to test if the Nef:MHC-I complex is present in late endosomes we visualized the 
Nef:MHC-I BiFC signal in the presence of the late endosomal marker Rab7, an effector 
molecule specifically loaded onto late endosomes (33). HeLa cells expressing Nef-VC 
and MHC-I-VN-Flag were co-transfected with a plasmid encoding mCherry tagged wild 
type Rab7 (mCherry-Rab7). We observed that the Nef:MHC-I interaction occurs in late 
endosomes that are positive for mCherry-Rab7 (Fig. 3.6A).  To further control for the 
Rab7 localization of Nef and MHC-I we utilized dominant-negative mCherry-tagged 
Rab7 (mCherry-Rab7-DN; Rab7 T22N). Previous expression of Rab7-DN has resulted in 
defects in trafficking of cargo transiting through late endosomes (34). When testing the 
co-localization of the Nef:MHC-I BiFC with overexpressed mCherry-Rab7-DN, we 
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observed no significant difference in colocalization between the wildtype and dominant-
negative Rab7 (Fig. 3.6A and B). To confirm the late endosomal localization of the 
Nef:MHC-I complex, we utilized ground-state depletion super-resolution microscopy to 
gain the resolution needed to identify Rab7-positive vesicles containing the Nef:MHC-I 
complex (Fig. 3.6C). We observed that the Nef:MHC-I complex associated closely with 
Rab7. The SAA analysis revealed that the association of the Nef:MHC-I BiFC complex 
with Rab7 is significantly greater than that of randomly simulated positions in either 
acquisition channel (Fig. 3.6D and E). Taken together, these data demonstrate the 
localization of the Nef:MHC-I complex within Rab7 positive late endosomes, thereby 
implicating  the late endosome in the re-routing of MHC-I away from the plasma 
membrane.  
3.2.5 Nef and MHC-I are not trafficked to the lysosome, but traffic 
to the trans-Golgi network 
Consistent with the maturation of certain late endosomes to lysosomes (29), we next 
tested if the Nef:MHC-I complex is present in lysosomes. HeLa cells overexpressing 
Nef-VC and MHC-I-VN-Flag were immunostained with an antibody recognizing LAMP-
1, a marker of lysosomes (35) (Fig. 3.7A; panel 1). Immunofluorescence analysis 
revealed no significant co-localization of the Nef-MHC-I complex with lysosomes 
(Pearson’s = 0.15), suggesting that the complex does not traffic through this 
compartment. As lysosomes are a prime site of proteolytic degradation (36, 37), we 
sought to control for any degradation of Nef:MHC-I complexes that may occur within 
lysosomes and thereby mask our ability to detect these complexes within this 
compartment prior to imaging. Accordingly, HeLa cells were treated with ammonium 
chloride (NH4Cl) at 20 hours post transfection for 4 hours, which will block lysosomal 
degradation by increasing the cellular pH and thereby inactivating protease activity 
within lysosomes (Fig. 3.7A; panel 2)(37). Despite increasing the cellular pH, we were 
unable to visualize the presence of the Nef:MHC-I complex within LAMP-1 positive 
lysosomes. In order to confirm that our NH4Cl treatment was sufficient to block 
lysosomal acidification we treated cells with Lysotracker, an agent retained in acidic 
compartments or we treated cells with complete media. Fluorescence intensity analysis 
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revealed that Lysotracker dye fluorescence intensity was decreased, and not retained 
within distinct vesicular structures in the presence of NH4Cl, confirming that our NH4Cl 







Figure 3.6: Nef:MHC-I interaction occurs within Rab7-positive late endosomes. 
(A) HeLa cells were co-transfected with Nef-VC and MHC-I-VN-Flag encoding 
















































































































mCherry-Rab7 (mCherry-Rab7-DN). BiFC fluorescence (green) was visualized under the 
FITC channel, mCherry-Rab7 (red) was detected under the Cy3 channel. Nuclei were 
stained with DAPI (scale bars represent 10μm). (B) Co-localization was quantified by 
using the Pearson’s correlation through the JaCoP Plug-in on ImageJ. Error bars were 
calculated by quantification of at least 40 cells between 3 independent experiments. 
Western blot analysis for mCherry to confirm expression levels of Rab7 and Rab7-DN, 
with actin as a loading control. (C) Cells were transfected with Nef-VC and MHC-I-VN-
Flag and immunostained for Rab7 and subsequently imaged utilizing ground state 
depletion microscopy (GSDM). (D) A histogram plotting the intermolecular distances 
between the nearest neighbor, representing either BiFC:Rab7 (Solid line) or 
BiFC:Simulated random positions (Sim. Positions; Dashed line). (E) A graphical 
representation of the fraction of co-localized particles observed in (D) which were 
observed to be under the cut-off value of ~40nm. Error bars were calculated by 
quantification at least 10 cells in 3 independent experiments (** indicates p-value < .01, 





In order to test the functional consequence of the Nef:MHC-I complex trafficking 
through early and late endosomes, we designed a lentiviral vector that expressed Flag-
tagged MHC-I simultaneously with HIV-1 viral proteins (Fig. 3.7E). This vector system, 
which we have previously described (24), utilizes the self-cleaving property of the 2A 
peptide (F2A) from the foot and mouth virus to express MHC-I that is not linked to HIV-
1 Gag/Pol. The infection of SupT1 cells with pNL4-3 F2A-MHC-I-Flag Nef and 
subsequent Western blotting demonstrated that the presence of Nef does not alter the 
protein expression levels of MHC-I, confirming that Nef does not direct MHC-I to 
degradative lysosomal compartment, consistent with previous experiments (Fig. 3.7E)(7, 
24). Conversely, infection of SupT1 cells with a virus that overexpresses the CD4 
receptor, pNL4-3 F2A-CD4-Flag ΔVpu Nef demonstrated that Nef is capable of reducing 
total cellular CD4 (Fig. 3.7E), which is consistent with previous reports of Nef-mediated 
degradation of CD4 (38).  Thus, the functional consequence of Nef on MHC-I and CD4 
expression is different. In addition, to confirm that Nef expression was not sufficient to 
traffic MHC-I to lysosomes, we expressed MHC-I-eGFP and Nef-mCherry under non-
BiFC conditions and found no significant localization of MHC-I-eGFP with the LAMP-1 
lysosomal marker in the presence of Nef, with or without ammonium chloride treatment 
















Figure 3.7: Nef:MHC-I interaction does not occur in lysosomes. 
(A) HeLa cells were co-transfected with Nef-VC and MHC-I-VN-Flag constructs and 
immunostained for LAMP-1 (Panel 1), or, treated with 100mM ammonium chloride 
(NH4Cl) for 3 hours prior to fixation and staining (Panel 2). BiFC fluorescence (green) 
was visualized under the FITC channel, whereas LAMP-1 stain was visualized under the 
Cy5 filter settings, and pseudo-colored red. Nuclei were stained with DAPI, and scale 
bars represent 10μm. (B) Co-localization was quantified by the Pearson’s Correlation 
through the JaCoP Plug-in on ImageJ. Error bars were calculated by quantification of at 
















































































































PBS, or 100mM of ammonium chloride for 3 hours, and then treated with 10μM 
Lysotracker Deep Red for 5 minutes. Live cells were then imaged at 37°C in 5% CO2 
and quantified for Lystotracker fluorescence. Error bars were calculated by quantification 
of at least 25 cells between 3 independent experiments. (** Indicates p-value < 0.01). (E) 
Sup-T1 cells were infected with F2A MHC-I-Flag-Nef/ΔNef or F2A-CD4-Flag-ΔVpu-
Nef/ΔNef viruses. 48 hours post infection, cells were lysed and analyzed by Western blot. 
Anti-Flag detected total MHC-I-Flag and CD4-Flag, whereas anti-Nef antibody marked 
the presence or absence of Nef. Anti-p24 and anti-actin antibodies were used as infection 
and loading controls, respectively. A representative Western blot from 3 independent 









Figure 3.8: Lysosomal localization of MHC-I-eGFP  
(A) HeLa cells were transfected with MHC-I-eGFP (green) and Nef-mCherry (red). 
Twenty hours post transfection cells were treated with 100mM ammonium chloride for 4 
hours. Following treatment, cells were fixed and immunostained for LAMP-1 (magenta). 
(B) HeLa cells were transfected with MHC-I-eGFP (green) and mCherry backbone (red). 
20 hours post transfection, cells were treated with 100mM Ammonium chloride for 4 
hours. Following treatment, cells were fixed and immunostained for LAMP-1 (magenta). 
(C) Co-localization of MHC-I and LAMP-1 were quantified by the Pearson’s correlation 
through the JaCoP Plug-in on ImageJ. Error bars were calculated by quantification of at 






Since the Nef-MHC-I complex did not traffic to lysosomes we sought to identify an 
alternative subcellular localization for the complex. Previous studies have demonstrated 
that MHC-I is re-routed by Nef to a paranuclear compartment (39). In order to visualize 
this compartment relative to the Nef:MHC-I complex, we counterstained HeLa cells co-
expressing Nef-VC and MHC-I-VN-Flag with a marker of the TGN, TGN46 (40)(Fig. 
3.9). A high degree of co-localization was observed between the Nef:MHC-I complex 
and TGN46 (Fig. 3.9; Pearson’s = 0.60) suggesting that the Nef:MHC-I complex traffics 
to the TGN (40). However, our previous work demonstrated that Nef localizes to an 
uncharacterized Golgi-proximal compartment that cannot be resolved from the TGN in 
conventional images (32, 40). As such, GSDM imaging was performed to map the 
localization of the Nef:MHC-I complexes with high precision. HeLa cells transfected 
with Nef-VC and MHC-I-VN and immunostained for the TGN marker TGN46 
demonstrated the close association of the Nef:MHC-I complex with TGN46 in both the 
epifluorescence image, and the super-resolution image (Fig. 3.9). Quantification of this 
complex demonstrated a significant increase in the association between the BiFC signal 
of the Nef:MHC-I complex with TGN46 compared to randomized images, confirming 




Figure 3.9: Nef targets MHC-I for sequestration within the trans-Golgi network.  
(A) Nef-VC and MHC-I-VN-Flag were transfected into HeLa cells, and 24 hours later 
fixed and immunostained for TGN46. BiFC fluorescence (green) was observed under the 
FITC channel, and TGN46 (red) was observed under the Far-Red filters. (B) Co-


























































































on ImageJ. Error bars were calculated by quantification of at least 25 cells between 3 
independent experiments. (* Indicates p-value < 0.05). (C) Cells were prepared as in (A) 
and imaged utilizing GSDM; scale bars represent 500nm. (D) A histogram plotting the 
distance between the nearest neighbor, representing BiFC:TGN46 (Solid line) or 
BiFC:Simulated random positions (Sim. Positions; Dashed line). (E) A graphical 
representation of the fraction of co-localized particles observed in (D) which were 
observed to be under the cut-off value of ~40nm. Error bars were calculated by 
quantification of 8 cells in 2 independent experiments (** indicates p-value < .01, *** 






3.2.6 PACS-1 recruitment by Nef alters the intracellular 
localization of the Nef:MHC-I complex 
Nef-mediated MHC-I downregulation relies on its interaction with multiple membrane 
trafficking regulators. The phosphofurin acidic cluster sorting protein – 1 has been 
identified as an important binding partner of Nef. Early studies have demonstrated the 
importance of the Nef:PACS-1 interaction in the downregulation of MHC-1 (12, 39, 41), 
however, the direct impact on the distribution of MHC-I when PACS-1 fails to interact 
with Nef is currently unknown. To determine the role of PACS-1 in the localization of 
the Nef:MHC-I complex, a mutant Nef construct was produced with the E62EEE65 acidic 
motif mutated to 4 sequential alanine residues. This mutant has previously been shown to 
not interact with PACS-1 (Nef (E4A)) (39).  HeLa cells were co-transfected with 
plasmids encoding Nef-Vc (Fig. 3.10A, B, C, D) or Nef (E4A)-Vc (Fig 3-10E, F, G, H) 
and MHC-I-Vn-FLAG,  and co-transfected with plasmids encoding mCherry-tagged 
Rab5 (Fig. 3.10A, E) or Rab7 (Fig 3-10B, F), or immunostained for LAMP-1 (Fig 3.10C, 
G) or TGN (Fig. 3.10D, H). Pearson’s coefficients were calculated using the JaCoP Plug-
in from ImageJ between the BiFC signals and different intracellular compartments. 
Interestingly, upon mutation of the Nef acidic cluster, we observed a significant 30% 
increase in the co-localization of Nef (E4A):MHC-I BiFC to Rab5 positive endosomes, 
respectively (Fig. 3.10I). Additionally, we observed a 38% decrease in the ability of the 
Nef-E4A mutant to localize to a TGN46-positive TGN compartment. Consistent with the 
previous results (Fig. 3.9), no significant difference was observed in the co-localization 
of wildtype or mutant BiFC signal to LAMP-1-positive lysosomes (Fig. 3.10L). These 
results suggest that PACS-1 promotes the sequestration of the Nef:MHC-I complex to the 
TGN by depleting the pool of the Nef:MHC-I complex residing in peripheral Rab5- and 




Figure 3.10: The Nef acidic cluster mutant alters the intracellular localization of the 
Nef:MHC-I complex.  
(A-D) HeLa cells were co-transfected with plasmids expressing Nef-Vc and MHC-I-VN-
FLAG. (E-H) HeLa cells were co-transfected with plasmids expressing Nef (E4A)-VC 
and MHC-I-VN-FLAG. In addition to the specified BiFC constructs, HeLa cells were co-
transfected with plasmids expressing the early endosomal marker Rab5 (A, E), or the late 
endosomal marker Rab7 (B, F), or immunostained for the TGN marker TGN46 (C, G) or 
immunostained for the lysosomal marker LAMP-1 (D, H). BiFC fluorescence (green) 
was observed under the FITC channel, mCherry-tagged constructs were visualized under 
Cy3 filters, and TGN46/LAMP-1 staing (red) was observed under the Far-Red filters. 
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Co-localization of BiFC fluorescence to each sub-cellular compartment was quantified 
using Pearson’s coefficient calculated by the JaCoP Plug-in on ImageJ. Error bars were 
calculated using at least 30 cells between 3 independent experiments. (*Indicates p-value 






3.2.7 Adaptor Protein -1 recruitment is enhanced by the Nef acidic 
cluster 
The movement of cargo between endosomes and the TGN relies on the ability of PACS-1 
to act as a connector molecule to recruit AP-1 to the cytoplasmic tail of itinerant cargo 
(12). Previous in vitro crystal structure studies revealed that MHC-I lacks the classical 
Yxxθ AP-1 interaction motif, however, Nef interacts with the cytoplasmic tail of MHC-I 
to provide enhanced binding of AP-1 to the complex (26). Due to the role of PACS-1 in 
connecting cargo molecules to adaptor proteins, we hypothesized that the PACS-1:Nef 
interaction promotes AP-1 recruitment to the complex. To test the role of PACS-1 in the 
recruitment of AP-1 to the Nef:MHC-I complex, we examined the colocalization of AP-1 
to either the wildtype Nef;MHC-I complex, or the mutant Nef(E4A):MHC-I BiFC 
complex. Accordingly, HeLa cells were co-transfected with plasmids expressing Nef-Vc 
or Nef(E4A)-Vc and MHC-I-VN-FLAG. Twenty-four hours post-transfection, cells were 
fixed, immunostained for the g subunit of AP-1 (Fig. 3.11A). Consistent with previous 
findings (Fig. 2.8), AP-1 had a high degree of co-localization with the wild-type 
Nef:MHC-I interaction (Fig. 3.11B; Pearson’s = 0.715). Conversely, abolishing the 
Nef:PACS-1 interaction through the Nef acidic cluster mutation resulted in a significant 
reduction in AP-1 co-localization with the Nef:MHC-I complex (Fig. 3.11B; Pearson’s = 
.470; ). As a negative control, we assessed the ability of the wildtype or mutant BiFC 
complexes to localize to AP-2. AP-2 is a related, clathrin adaptor, and functions by 
downregulating CD4 by forming a ternary complex with Nef and CD4 (Fig 3.11C, 
D)(42). AP-2 co-localization did not significantly differ between Nef:MHC-I BiFC and 
Nef (E4A):MHC-I BiFC (Fig. 3.11D; Pearson’s = 0.173 and Pearson’s = 0.140, 
respectively). Overall, this supports a role for Nef’s E62EEE65 acidic motif, in the 
recruitment of AP-1 to the Nef:MHC-I complex. 
To confirm the role of PACS-1 recruitment by the E62EEE65 acidic motif in Nef on the 
co-localization of the host trafficking molecule AP-1 to the Nef:MHC-I complex, BiFC 
was also analyzed using super resolution ground state depletion microscopy (GSDM). 
HeLa cells were co-transfected with Nef-VC and MHC-I-VN-FLAG (Fig. 3.12Α). In 
parallel, HeLa cells were co-transfected with Nef (E4A)-VC and MHC-VN-FLAG (Fig. 
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3.12Β). All cells were subsequently fixed and immunostained 24 hours post-transfections 
for the g subunit of AP-1. Consistent with results represented in Figure 3.11, AP-1 and 
Nef:MHC-I BiFC were localized to discrete vesicles (Fig. 3.11A), whereas, 
Nef(E4A):MHC-I BiFC and AP-1 did not closely associate (Fig. 3.12B). To define their 
association to each other, distances between Nef:MHC-I complexes and the stained 
adapter proteins were quantified using spatial association analysis (43). We observed that 
a significantly greater fraction of co-localized particles were present with the wildtype 
Nef:MHC-I BiFC, compared to the mutant interaction (Fig. 3.12C). Additionally, we 
determined that AP-1 was, on average, at a 2-fold greater distance away from the 
Nef(E4A):MHC-I BiFC complex than the wildtype (Fig. 3.12D; 75 nm and 35 nm, 
respectively), reinforcing our previous finding that Nef requires its interaction with 





Figure 3.11: Wide-field microscopy demonstrates that PACS-1 recruitment by Nef 
enhances the co-localization of AP-1 to the Nef:MHC-I complex.  
(A) HeLa cells were co-transfected with Nef-Vc or Nef (E4A)-VC and MHC-I-VN-
FLAG. Twenty-four hours post transfection cells were fixed and immunostained for AP-
1. (B) The co-localization between BiFC (green) and AP-1γ (red) was quantified between 
green and red signals using Pearson’s correlation calculated by the JaCoP Plug-in on 
ImageJ. (C) Similarly, HeLa cells were co-transfected with Nef-Vc or Nef (E4A)-VC and 
MHC-I-VN-FLAG, and were subsequently fixed and immunostainded for AP-2μ. (D) The 
co-localization between BiFC (green) and AP-2μ (red) was quantified between green and 
red signals using Pearson’s correlation calculated by the JaCoP Plug-in on ImageJ. All 
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cells were mounted with DAPI Fluoromount-G. BiFC fluorescent signal (green) was 
visualized using the FITC channel. Both AP-1γ and AP-2μ (red) were observed using the 
Far-Red filter. Nuclei were visualized under the DAPI channel (blue). Scale bar 
represents 10 µm. Error bars were calculated by quantification of at least 20 cells from 2 







Figure 3.12: Ground state depletion microscopy (GSDM) demonstrates that PACS-1 
recruitment by Nef enhances the localization of AP-1 to the Nef:MHC-I complex. 
(A-B) HeLa cells were co-transfected with Nef-VC or Nef (E4A)-VC and MHC-I-VN-
FLAG, and were subsequently immunostained for AP-1γ 24 hours later. Magnified insets 
are shown (right panel). BiFC fluorescent signal (green) was visualized using the 488 nm 
laser line. AP-1γ (red) was observed using a 647 nm laser line. Scale bars represent 
2.5µm. (C) A graphical representation of the fraction of co-localized particles was 
calculated between BiFC complex (green) and AP-1γ using the nearest-neighbour 
algorithm in the MIiSR software as previously described (28). (D) A graphical 
representation of the mean separation distance between the BiFC complex (green) and 
AP-1γ (red). Error bars were calculated by quantification of 5 cells between 2 
independent experiments. All images were validated by comparing the observed degree 
of colocalization to that observed in 10 images containing the same number of particles 










































































3.2.8 PACS-1 directly facilitates localization of MHC-I to the trans-
Golgi Network 
To further investigate the mechanism of AP-1 recruitment to the Nef:MHC-I complex we 
conducted additional experiments to directly test the role of PACS-1. To test this, 
Nef:MHC-I BiFC fluorescence microscopy experiments were performed in conjunction 
with a dominant negative mutant of PACS-1 (ADMUT), which is unable to bind AP-1 
but can still bind to acidic clusters, and Nef (22). HeLa cells were co-transfected with 
plasmids expressing Nef-VC, MHC-I-VN-FLAG and mCherry-tagged PACS-1 or 
mCherry-tagged ADMUT. Twenty-four hours post-transfection, cells were fixed, 
immunostained for TGN46, and imaged (Fig. 3.13A). Indeed, expression of the 
Nef:MHC-I BiFC constructs with the wildtype mCherry-tagged PACS-1 exhibited a 
robust TGN localization (Fig. 3.13A). In contrast, upon expression of the dominant 
negative ADMUT, numerous BiFC-positive peripheral vesicles became apparent (Fig. 
3.13B). The co-localization between the Nef:MHC-I BiFC complex (green), and the 
TGN46 marker (magenta), were quantified in PACS-1/ADMUT-positive cells by the 
Pearson’s coefficient. We observed a modest, but significant 11% reduction in the ability 
of ADMUT expressing cell to localize the Nef:MHC-I complex to the TGN (Fig. 3.13C; 
Pearson’s = 0.562 and Pearson’s = 0.635, respectively). In parallel, the expression of 
Nef-VC, MHC-I-VN-FLAG, and PACS-1/ADMUT-mCherry constructs were confirmed 
using Western blots (Fig. 3.13D). Overall, these results demonstrate the key role of 
PACS-1 as a connector molecule to AP-1, thereby mediating the efficient trafficking of 


















Figure 3.13: PACS-1:Adaptor Protein interaction promotes TGN localization of Nef 
and MHC-I  
(A) HeLa cells were co-transfected with Nef-VC and MHC-I-VN – FLAG BiFC constructs 
along with either mCherry-tagged PACS-1 or ADMUT. Cells were fixed, and 
immunostained for the TGN marker TGN46 with AlexaFluor 647 secondary antibody, 
and mounted in Fluoromount G-DAPI mounting media. BiFC fluorescence (green), 
mCherry (red), TGN46 (magenta) and DAPI (blue) were detected using FITC, Cy3, Cy5 
and DAPI filter settings, respectively.  (B) Colocalization of the BiFC (green) and 
TGN46 (magenta) were calculated using the Pearson’s coefficient using the JaCOP 
plugin in ImageJ. Error bars were calculated based on at least 20 cells from 2 independent 
experiments (* indicates p < 0.05). (C) In parallel, western blots were conducted to 




















































































constructs were detected using an anti-GFP antibody, mCherry-tagged PACS-1 and 
ADMUT constructs were detected using an mCherry specific western blot, and an actin 
specific western blot was used as a loading control. Untransfected cells were used as a 







In the present study, we have tracked a complex between the HIV-1 protein Nef and 
MHC-I within the endosomal network. Our results demonstrate that a Nef:MHC-I 
complex traffics to both early and late endosomes in addition to the paranuclear TGN 
compartment. Furthermore, Nef impedes MHC-I from recycling to the cell surface by re-
routing MHC-I through both early endosomes and late endosomes and subsequently to 
the TGN. Additionally, we provide evidence supporting the role of PACS-1in facilitating 
the endosome-to-Golgi trafficking step of the Nef:MHC-I complex. Overall, this 
mechanism inhibits MHC-I molecules from presenting antigens extracellularly, 
contributing to the ability of HIV-1 to evade host immune surveillance (14).  
Nef has the capability to disrupt the normal membrane trafficking events that occur 
within cells. Indeed, Nef downregulates the cell surface expression of over 36 surface 
receptors (44). Interestingly, there is some degree of specificity within this seemingly 
non-discriminatory razing of the cell surface topography. This specificity lies within the 
host membrane adaptor molecules that are used by Nef to internalize specific receptors. 
For example, the membrane adaptor molecule AP-1 interacts with MHC-I and is 
implicated in the Nef-dependent internalization of MHC-I (8). Conversely, the related 
membrane adaptor molecule, AP-2, is critical for the Nef-dependent internalization of 
CD4 (45). Overall, these adaptor molecules are indispensable for the ability of Nef to 
bind and downregulate MHC-I and CD4 receptors. Structural studies have revealed that 
the cytoplasmic tails of MHC-I and CD4 mediate this specificity with adaptor 
molecules(10). Specifically, AP-1 recognizes the Yxxθ motif (where θ represents a bulky 
hydrophobic residue) in the MHC-I cytoplasmic tail, as demonstrated by the complex 
crystal structure between Nef:MHC-I and the mu-1 subunit of AP-1 (10). In contrast, 
structural modeling of the CD4 cytoplasmic tail has implicated the canonical di-leucine 
motif of CD4 to be necessary for its downregulation by Nef (42). In this study, residues 
Y320 and D327 in the MHC-I cytoplasmic tail were deemed critical to maintain the 
Nef:MHC-I complex in cells (Fig. 3.1). As these residues were implicated in interacting 
with both AP-1 and Nef within crystal structures, this supports the formation of a 
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Nef:MHC-1:AP-1 ternary complex within cells, in agreement with previous studies 
utilizing co-immunoprecipiation (8, 46). 
Functionally, the differences in Nef dependent internalization of CD4 and MHC-I are 
linked to the distinction that AP-2 dependent trafficking is linked to degradative 
compartments whereas AP-1 dependent trafficking is not (7, 45, 47). We confirmed this 
assertion as Nef and MHC-I complexes were not directed to degradative compartments 
(Fig. 3.7A) and MHC-I was not degraded (Fig. 3.7E), whereas Nef mediated the 
degradation of CD4 as previously described (Fig. 3.7E and (45)). 
BiFC is a powerful technique that demonstrates the interaction or close proximity of two 
proteins within a cell. Previously, BiFC was used to illustrate the interaction between Nef 
and the membrane trafficking regulator PACS proteins, PACS-1 and PACS-2, in late and 
early endosomes, respectively (2). Thus, the BiFC interaction between Nef and MHC-I 
provides a platform to study the various models of Nef-dependent MHC-I 
downregulation. Our results demonstrate that newly endocytosed MHC-I originating 
from the cell surface is targeted by Nef (Fig. 3.3C and D). Further experiments highlight 
the presence of the Nef:MHC-I complex throughout the early and late endosomes, and 
demonstrate the importance of the early endosomal effector molecule Rab5 in this 
process  (Fig. 3.4 and Fig. 3.5). As Rab5 functions to sort cargo early upon endocytosis 
(48), it is logical that the expression of Rab5-CA, which disrupts the maturation of 
endosomes (48), disrupts Nef-dependent MHC-I cell surface downregulation (49). A 
possible mechanism governing this trafficking step may rely on a ternary complex 
between Nef, MHC-I and the PACS proteins, as previously demonstrated biochemically 
for PACS-1 (2). Specifically, we highlight the role of PACS-1 in the TGN sequestration 
step of Nef and MHC-I, as when PACS-1 is unable to interact with the acidic cluster of 
Nef, MHC-I is no longer able to trafficking to the TGN (Figure 3.10)(2, 49). Such a 
trafficking defect is similar to that of an acidic cluster mutant of the cellular protease 
furin (50-52). Indeed, mutation of the furin acidic cluster results in a peripheral 
endosomal localization(50-52). PACS-1 often acts as a connector molecule between 
cytoplasmic tails of cargo and AP-1. Consistent with this, we observed that the acidic 
cluster of Nef drastically reduces the AP-1 recruitment to the complex (Figure 3.11 & 
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3.12). Additionally, over expression of a mutant PACS-1 unable to interact with AP-1 
also reduced the ability for the Nef:MHC-I complex to transit to the Golgi from 
peripheral endosomes. Interestingly, expression of the Nef (E4A):MHC-I complex was 
still visible despite the reduced recruitment of AP-1 complex, which was inconsistent 
with the mutational analysis of the MHC-I cytoplasmic tail aimed to disrupt the 
interaction between Nef, MHC-I, and AP-1. This suggests that different protein 
complexes may be required at different endosomal locations to ensure MHC-I 
downregulation. Overall, these results highlight the importance of different motifs 
involved in the recruitment of AP-1 to the cytoplasmic tail of MHC-I. Indeed, different 
motifs may be required within different locals of the cell.  
Interestingly, our results are directly linked to the signaling model of Nef-dependent 
MHC-I downregulation (7), which is dependent on the PACS protein dependent 
endocytosis of MHC-I from the cell surface and not a block of MHC-I trafficking from 
the endoplasmic reticulum to plasma membrane which is linked to the Nef-dependent 
degradation of MHC-I in lysosomes (53). We failed to observe the localization of the 
Nef:MHC-I complex in lysosomes even upon rendering these compartments more basic 
(Fig. 3.7A, B and C), suggesting that our experiments closely mimicked early time points 
in an infection (7). This trafficking route would not result in the degradation of MHC-I, a 
phenomenon observed readily in other viral infections, such as Kaposi-sarcoma related 
herpesvirus infections, which mediates degradation of MHC-I by the K3 and K5 proteins 
(54). Instead, the Nef:MHC-I complex was routed from Rab5 positive early endosomes to 
Rab7 positive late endosomes and the TGN and these interactions were observed at the 
20nm resolution offered by GSDM, unequivocally defining the subcellular route 
undertaken by MHC-I in the presence of Nef (Figs. 3.4, 3.6 and 3.9). Moreover, the 
localization of the Nef-MHC-I complex in Rab7 positive late endosomes is reminiscent 
of the Nef dependent-localization of SERINC5 within this compartment (55, 56). 
SERINC5 was recently identified as a host cellular antiretroviral factor that inhibits HIV-
1 replication (56). Thus, it appears that Rab7-positive late endosomes are used by Nef to 
block both infectivity and the CTL response. Overall, Rab7-positive late endosomes are 
compartments used by multiple viruses for various steps of the viral infectious cycle 
including entry (57, 58) and would also represent a central compartment used by Nef to 
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enable key HIV-1 functions such as the sequestration of MHC-I in an intracellular 
compartment.  
The Nef:MHC-I interaction was also observed in the TGN, consistent with the Nef and 
AP-1 dependent sequestration of MHC-I in a paranuclear compartment  (Fig. 3.9A)(39, 
49). We postulate that this compartment contains the re-routed MHC-I that has been 
pulled away by Nef from the cell surface. Previous studies by Blagoveshchenskaya et al. 
demonstrated that Nef increased the rates of endocytosed MHC-I in an Arf6 dependent 
manner (3). Herein, we demonstrate that this endocytosed MHC-I localizes to the TGN in 
complex with Nef (Fig. 3.9). Indeed, we show that MHC-I is excluded from Rab11-
positive recycling endosomes when in complex with Nef, suggesting that this represents a 
membrane trafficking junction point that differs between cells that do or do not express 
Nef (Fig. 3.3A and B). In uninfected cells, normal MHC-I recycling occurs via Rab11-
positive compartments to enable antigen cross presentation, while maintaining 
physiological MHC-I levels on the cell surface (59, 60).  
Overall, we propose a model for the Nef-dependent downregulation of cell surface MHC-
I that highlights the cellular compartments that are subverted by Nef in order to 
coordinate the removal of MHC-I away from the cell surface. Our results demonstrate 
that a Nef:MHC-I complex traffics to both early and late endosomes in addition to the 
paranuclear TGN compartment in a PACS-1and AP-1-dependent manner. Further studies 
will be aimed at determining whether the transition between early and late endosomes is 
required for MHC-I sequestration, or if sequestration of MHC-I is independent of 
endosomal maturation. This work builds on the model of Nef-mediated MHC-I 
downregulation by identifying key cellular compartments in which Nef targets MHC-I. 
Understanding how Nef targets MHC-I will lead to new insights into how viruses 
mediate immune evasion, and specifically how HIV-1 persists within the infected host. 
3.4 Methods  
3.4.1 Cells 
HeLa and HEK-293T cells (ATCC, Manassas, VA) were grown in complete DMEM 
(HyClone, Logan, UT) containing 10% fetal bovine serum (FBS) (Wisent, Montreal, 
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Canada) and 100μg/ml penicillin-streptomycin (HyClone). Sup-T1 cells were grown in 
complete RPMI (HyClone) containing 10% FBS and 10μM L-Glutamine (HyClone). All 
cell lines were grown at 37°C in the presence of 5% CO2 and sub-cultured in accordance 
with supplier’s recommendations.  
3.4.2 Plasmids 
HLA-A2 cDNA (provided by Dr. G. Thomas, University of Pittsburgh Medical School) 
was subcloned into a pcDNA 3.1 (+) plasmid encoding the N-terminal portion of the 
Venus fluorophore (VN 1-173), as previously described (24). NL4.3 nef was subcloned 
into a pVC-N1 backbone plasmid encoding the C-terminal portion of the split Venus 
fluorophore (VC 155-273) Overlap PCR mutagenesis was performed to mutate Nef 
EEEE65 to AAAA65. HLA-A2 mutants were generated using overlap extension 
polymerase chain reaction. Expression vectors encoding mCherry-Rab5, mCherry-Rab5-
DN, mCherry-Rab5-CA, mCherry-Rab7, mCherry-Rab7-DN, dsRed-Rab11a were 
provided by Dr. R. Flanagan, UWO and were previously described(30, 61). PACS-1 
cDNA was sub cloned into a pmCherry-N1 vector. Primer overlap extension PCR was 
performed to mutate PACS-1 168-175 to alanines. The MHC-I-eGFP plasmid was 
generated by subcloning the HLA-A2 gene into a peGFP-N1 (Clontech) using EcoRI and 
BamHI restriction digest enzymes. Viral vectors: pNL4.3 F2A-CD4-Flag Δvpu Nef/ΔNef 
and pNL4.3 F2A MHC-I-MHC-I-Flag Nef/ΔNef were generated by sub cloning MHC-I-
Flag and CD4-Flag into the previously described base vector pNL4.3 F2A-X-
Nef/ΔNef(24).  
3.4.3 Transfections 
For BiFC and subcellular localization studies, 2.5x105 HeLa cells were seeded onto 
coverslips and 24 hours later plasmids were transfected into cells at equal molar ratios 
using PolyJet transfection reagent (FroggaBio, Toronto, Canada). Twenty-four hours post 
transfection cells were incubated for one hour at room temperature to allow for 
fluorophore maturation, as described previously(24). Subsequently, cells were fixed in 
4% PFA and prepared for immunofluorescence as described below. 
125 
 
3.4.4 Western Blots 
For analysis of BiFC protein expression, HeLa cells were transfected with the specified 
BiFC vectors, incubated for 24 hours, washed once with phosphate buffered saline (PBS) 
and lysed in lysis buffer (0.5M HEPES, 1.25M NaCl, 1M MgCl2, 0.25M EDTA, 0.1% 
Triton X-100, 1X complete Protease inhibitor Tablets (Roche, Indianapolis, IN)). Cells 
were incubated on a rotator for 20 minutes at 4°C before removing insoluble cellular 
debris by centrifugation at 20,000xg for 20 minutes. Lysates were boiled at 98°C in 5X 
SDS-PAGE sample buffer (0.312M Tris pH 6.8, 25% 2-Mercaptoethanol, 50% glycerol, 
10% SDS) and proteins were separated on a 12% SDS-PAGE gel and subsequently 
transferred to nitrocellulose membranes. Membranes were blocked in 5% non-fat 
skimmed milk (BioShop Canada, Burlington, Canada) in TBST containing 0.1% Triton 
X-100 for 1 hour, then incubated overnight at 4°C with various antibodies: rabbit anti-
Nef polyclonal antibody (1:2000; catalog number 2949, NIH AIDS Research and 
Reference Reagent Program, USA (62), rat anti-DYKDDDK monoclonal IgG (1:2500; 
BioLegend, San Diego, CA), anti-p24 (1:800; catalog number 4121, NIH AIDS Research 
and Reference Reagent Program, USA) and anti-Actin (1:2000; Thermo Scientific). 
Membranes were then washed and incubated for two hours with the appropriate species-
specific HRP-conjugated antibodies (1:3000; Thermo Scientific). All blots were 
developed and quantified using ECL substrates (Millipore Inc., Billerica, MA) and a C-
DiGit chemiluminescence Western blot scanner (LI-COR Biosciences, Lincoln, NE). To 
test Nef’s ability to mediate MHC-I or CD4 expression, we utilized our previously 
described viral vector system(24) to express MHC-I-Flag or CD4-Flag, in the presence or 
absence of Nef. The resulting vectors: pNL4.3 F2A MHC-I-Flag Nef/ΔΝef or pNL4.3 
F2A CD4-Flag Δvpu Nef/ΔNef were used to generate pseudoviral particles as previously 
described(24). Sup-T1 cells were subsequently infected, and 48 hours post infection, cells 
were lysed and levels of MHC-I and CD4 were analyzed by Western blot as described 
above. 
3.4.5 Immunofluorescence 
For subcellular localization studies, transfections were performed as described above. 
Cells used in BiFC studies were incubated at room temperature for 1 hour prior to 
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fixation to allow the reconstituted fluorophore to mature(24). All cells were fixed by 
washing twice with PBS, incubating for 20 minutes in 4% PFA and subsequently 
washing three times in PBS. To stain for the split fluorophore halves and various 
intracellular compartments, fixed HeLa cells were incubated in permeabilization/blocking 
buffer (5% BSA in PBS and 0.2% Triton X-100) for 1 hour. Cells were then incubated 
with the appropriate antibodies diluted in blocking buffer for 2 hours (anti-Rab5 (Cell 
Signaling); 1:200, anti-Rab7 (Santa-Cruz); 1:100, anti-LAMP-1 (DSHB); 1:200, anti-
TGN46 (Sigma Aldrich); 1:200, anti-Flag (Biolegend): 1:400, anti-AP-1γ 1:100 (Sigma 
Aldrich), anti-AP-2μ (Santa-Cruz)). Cells were subsequently washed three times in 
blocking buffer and incubated with the appropriate secondary antibody diluted in 
blocking buffer (donkey anti-rabbit AlexaFluor 647 or donkey anti-mouse AlexaFluor 
647 (1:1000; Jackson ImmunoResearch)) for 2 hours at room temperature. Finally, cells 
were washed three times in PBS (3 minute each) and mounted onto glass slides using 
Fluormount-G or DAPI-fluoromount-G (Southern Biotech, Birmingham, AL). 
Fluorescence intensity of the BiFC signal was measured by selecting cells positive for 
both Nef and Flag-tagged MHC-I, then subtracting the background fluorescence using 
ImageJ(63, 64). To test the localization of MHC-I-eGFP with LAMP-1, cells were 
transfected with MHC-I-eGFP with Nef-mCherry or mCherry and immunostained as 
above. Co-localization of MHC-I-eGFP and LAMP-I was then measured in cells 
expressing either Nef-mCherry or mCherry in the presence or absence of ammonium 
chloride.  
 
3.4.6 Antibody Uptake  
HeLa cells were transfected with equal molar amounts of MHC-I-VN-Flag and Nef-VC. 
Twenty-four hours post-transfection cells were washed with ice cold PBS, and 
subsequently anti-HLA-A2 (BB7.2; Biolegend) antibody was added at a dilution of 
1:300. Antibody was allowed to bind for 20 minutes at 4°C. Following antibody binding, 
cells were washed 3X with cold PBS, and either fixed (time 0 minutes), or supplemented 
with warm complete media and incubated for 90 minutes at 37°C. Cells were then fixed, 
permeabilized, and immunostained with donkey anti-mouse AlexaFluor 647 (1:400; 
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Jackson ImmunoResearch) secondary antibody for 2 hours to detect the internalized 
antibody. Coverslips were then washed 3X in PBS and mounted using DAPI-
Fluoromount-G (Southern Biotech).  
3.4.7 Ammonium chloride treatment of cells to assess lysosomal 
trafficking 
For assessing lysosomal subcellular localization, staining was performed as described 
above with anti-human LAMP-1 1:200 (Developmental Studies Hybridoma Bank; Iowa 
City, IA). Ammonium chloride was added to a concentration of 100mM to prevent 
lysosomal acidification for 4 hours. To ensure the ammonium chloride treatment affected 
lysosomal acidification, HeLa cells treated in an equivalent manner were stained with 
Lysotracker DeepRed (10μM; Life Technologies). Live cells were then imaged, and 
mean fluorescence intensity was measured using ImageJ.  
3.4.8  Microscopy 
Cells were viewed on a Leica DMI6000 B at 63X or 100X magnification using the FITC, 
Cy3, CY5 and DAPI filter settings and imaged with a Hamamatsu Photometrics Delta 
Evolve camera. Images were subsequently deconvolved using the Advanced 
Fluorescence Deconvolution (Lecia, Wetzlar, Germany) application on the Leica 
Application Suite software. Co-localization analysis was conducted using Pearson’s 
Correlation from the ImageJ plugin JACoP, as described previously(65). 
Super-resolution imaging was performed as previously described(32). Briefly, HeLa cells 
were transfected with plasmid DNA, and 24 hours later immunostained as described 
above. Prior to imaging, cells were mounted in a depression slide containing 100mM 
cysteamine (Sigma) buffer in PBS. Coverslips were sealed with Twinsil (Picodent), and 
imaged within 4 hours of mounting. All images were acquired using a Lecia SR GSD 
microscope with the 100X/1.43 NA objective lens containing an additional 1.6X 
magnifier. Fluorophores were excited using 125mW-250mW lasers (488, 532 and 
647nm) and a 30mW backpumping 405nm laser. Channels were acquired sequentially at 
100fps for 7,000 – 15,000 frames, with minor adjustments on laser power and 
backpumping to maintain 10 to 30 active fluorophores per frame. The resulting images 
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were exported and molecule position files were converted to ASCII for analysis. 
Intermolecular interactions and localization within labeled endocytic compartments was 
quantified using spatial association analysis (SAA), performed using our custom-written 
MIiSR software(32), with datasets filtered to remove molecules detected with a precision 
of <25 nm prior to analysis. All interactions were validated by comparing the observed 
degree of interaction to that observed in 10 images containing the same number of 
particles randomly scattered in an image of equal area. 
3.4.9 Flow cytometry 
To test the functional significance of disrupting Rab5, HeLa cells were transfected with 
mCherry-tagged Rab5-CA or Rab5 (wt) constructs in conjunction with Nef-eGFP or 
empty eGFP encoding backbone. Twenty-four hours post transfection, cells were 
trypsinized, washed twice with PBS and fixed in 2% PFA for 15 minutes. Following 
fixation, cells were washed in FACS buffer (0.5% FBS and 50mM EDTA in PBS) and 
stained with W6/32 anti-MHC-I (1:4000) antibody for 30 minutes (provided by D. 
Johnson, Oregon Health and Science University). Cells were then washed twice and 
stained with donkey anti-mouse AlexaFluor 647 (1:1000) for 20 minutes, followed by 
two more washes in FACS buffer. Flow cytometry was then performed using a BD 
FACSCanto (BD Biosciences) and the geometric mean fluorescence intensity of 
AlexaFluor 647 (MHC-I) was determined for mCherry and eGFP positive cells. 
To test the functionality of the MHC-I-VN-Flag fusion proteins, we transfected HeLa 
cells with vectors encoding MHC-I-VN-Flag or MHC-I-Y320A/D327N-VN-Flag in 
combination with either Nef-eGFP or eGFP alone. Twenty-four hours post transfection 
cells, were stained with BB7.2 anti-HLA-A2 (1:4000) and donkey anti-mouse AlexaFluor 
647 (1:2000), as above, to specifically detect cell surface MHC-I fusion proteins. Cells 
were then analyzed by flow cytometry as above and geometric mean fluorescence 
intensity of AlexaFluor 647 (MHC-I) was determined for eGFP and AlexaFluor 647 
positive cells. 
To test the functionality of Nef-VC, HeLa cells were transfected with vectors encoding 
Nef-VC and eGFP as a transfection control, or a vector encoding eGFP alone. GFP 
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positive cells were subsequently analyzed for cell surface MHC-I levels by flow 
cytometry using W6/32 anti-MHC-I antibody as described above.  
3.4.10 Statistics 
All statistics were conducted using a paired T-test, or a one-way ANOVA where 
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4 PACS-1 and Adaptor Protein 1 mediate ACTH 
trafficking to the regulated secretory pathway 
4.1 Introduction 
In addition to the constitutive secretion of proteins into the extracellular milieu, endocrine 
and neuroendocrine cells also possess a specialized form of secretion termed “regulated 
secretion” (1-3). The latter pathway is a controlled cellular process that ensures the 
release of intracellular contents, such as hormones in response to the appropriate 
physiological stimuli (4). Interestingly, regulated secretion is often preceded by the 
specific targeting of unprocessed pro-hormones to a specialized subcellular storage 
organelle termed the dense core secretory granule (DCSG) (5, 6). Within DCSGs, pro-
hormones and their substrates can be processed into their active forms. Upon receiving 
the appropriate physiological stimulus, vesicles containing DCSG resident cargo fuse 
with the plasma membrane, and are secreted into the extracellular milieu (6).  
Pro-opiomelanocortin (POMC) is a pro-hormone that undergoes proteolytic cleavage to 
produce smaller active peptide hormones within DCSGs (7-9). This activity requires the 
co-targeting of both POMC, and the pro-hormone convertases (PC) family of enzymes to 
DCSGs where they mediate the conversion of POMC to its active forms ((10) and 
reviewed in (11)). The products generated upon the proteolytic processing of the POMC 
precursor in pituitary DCSGs induce drastic sympathetic and cellular responses upon 
their regulated secretion (12). Products generated from POMC cleavage by PCs include 
peptide hormones, such as α/β/γ melanotropin; which regulate skin pigmentation (13), β-
endorphin; an endogenous opioid (14), and adrenocorticotropic hormone (ACTH); a key 
mediator in hypothalamic-pituitary-adrenal signaling (12). ACTH specifically controls 
the release of additional steroid hormones and cholesterol from the adrenal glands. 
Importantly, the mis-sorting of POMC and its processing enzymes away from DCSGs 
has been associated with various disease states, such as Addison’s disease (15), 




Multiple membrane trafficking proteins have been described as playing distinct roles in 
the sorting and processing of peptide hormones, however it remains unknown if these 
proteins affect the sorting of POMC to DCSGs. A critical membrane trafficking protein 
family is the heterotetrameric clathrin adaptor proteins (APs), AP-1 and AP-3, which 
mediate key stages of DCSG formation and release (18). AP-1 is critical in selectively 
removing cargo from the maturing DCSGs, such as the Vesicular Associated Membrane 
Protein-4 (VAMP4) (19), Calcium Independent-Mannose-6-Phosphate Receptor (CI-
MPR) (20) and furin (21). Furthermore, knockdown of the AP-3δ subunit in C. elegans 
results in defects in DCSG density, size, and number (22). Interestingly, the regulation of 
AP-1 and AP-3 relies on their ability to interact with the multifunctional membrane 
trafficking regulator Phosphofurin Acidic Cluster Sorting protein 1 (PACS-1) (23). 
Specifically, the PACS-1:AP-1 interaction is mediated through PACS-1 residues 174-
182, and facilitates the removal of VAMP4 from immature secretory granules through the 
VAMP4 motif (E27DDSDEEED) located in the VAMP4 cytoplasmic tail (19, 23). 
Furthermore, sorting of the cellular endopeptidase furin away from maturing secretory 
vesicles is mediated through PACS-1 and AP-1 (21). Additionally, the tight regulation of 
CI-MPR trafficking mediated by PACS-1 and AP-1 aids in the targeting of lysosomal 
hydrolases to endosomes, thereby decreasing luminal pH (24), a phenomenon that is 
associated with the regulation of DCSG formation and proper sorting of ACTH to the 
regulated secretory pathway (25, 26). Thus, through its ability to regulate AP-mediated 
trafficking, PACS-1 regulates multiple membrane trafficking steps within the cell, 
making it a hub for membrane trafficking, including cargo in the regulated secretory 
pathway.  
Herein, we provide evidence that identifies PACS-1 and AP-1 as key mediators in the 
sorting of POMC to the regulated secretory pathway. We observed that mutation of the 
PACS-1: AP binding site decreases the ability of PACS-1 to co-localize with ACTH-
positive DCSGs. Furthermore, knockdown of PACS-1 and AP-1 decreases DCSG 
formation, decreases intracellular ACTH storage, and increases extracellular ACTH 
levels in the absence of stimuli. Importantly, upon knockdown of PACS-1 and AP-1, we 




4.2.1 PACS-1 and AP-1 promote intracellular storage of POMC 
PACS-1 mediates trafficking of multiple proteins to and from the TGN (TGN) through its 
ability to recruit AP-1 and AP-3 (23). Thus, we sought to test for a role of PACS-1, AP-1, 
and AP-3 in the sorting of POMC to DCSGs by performing knockdown studies in mouse 
pituitary AtT-20 cells, which endogenously expresses POMC (7). Transfection of 
siRNAs targeting the PACS-1, AP-1, or AP-3 genes resulted in approximately 50% 
knockdown relative to non-specific siRNA, as determined by qRT-PCR, confirming that 
our knockdowns were effective (Fig. 4.1A). Subsequent to siRNA transfection, 
intracellular levels of POMC and its intermediates were assessed by Western blotting 
(Fig. 4.1B). Specifically, we utilized the previously described antibody that recognizes 
residues 1-18 of the POMC-derived ACTH peptide, thus detecting the ACTH-containing 
processed forms from full length POMC (27). Total intracellular POMC cleavage 
products detected by Western blot were quantified using densitometry (Fig. 4.1C). 
Strikingly, upon knockdown of PACS-1, we observed a 50% reduction in intracellular 
POMC-derived peptides compared to that of the non-specific siRNA. The knockdown of 
AP-1 resulted in a similar reduction of intracellular POMC, however, knockdown of AP-
3 did not significantly alter the intracellular storage levels of POMC (Fig. 4.1C).  
Upon external stimulation, DCSGs undergo fusion with the plasma membrane to release 
their contents into the extracellular environment via exocytosis (4). Therefore, we next 
sought to determine if the observed decrease in intracellular storage of POMC-derived 
peptides upon knockdown of PACS-1 or AP-1 is the result of increased secretion of the 
POMC-derived peptide, ACTH, in the absence of external stimulation. To test this, we 
transfected AtT-20 cells with siRNA towards PACS-1, AP-1, AP-3 or a non-specific 
control and subjected the cell culture supernatants to MAGPIX analysis. These 
experiments were conducted in the absence of stimulus and thus represent the 
constitutive, or unregulated secretion of ACTH. We observed 1.5 fold and 1.25 fold 
increases in ACTH in the cell culture supernatant upon knockdown of PACS-1 and AP-1, 
respectively, compared to the non-specific control siRNA (Fig. 4.1D). In contrast, 
increased levels of extracellular ACTH were not detected in cell culture supernatants 
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from AP-3 knockdown cells (Fig. 4.1D). These findings indicate that upon knockdown of 
PACS-1 or AP-1 unregulated secretion of ACTH occurs, suggesting that sorting of 
POMC to the regulated secretory pathway is dependent on the membrane trafficking 
proteins PACS-1 and AP-1, but not necessarily AP-3. 
To further assess the role of PACS-1 and its binding partners AP-1 and AP-3 in the 
sorting of POMC-derived peptides to DCSGs, we visualized the localization of ACTH in 
AtT-20 cells using widefield microscopy (Fig. 4.2). Accordingly, we co-transfected 
siRNA against PACS-1, AP-1, AP-3 or a non-specific sequence with a plasmid 
expressing a fluorescently labeled marker of the unregulated secretory pathway, the 
transferrin receptor (TfnR) (28), and examined the cells via microscopy (Fig. 4.2A). We 
subsequently compared the co-localization of POMC/ACTH with GFP-tagged TfnR 
(TfnR-GFP) in the presence or absence of siRNA targeting the various trafficking 
proteins (Fig. 4.2B). Interestingly, our results suggest that in PACS-1 knockdown cells, 
POMC/ACTH is shunted to the unregulated secretory pathway, as we observed an 
increased co-localization of POMC/ACTH with TfnR-GFP (siPACS-1; Fig. 4.2B & C; 
Pearson’s Coefficient = 0.49), compared to the scrambled siRNA control (siNS; Fig. 
4.2B & C; Pearson’s Coefficient = 0.32). Similarly, knockdown of AP-1 or AP-3 resulted 
in a significant increase in the co-localization of ACTH with TfnR-GFP (Pearson’s 
Coefficient = 0.46, 0.49, respectively). Taken together, these results support the 
hypothesis that PACS-1 and Adaptor Proteins play important roles in the trafficking of 



















Figure 4.1: Intracellular storage of POMC is regulated by PACS-1 and AP-1.  
AtT-20 cells were transfected with siRNA targeting PACS-1, AP-1, AP-3 or scrambled 
control. Forty-eight hours post transfection, cell-associated and cell culture supernatant-
associated POMC was quantified. (A) Knockdown efficiency of siRNA transfections was 
determined by reverse transcription of cellular RNA to cDNA followed by quantification 
of siRNA target cDNA via qRT-PCR. Percent knockdown was calculated by comparing 
relative cDNA levels within cells transfected with targeting siRNA versus the scrambled 
control (n=6). (B) AtT-20 cell lysates were subjected to Western blot 48 hours post 
siRNA transfection with antibodies targeting ACTH 1-18, and the loading control Actin. 


























































































































completed following Western blot quantification. Levels of POMC were calculated 
relative to actin and subsequently normalized to that of POMC in the scrambled control 
siRNA treated cells. Shown is the quantification of 5 independent experiments (n=5). (D) 
Supernatants of siRNA transfected cells were subjected to quantification of secreted 
extracellular ACTH using a MAGPIX assay. Mean relative extracellular ACTH (+/- 
standard error), compared to scrambled control siRNA, was calculated from 3 








Figure 4.2: PACS-1, AP-1 and AP-3 are required for the sorting of ACTH to the 
regulated secretory pathway.  
AtT-20 cells were co-transfected with siRNA targeting PACS-1, AP-1, AP-3 or a 
scrambled control and GFP-tagged transferrin receptor (TfnR-GFP). Forty-eight hours 
post transfection cells were immunostained for ACTH 1-18 and imaged via widefield 
microscopy. (A) Schematic of potential fates of POMC-derived peptides in 
neuroendocrine cells. Highlighted is the constitutive secretory pathway wherein TfnR+ 
vesicles are present. (B) Representative images of cells co-transfected with siRNA 
targeting PACS-1 (siPACS-1), AP-1 (siAP-1), AP-3 (siAP-3) or a scrambled control 
(siNS), and TfnR-GFP. Shown are TfnR-GFP (Green), ACTH (Red) and DAPI (Blue). 
Scale bar represent 10μm, inset scale bars represent 5μm. (C) The co-localization 


































































error) Pearson’s correlation coefficient in at least 30 cells from 3 independent 




















4.2.2 ACTH is not directed to a lysosomal degradation pathway 
We next tested if the reduced intracellular storage of POMC-derived peptides upon 
PACS-1 and AP-1 silencing could be attributed to the trafficking of POMC molecules to 
a degradative lysosomal compartment. To assess this, we analyzed ACTH co-localization 
with the lysosomal marker LAMP-1 in the presence of PACS-1, AP-1, AP-3 or control 
siRNA (Fig. 4.3A). Forty-eight hours post transfection, cells were fixed and 
immunostained for ACTH (Red; Fig. 4.3B) and the lysosomal marker LAMP1 (Green; 
Fig. 4.3B). Co-localization analysis between LAMP1 and ACTH revealed that decreased 
expression of PACS-1, AP-1 or AP-3 does not result in the trafficking of ACTH to a 
lysosomal compartment, compared to control siRNA (Fig. 4.3C). Taken together, these 
results suggest that the observed decrease in intracellular storage of POMC-derived 
peptides is not driven through the degradation of ACTH, but rather through mis-















Figure 4.3: ACTH is not targeted to the degradative lysosomal compartment.  
AtT-20 cells were transfected with siRNA towards PACS-1, AP-1, AP-3 and scrambled 
control. Forty-eight hours post transfection, AtT-20 cells were immunostained for 
LAMP1 and ACTH. (A) Schematic of potential fates of POMC-derived peptides in 
neuroendocrine cells. Highlighted is the degradative pathway wherein LAMP1+ 
lysosomes are present. (B) Representative images of cells transfected with siRNA 
targeting PACS-1 (siPACS-1), AP-1 (siAP-1), AP-3 (siAP-3) or a scrambled control 
(siNS). Cells are stained for LAMP1 (Green) and ACTH (Red). Scale bar represent 
10μm. (C) Co-localization between LAMP1 and ACTH staining was scored by 
calculating the mean (+/- standard error) Pearson’s correlation coefficient by 
quantification of at least 40 cells in 3 independent experiments. (n.s. represents not 


































































4.2.3 PACS-1: Adaptor Protein interactions modulate PACS-
1:ACTH co-localization 
Both PACS-1 and AP-1 act in concert to recognize cargo and modulate their localization 
within cells. Alteration of the AP-1 binding site on PACS-1 can modify the trafficking of 
itinerant cargo (23). For example, expression of a dominant-negative form of PACS-1, 
which is defective in AP-1/3 binding (termed ADMUT; Adaptor Protein binding 
Mutant), alters the localization AP-1, preventing Furin trafficking from endosomes to the 
TGN (23). Our findings demonstrate that PACS-1, AP-1, and AP-3 are critical in the 
sorting of POMC, and its derivatives, to the regulated secretory pathway (Fig. 4.2). 
Therefore, we sought to determine if PACS-1 co-localized with POMC-positive vesicles 
in an Adaptor Protein dependent manner. To test this, we transfected expression vectors 
encoding wildtype PACS-1-GFP (Green; Fig. 4.4A) into AtT-20 cells, or the dominant 
negative mutant of PACS-1, ADMUT-GFP (Green; Fig. 4.4B), and immunostained for 
ACTH (Red, Fig 4.4A and B). We subsequently examined co-localization between 
PACS-1/ADMUT and ACTH through super-resolution ground-state depletion 
microscopy (GSDM) using nearest neighbor spatial association analysis (29, 30) (SAA; 
Fig. 4.4). GSDM allows for a 10-fold increase in resolution compared to conventional 
widefield or confocal microscopy, and therefore enables the quantitative measurement of 
intermolecular distances between acquisition channels to determine the ability of 
fluorescently labeled proteins to associate (30). Interestingly, we observed that over 60% 
of ACTH co-localized with PACS-1-GFP (Fig. 4.4A and D). Furthermore, SAA revealed 
that this co-localization occurred at a much greater rate than expected of randomly 
positioned molecules, suggesting that PACS-1 is within close proximity to ACTH 
vesicles, whereby it may be exerting its sorting function (Fig. 4.4C and D). Upon 
expression of ADMUT-GFP we observed a 30% reduction in co-localization of ACTH 
and ADMUT-GFP compared to wildtype PACS-1-GFP, as determined via super-
resolution nearest-neighbor analysis (Fig. 4.4B and D). Overall, these results indicate that 
the interaction between PACS-1 and Adaptor Proteins, such as AP-1, facilitate 





Figure 4.4: PACS-1 co-localizes to POMC+ vesicles in AtT-20 cells.  
AtT-20 cells were transfected with PACS-1-GFP or ADMUT-GFP and forty-eight hours 
post transfection, cells were fixed, immunostained for ACTH, and imaged using ground-
state depletion super-resolution microcopy. (A+B) Representative images of AtT-20 cells 
transfected with PACS-1-GFP (A; Green) or ADMUT-GFP (B; Green) and 
immunostained for ACTH (Red) (scale bars represent 2.5μm, inset scale bars represent 














































































ACTH and PACS-1 (Green) or simulated random position (Orange). Co-localization cut-
off is illustrated (black dashed line). (D) A graphical representation of the mean (+/- 
standard error) percent of ACTH co-localized to PACS-1 or ADMUT-GFP, or ACTH co-
localized to randomly simulated positions.  Error bars were calculated by quantification 






4.2.4 PACS-1 facilitates the trafficking of ACTH to mature 
secretory granules 
We next sought to define if PACS-1 and Adaptor Proteins specifically mediate the 
targeting of ACTH to DCSGs. To ascertain this, we used the vesicular associated 
membrane protein 2 (VAMP2) as a marker for DCSGs (31). Due to the observed increase 
in constitutive secretion of ACTH upon knockdown of PACS-1 and AP-1 (Fig. 4.1D), we 
investigated the ability for ACTH to be targeted to VAMP2 positive DCSGs in the 
presence or absence of siRNA targeting PACS-1, AP-1 or AP-3 (Fig. 4.5A).  To test this, 
we co-transfected AtT-20 cells with siRNA targeting PACS-1, AP-1, AP-3 or a 
scrambled control siRNA and a GFP-tagged VAMP2 (Green). Cells were imaged by 
widefield fluorescence microscopy and scored for ACTH (Red) and VAMP2 (Green) co-
localization through the Pearson’s Coefficient (Fig. 4.5B and C). We observed a robust 
co-localization in control cells (Pearson’s Coefficient ~0.41), consistent with the storage 
of the ACTH peptide hormone within mature granules. Strikingly, upon knockdown of 
PACS-1, we observed a significant reduction in the ability of ACTH to be localized to a 
VAMP2-positive compartment (Fig. 4.5C), highlighting the role of PACS-1 in sorting 
ACTH to mature granules. Furthermore, knockdown of AP-1 resulted in an even greater 
reduction of ACTH localization to VAMP2-positive compartments (Fig. 4.5B and C).  
However, knockdown of AP-3 did not have a significant effect on VAMP2 co-
localization, consistent with our previous secretion assay results (Fig. 4.1D). Taken 
together, the results demonstrate the importance of PACS-1 and AP-1 in sorting ACTH 







Figure 4.5: PACS-1 and AP-1 facilitate the sorting of POMC to mature secretory 
granules. 
AtT-20 cells were co-transfected with siRNA against PACS-1, AP-1, AP-3 or scrambled 
control and a plasmid encoding GFP-tagged Vesicular Associated Membrane Protein – 2 
(VAMP2-GFP). Forty-eight hours post transfection cells were fixed and immunostained 
for ACTH. (A) Schematic of potential fates of POMC-derived peptides in neuroendocrine 
cells. Highlighted is the regulated secretory pathway wherein VAMP2+ mature secretory 
vesicles / DCSGs are present. (B) Shown are representative images illustrating VAMP2-
GFP (Green), ACTH (Red) and DAPI (Blue) in cells transfected with siRNA targeting 
PACS-1 (siPACS-1), AP-1 (siAP-1), AP-3 (siAP-3) or a scrambled control (siNS). Scale 
bar represent 10μm, inset scale bars represent 5μm. (C) The mean (+/- standard error) co-
localization between ACTH and VAMP2-GFP was scored by calculating the Pearson’s 








































































least 25 cells from 3 independent experiments. (* indicates p-value < 0.05; *** p-value < 







































4.3 Discussion  
In the current report, we demonstrate that the membrane trafficking regulator proteins 
PACS-1 and AP-1 regulate trafficking of the peptide hormone ACTH to DCSGs. We 
observed decreased DCSG sorting of ACTH upon PACS-1 and AP-1 depletion (Fig. 4.5). 
Moreover, in the absence of PACS-1 and AP-1, ACTH was secreted into the extracellular 
environment in the absence of a stimulus (Fig. 4.1D).  
The role of PACS-1 in the trafficking of cellular cargo is essential for cellular 
homeostasis. To achieve this, PACS-1 has been described as a multifunctional connector 
molecule that bridges itinerant cargo to Adaptor Proteins, such as AP-1 (23). These 
protein-protein interactions are assured by binding sites that are primarily located in the 
PACS-1 binding site for the prototypical PACS-1 cargo protein, furin, known as the furin 
binding region (32). Characterizing these PACS-1 protein-binding sites had previously 
enabled a preliminary understanding its role in the secretory pathway. Indeed, mutational 
analysis of the protein-binding sites in PACS-1 demonstrated that PACS-1 retrieves furin 
from immature secretory granules and traffics it to the TGN (21). Furthermore, 
trafficking of furin away from immature secretory granules was blocked in the presence 
of PACS-1 ADMUT, demonstrating the importance of the PACS-1:AP-1 interaction on 
targeting proteins to the secretory pathway, consistent with our determination of a role for 
PACS-1:AP-1 interaction in sorting ACTH to DCSGs (Fig. 4.4) (32). Interestingly, 
PACS-1 also serves an important role in HIV-1 mediated immune evasion by acting as a 
connector molecule between the viral accessory protein Nef and AP-1 to downregulate 
the antiviral molecule MHC-I from the surface of immune cells (33-35). Thus, viruses, 
such as HIV-1, have also evolved to use PACS-1 and AP-1 to shuttle cargo to diverse 
locations (36). 
Here, we present data identifying novel membrane trafficking proteins that mediate 
sorting of the ACTH precursor protein POMC. Processing of POMC is mediated by 
prohormone convertase- 1 and 2 (PC-1 and PC-2)(9). The cleavage events that activate 
POMC can occur at both early stages in the regulated secretory pathway, within the TGN, 
and at later stages within acidic DCSG compartments (7, 9, 37, 38).  Thus, processing to 
produce ACTH and other peptide hormones requires the correct sorting of POMC, PC1, 
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and PC2 to the TGN and subsequently DCSGs (11, 39). Defects in the processing ability 
of POMC can be observed upon knockout of PC1 or PC2, or mutation of POMC itself 
(38). Interestingly, the processing of POMC was not affected when PACS-1 or Adaptor 
Protein levels were reduced (Fig. 4.1). This is consistent with the notion that PACS-1 
may mediate sorting of POMC-derived peptides following PC cleavage. Alternatively, 
upon depletion of PACS-1 and AP-1, PCs and POMC may mis-localize to the same 
compartment, wherein POMC can still be cleaved into active components, yet is secreted 
in an unregulated fashion. Therefore, in future experiments it would be interesting to 
examine localization of PC-1 and PC-2 upon knockdown of PACS-1 or AP-1. 
Nonetheless, our results demonstrate a distinct role of PACS-1 and AP-1 in routing 
POMC-derived ACTH toward the regulated secretory pathway as knockdown of PACS-1 
and AP-1 resulted in shuttling of ACTH toward the unregulated secretory pathway (Fig. 
4.2), and away from DCSGs (Fig. 4.5). Interestingly, similar defects in ACTH trafficking 
have been observed when endosomes have been globally de-acidified through NH4Cl 
treatment or inhibition of vacuolar ATPase activity (25, 26). This suggests that PACS-1 
may be impacting the acidification of secretory granules through the altered trafficking of 
a cellular ATPase. 
Cleavage and activation of POMC is also achieved by the peptidase Carboxypeptidase E 
(CPE) (40, 41). CPE itself has also been proposed to assist in the targeting of POMC-
derived hormones, such as ACTH, to the secretory pathway (42). Indeed, CPE knockout 
mice exhibit decreased ability to process POMC (42). Furthermore, the POMC-derived 
peptides that became processed were unable to be properly stored within granules, 
resulting in these mice containing elevated serum levels of ACTH (43). These results are 
akin to our data, whereby upon reduced expression of PACS-1 and AP-1 we observed a 
striking defect in POMC storage and increased ACTH secretion, even in the absence of 
stimuli (Fig. 4.1). This data suggests that PACS-1 and AP-1 may be impacting trafficking 
and sorting steps similar to those mediated by CPE, or alternatively may act in concert 
with CPE. However, it is unlikely that PACS-1 or Adaptor Proteins directly affect CPE 
itself given that it lacks a canonical PACS-1 recognition motif and may not be accessible 
to the cytosolic PACS-1 protein (44, 45). 
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Previous studies utilizing a siRNA knockdown model identified a role for AP-3 in 
mediating specific sorting steps of cargo into storage granules, as well as inducing their 
ability to fuse with the plasma membrane upon stimulation (22). However, little is known 
about the specific role of AP-3 in the sorting of diverse cargo, such as POMC. AP-3 is 
responsible for the localization of vesicle fusion proteins to neuronal synapses (46), and 
is required for efficient release of neurotransmitters (47). Likewise, AP-3 also facilitates 
trafficking of fusion proteins to cytolytic granules in CD8 positive T cells (48). 
Moreover, loss of AP-3 function can lead to impairment in these processes and 
development of diseased states (17). Interestingly, knockdown of AP-3 has been 
associated with the routing of the DCSG-resident protein, Secretogranin II, to the 
unregulated secretory pathway (22). In agreement with these findings, we observed that 
knockdown of AP-3 resulted in an increase in ACTH localization to the constitutive 
pathway (Fig. 4.2C). However, we did not observe a corresponding decrease in sorting of 
ACTH into VAMP2 positive granules (Fig. 4.5C), nor did we observe an increase in 
extracellular ACTH secretion upon AP-3 knockdown (Fig. 4.1D). It is possible that AP-3 
knockdown results in the compensation by other adaptor protein molecules, or that 
ACTH does not follow the AP-3 dependent pathway previously described. Indeed, not all 
DCSGs contain the same cargo, suggesting that different adaptors can modulate cargo 
differently (49). 
Overall, we provide evidence supporting the key role of PACS-1 and AP-1 in controlling 
peptide hormone storage within AtT-20 cells. We also highlight the role of the PACS-1: 
Adaptor Protein interaction in the recruitment of PACS-1 to ACTH positive vesicles, and 
the role of PACS-1 and AP-1 in the storage of ACTH within cells. Controlling the release 
of peptide hormones is an important physiological process, which requires multiple 
proteins. Studying how these proteins work together is fundamental to understanding how 




4.4 Materials and Methods 
4.4.1 Cell Culture 
AtT-20 cells (ATCC; catalog #CCL-89) were cultured in complete Dulbecco’s Modified 
Eagle’s Medium (DMEM; Hyclone, Logan, UT) supplemented with 10% fetal bovine 
serum (Wisent, Montreal, Canada), 10μM L-Glutamine (HyClone), and 100μM penicillin 
and streptomycin (Hyclone). Cells were grown at 37 °C in the presence of 5% CO2 and 
sub-cultured in accordance with supplier’s recommendations.  
4.4.2 Plasmids and siRNA 
Plasmids encoding VAMP2-GFP-C3 and GFP-tagged transferrin receptor were obtained 
as a kind gift by Thierry Galli (French Institute for Health and Medical Research; 
Addgene plasmid #42308) (50), and by Dr. Ron Flanagan (Western University), 
respectively. PACS-1 cDNA was provided by Dr. Gary Thomas (University of 
Pittsburgh), and was sub-cloned into the pEGFP-N1 vector to yield a C-terminally GFP-
tagged PACS-1 construct. Additionally, ADMUT-GFP was generated by PCR overlap 
mutagenesis (Primers in Table 1). For knockdown experiments, siRNA against PACS-1 
(CCUUAGCUGUGGGACUCAUTT), AP-1 mu-1 
(GUAUCGGAAGAAUGAAGUATT), AP-3 delta-1 
(GCGAUGAACUGCUCACCAATT) and a scrambled control were obtained from Life 
Technologies (Carlsbad, California, USA).  
4.4.3 Transfections 
To quantify intracellular and extracellular levels of ACTH, 3 x 105 AtT-20 cells were 
seeded into 12 well dishes and 24 hours later, cells were transfected with 2.5μM siRNA 
using PepMuteTM siRNA Transfection Reagent (FroggaBio, North York, Canada) in 
accordance with the manufacturers’ recommendations. Twenty-four hours post 
transfection, media was replaced with complete DMEM, and 48 hours post-transfection 
cells lysates and supernatants were collected for Western blot and MAGPIX analysis, 
respectively. For microscopy experiments, 3 x 105 AtT-20 cells were seeded on 
coverslips, and 24 hours later, cells were transfected with 2.5µM siRNA and 1µg of the 
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appropriate plasmid DNA using PepMuteTM siRNA transfection Reagent. Forty-eight 
hours post transfection, cells were fixed and prepared for imaging. For ground-state-
depletion imaging, cells were seeded on coverslips as previously described above. Cells 
were then transfected with plasmids encoding GFP-tagged PACS-1 or GFP-tagged 
ADMUT using PolyJetTM In Vitro DNA Transfection Reagent (FroggaBio), in 
accordance with manufacturers’ recommendations. Forty-eight hours post transfection, 
cells were prepared for imaging and analysis. 
4.4.4 qRT-PCR 
AtT-20 cells were transfected with siRNA, as described above. Cells were collected 48 
hours post transfection, and RNA was extracted using Ambion RNA extraction kit (Life 
Technologies), as per the supplier’s instructions. First strand cDNA synthesis was 
performed using the Superscript III RT cDNA synthesis kit (Life Technologies). Primer 
sequences for reverse-transcription quantitative PCR are outlined in Table 3. 
Subsequently, cDNA was subjected to quantitative PCR using the SensiFast Probe Hi-
Rox Kit (Bioline, Taunton, MA) and the Applied Biosystems QuantStudio 5 Real-time 
PCR system (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Using actin as 
the reference gene, fold change in expression of the target gene was calculated using the 
delta CT (actin/target), and compared to that of scrambled control siRNA. Fold change 
expression = 1 - 2^-((CTactintarget – CTsiRNAtarget) - ( CTactincontrol – CTsiRNAcontrol)). 
4.4.5 Western Blots  
To assess intracellular protein levels in siRNA transfected cells, forty-eight hours post-
transfection cells were washed 2X with phosphate buffered saline (PBS), and lysed on ice 
with lysis buffer (0.5M HEPES, 1.25M NaCl, 1M MgCl2, 0.25M EDTA, 0.1% Triton X-
100, 1X complete protease inhibitor tablets (Roche, Indianapolis, IN)). Cells were 
incubated on a rotator for 20 minutes at 4°C prior to centrifugation at 20,000 x g at 4°C 
for 30 minutes. Supernatants were collected and boiled for 10 minutes after addition of 
5X SDS-PAGE sample buffer (5X Sample Buffer; 0.312M Tris pH 6.8, 25% 2-
Mercaptoethanol, 50% glycerol and 10% SDS). Samples were run on a 14% SDS-PAGE 
gel and transferred onto a nitrocellulose membrane. Membranes were blocked in 5% 
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skim milk powder in TBST for 1 hour, and incubated overnight at 4°C with antibodies 
specific for the ACTH peptide residues 1-18 (1:1000; generously provided by Dr. 
Lindberg, University of Marlyand) or Actin (1:3000; Thermo Scientific). Membranes 
were then washed 3X in TBST, incubated in species-specific HRP-conjugated secondary 
antibodies for 2 hours (1:2000; Thermo Scientific), and washed 3X in TBST. All blots 
were imaged using the C-Digit chemiluminescence Western blot scanner (LI-COR 
Biosciences, Lincoln, NE) with Crescendo ECL substrates (Millipore Inc.; Billerica, 
MA). Band intensities corresponding to peptides of 29 kDa, 26 kDa, and 9 kDa were 
quantified using the ImageQuant Studio software (LI-COR) and normalized to the Actin 
loading control.  
4.4.6 Extracellular ACTH Quantification 
To quantify basal extracellular levels of ACTH, cells were transfected with siRNA, as 
described above. Forty-eight hours post transfection, cell culture media was removed and 
250µl of fresh complete DMEM was added. Cells were then incubated at 37°C for 2 
hours. Subsequently, cell supernatants were collected and centrifuged at 10 000 x g to 
remove particulate matter and supernatants were then subjected to MAGPIX analysis. 
Specifically, cell culture supernatants were subjected to the ACTH MILLIPLEX MAP 
mouse pituitary magnetic bead panel (Millipore, Burlington, Massachusetts) to quantify 
extracellular ACTH, as per the suppliers’ protocol. Experimental samples were conducted 
in duplicate, and average values were reported as fold increase over the scrambled siRNA 
control treated cells.  
4.4.7 Widefield microscopy 
Forty-eight hours post transfection, cells were washed 3X in PBS, fixed in 4% 
paraformaldehyde for 15 minutes, and subsequently washed 3X with PBS. All cells were 
blocked for 1 hour in blocking buffer (5% bovine serum albumin and 0.1% Triton X-100 
in PBS). Cells were then incubated with rabbit anti-ACTH antibody diluted in blocking 
buffer (1:200;) and/or mouse anti-LAMP1 (1:100; clone 1D4B; Developmental Studies 
Hybridoma Bank; Iowa, USA) for 2 hours. Cells were washed 2X with blocking buffer, 
and incubated with the Goat-anti-mouse Cy3, or Goat-anti-Rabbit Alexafluor 647 
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secondary antibody (1:800; Jackson ImmunoResearch) for 1.5 hours. Following 
secondary antibody staining, cells were washed 3X with PBS, and mounted on 
Fluoromount-G mounting media containing DAPI nuclear stain. Cells were viewed on a 
Lecia DMI6000B at 63X or 100X magnification using the FITC, CY5 and DAPI filter 
settings, and imaged with a Hamamatsu Photometrics Delta Evolve camera (Leica, 
Wetzlar, Germany). Images were deconvolved using the advanced fluorescence (Leica) 
application on the Lecia Application Suite software. Co-localization analysis was 
performed using the Pearson’s correlation coefficient from the ImageJ plugin JACoP, as 
described previously (51). 
4.4.8 Ground-state depletion microscopy 
Super-Resolution imaging was performed as described previously (51). Briefly, cells 
were mounted, and imaged in a depression slide containing 100mM cysteamine (Sigma 
Aldrich). All images were acquired using a Leica SR GSD microscope with a 100X/1.43 
NA objective lens containing a 1.6X magnifier. GFP and AlexaFluor 647 fluorophores 
were excited using 488nm and 647 nm laser lines respectively, and back pumped with a 
30 mW 405 laser line. Resulting images were quantified using the spatial association 
analysis MIiSR software as previously described (51) (Available for download: 
http://phagocytes.ca/miisr/). Co-localization between the two channels was quantified as 
percent association of ACTH to PACS-1/ADMUT.  
4.4.9 Statistics 
All statistics were conducted using the unpaired t-test or the one-way ANOVA with 
multiple comparisons where indicated using Graph Pad Prism (Graph Pad Software Inc., 






Table 3 Primers for mutagenesis and qRT-PCR 
Target Primer ID Sequence 5’è3’ 
ADMUT forward JD-136 CTTCCAGCTAGTGGACTGGTGGCAGCAG
CGGCCGCAGCAGCCGCCTCCCTTCAGTA
CCCTCATTTCCTT 
ADMUT reverse JD-137 AAGGAAATGAGGGTACTGAAGGGAGGC
GGCTGCTGCGGCCGCTGCTGCCACCAGT
CCACTAGCTGGAAG 
pacs1 forward JD-706 TTGTATGCTACCTGGGAGGTG 
pacs1 reverse JD-707 AAATGAGGGTACTGGAGGGAG 
ap1m1 forward JD-712 TGGTGGCGTTCGTTTCATGT 
apm1m1 reverse JD-713 GCAGCTCGTAGATGATGACAAA 
ap3d1 forward JD-708 CGACCGCATGTTCGATAAGAA 
ap3d1 reverse JD-709 GCTTGATCTCGTCAATGCACTG 
actin forward JD-702 TCCTTCGTTGCCGGTCCACA 
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5 Thesis Overview 
5.1 Discussion 
5.1.1 General Discussion Overview 
This dissertation highlights the importance of trafficking cellular cargo to precise 
subcellular locations. Examples of cargo that were highlighted include a cellular receptor 
critical for the immune response, MHC-I (1), and the peptide hormone, ACTH, that 
mediates multiple physiological responses (2, 3). In both cases, PACS-1 was a membrane 
trafficking regulator protein pivotal in ensuring the correct localization of both cargo and 
was thus the primary focus of this dissertation. In addition, it was observed that PACS-1 
requires the recruitment of APs to ensure the sorting of both MHC-I and ACTH (Fig. 
4.4), thereby demonstrating that PACS-1-dependent sorting steps are also dependent on 
AP-1. Overall, in the presence of HIV-1 Nef, disruption of the Nef:PACS-1 or PACS-
1:AP-1 interactions resulted in a drastic redistribution of MHC-I within the cell (Fig. 
3.10). Similarly, mutation of the PACS-1:AP-1 binding site also impaired the ability of 
PACS-1 to localize to ACTH-positive vesicles (Fig. 4.4). Lastly, these studies also 
highlight the importance of quantitative fluorescence microscopy to visualize protein-
protein interactions and associations within cells.  
5.1.2 Summary of Findings 
HIV-1 is a master of hijacking the cell to permit its own replication. A primary 
contributor enabling this success is the Nef protein (4-8). As a small non-enzymatic viral 
protein, Nef relies almost exclusively on its ability to interact with a multitude of host 
cellular proteins to circumvent their functions. Most notably, Nef mediates the 
downregulation or upregulation of upwards of 35 cell surface molecules (9). To study 
Nef’s role in hijacking host cellular proteins, I employed a novel tool that we defined as 
viral BiFC in Chapter 2 of this dissertation. Viral BiFC enables the detection of an 
association between putative protein partners expressed from the same vector. In 
addition, this technique permits the localization of this interaction to a precise subcellular 
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locale by counterstaining for vesicular markers. This novel experimental tool enabled the 
identification of the Nef:PACS-1 (Fig. 2.5), Nef:MHC-I (Fig. 2.7) and Nef:SNX-18 (Fig. 
2.7) interactions which were observed throughout the endosomal network. Importantly, 
these interactions were described within the context of a viral infection. These studies 
represented the first demonstration of a Nef:PACS-1 interaction in cells in the context of 
viral infection, and the first visualization of a Nef:MHC-I interaction within cells. 
Moreover, we demonstrated the first reported interaction of the SNX18 protein with Nef, 
a protein which is believed to localize within the same vesicular structure as PACS-1 and 
AP-1 (10).  
Nef’s function during MHC-I downregulation has been previously explored however a 
complete understanding of the molecular players involved and the location of their 
activities remains unknown. Two major models exist to explain Nef-mediated MHC-I 
downregulation (6, 11). The first describes a process in which newly synthesized MHC-I 
is blocked from reaching the cell surface (11-13). The second identifies an endocytic 
event leading to the sequestration of MHC-I within the cell, which is dependent on the 
cellular PACS proteins (6, 11, 14-16). In Chapter 3, I outlined the detailed trafficking 
itinerary for the Nef MHC-I complex which is endocytosed from the cell surface. 
Importantly, this work identified the distinct endosomal localization for the interaction, 
and the Nef-dependent sequestration of MHC-I within the TGN. Furthermore, I 
discovered that Nef hijacks early recycling pathways of MHC-I trafficking, and requires 
Nef’s acidic cluster (EEEE62-65) to recruit PACS-1, and subsequently AP-1 to the 
Nef:MHC-I complex. By perturbing the regulation of the early endosomal marker, Rab5, 
by over expressing a constitutively active mutant of Rab5 (Rab5-Q67L; Fig. 3.5), we 
abrogated MHC-I downregulation by Nef. This long-hypothesized sequence of events 
had never been previously visualized in cells. Moreover, the use of super-resolution 
imaging greatly aided in the identification of the role of PACS-1 in the recruitment of 
AP-1, and the localization of the Nef:MHC-I complex to discrete sub cellular 
compartments (Fig. 3.12). These data directly support the molecular events encompassed 
within the signaling model of MHC-I downregulation (14, 15, 17). More specifically, 
MHC-I was not found to traffic to the lysosome, and PACS-1 was identified to mediate 
the retrograde transport of MHC-I from endosomes to TGN (Fig. 3.10). Importantly, 
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these results further support the importance of a Nef:MHC-I:AP-1 complex, but add an 
additional layer of complexity by incorporating PACS-1 as an additional protein to this 
complex. Additional co-immunoprecipitation experiments will be needed to confirm this 
biochemically, but the extensive microscopic data provided in Chapter 3 strongly 
supports this assertation.  
The data presented in Chapter 4 identified a previously unidentified role of PACS-1. 
PACS-1 has multiple cellular functions (11, 18-22). It is critical in the early development 
of the human embryo, during the trafficking of the cellular protease furin, and has been 
recently described as a protein that when expressed in a mutant form in humans causes 
cranial malformations and growth defects (23, 24). The latter disease is termed PACS-1 
syndrome. Thus, we aimed to study PACS-1’s role in a different cellular process: the 
packaging and storage of ACTH with specialized storage granules in anterior pituitary 
cells. The role of PACS-1 in this process has not been fully studied, rather, had focused 
on the role of adaptor proteins AP-1 and AP-3 in the sorting of proteins and receptors to 
synaptic and storage vesicles within neuroendocrine cells (25-28). In Chapter 4, I 
implicated PACS-1, through both knockdown and mutational analysis in the storage of 
ACTH within neuroendocrine cells (Fig. 4.1). Through super-resolution imaging, I 
determined that PACS-1 localizes to ACTH positive vesicles, which is dependent on its 
interaction with APs (Fig. 4.4). Moreover, upon knockdown of PACS-1 or AP-1, ACTH 
undergoes unregulated release into the extracellular environment (Fig 4.1). Overall, we 
propose a role for PACS-1 in the sorting of ACTH towards the regulated secretory 
pathway.  
5.1.3 Interrogating Nef’s interacting partners during MHC-I 
downregulation 
Viruses are small genomic machines which have optimized their protein coding capacity 
to optimize their replication within host cells. Their genome size is limited by a number 
of factors including, but not limited to, the size of the viral capsid, the stability of their 
genome, and their sensitivity to mutation (29). Because of this, viral proteins have 
evolved to be multifunctional and thereby mediate a variety of diverse functions within 
the cell to optimize viral replication. Thus, viral proteins hijack the function of a plethora 
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of proteins by forming specific protein-protein interactions. To adapt to such a wide 
range of protein-protein interactions, viral proteins are often intrinsically disordered; 
lacking a defined tertiary structure (30, 31). In doing so, they can undergo conformational 
changes necessary to interact with host proteins. Often, viruses employ strategies known 
as ‘viral mimicry’ to imitate binding motifs of host cellular proteins (32-34). Notably, the 
adenovirus E1A protein employs this strategy to hijack the cellular protein PKR to 
enhance nuclear localization and viral transcription (35). HIV-1 accessory proteins are no 
exception to this, as the Nef protein can regulate the cell surface expression of over 35 
different receptors, mediate apoptosis pathways, and alter cellular activation (9).  
Nef employs multiple short yet well conserved motifs often located in flexible regions of 
the protein, thereby optimizing its ability to bind multiple protein partners (36). The Nef-
encoded dileucine (LL164-165) motif, for example, mimics the recognition motif of AP-2 to 
downregulate the viral receptor CD4 from the cell surface of virally infected cells (37-
40). The Nef poly-proline PxxP75 motif bares similarity to the cellular PxxP motif present 
in host cell proteins which recognizes SH3 domains (11, 16). In the context of HIV-1 
infection, Nef interacts with Src-family kinases at the TGN via the PxxP75 motif to 
initiate a signaling cascade resulting in MHC-I endocytosis. The SNX18 protein also 
contains an SH3 domain within its N-terminus (41), and could represent a potential 
binding interface involving Nef PxxP75 (Figure 2.8). Extensively investigated in Chapter 
3, the Nef acidic cluster (EEEE65) mimics the cellular acidic cluster found in the 
cytoplasmic tail of multiple cellular receptors; furin, CI-MPR, VAMP4 and sortilin, 
among others (18, 19, 42-46). The acidic cluster serves as a canonical recognition motif 
to the PACS family of proteins (43). Much like the well-described endosome-to-Golgi 
trafficking of cellular receptors, we demonstrated a similar Nef-dependent trafficking of 
MHC-I by hijacking PACS-1. Moreover, we demonstrated the importance of PACS-1 to 
recruit AP-1 to the cytoplasmic tail of MHC-I.  
Multiple studies have aimed to decipher the precise mechanism of Nef-mediated MHC-I 
downregulation. Multiple studies have demonstrated roles for Nef and PACS-2- in the 
activation of SFKs and PI3K (11, 14). These data convincingly demonstrated that within 
PBMCs, SFK and PI3K activation is a requirement for MHC-I downregulation (11, 14). 
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Further supporting this data is the fact that putative Nef inhibitors targeting the Nef:SFK 
interaction drastically increased MHC-I on the cell surface (11, 47). Other reports 
questioned this hypothesis; however, these results were primarily conducted in PTEN 
deficient cell lines, which bypass the requirement of PI3K activation (48-50). Therefore, 
in these circumstances, PACS-2 involvement may be dispensable. The specific 
contribution of PACS-1 has also been unclear. The interaction of PACS-1 and Nef has 
been demonstrated convincingly in both yeast-2-hybrid, co-immunoprecipitation, and 
BiFC assays (51, 52). Moreover, multiple studies have re-capitulated the importance of 
the Nef:PACS-1 interaction along with the PACS-1:AP-1 interactions in the 
downregulation of MHC-I (14, 15, 20). However, it remained unknown if these protein 
complexes were interconnected, and what trafficking steps they regulated. In Chapter 3, 
we propose a role for PACS-1 in the retrograde transport of the Nef:MHC-I complex 
from the peripheral endosomal compartments to the TGN for sequestration (Fig. 3.10 and 
3.13). These studies were made possible using the BiFC assay combined with GSDM 
imaging. Indeed, with the 10-fold gain in resolution we demonstrated the requirement of 
the Nef:PACS-1 interaction in the recruitment of AP-1 to the cytoplasmic tail of MHC-I 
(Fig. 3.12), highlighting the role of a possible Nef:PACS-1:AP-1:MHC-I quaternary 
complex .  
 The identification of SNX18 as a potential Nef binding partner in Chapter 2 is also 
intriguing. The sorting nexin family of proteins is implicated in a wide variety of cellular 
sorting pathways, from endocytosis, to Golgi trafficking (10, 41). SNX18 can directly 
interact with AP-1, and co-localizes with PACS-1 in uninfected cells (10). In this context, 
SNX18 can also bind to curved membranes and interact with the membrane scission 
protein dynamin to pinch off newly budded vesicles (53, 54). The contribution of SNX18 
to the downregulation of receptors by Nef is not fully known, but is currently under 
investigation within our laboratory (55). An attractive hypothesis includes the assembly 
of a multi-protein complex, in which SNX18 is recruited to sites of Nef and MHC-I, 
thereby facilitating the scission event required for Nef to shuttle MHC-I from one cellular 
location to another.  
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5.1.4 Role of PACS-1 and AP-1 in protein sorting 
Separate from the PACS-1 dependent trafficking steps in HIV-1 Nef-expressing cells, is 
the role of PACS-1 in uninfected cells. The role of PACS-1 in the regulated secretory 
pathway has evolved around its function in trafficking the endopeptidase furin (56-58). 
The coordinated trafficking of furin by PACS-1 allows the cleavage of multiple 
substrates such as the pro-parathyroid hormone, the pro-nerve growth factor and the von 
Willebrand factor in specialized secretory compartments (56). DCSGs are one such 
compartment where inactive proteins are activated via processing events (59). The 
maturation process of immature secretory granules to DCSGs is still not well understood, 
including how different cargo proteins become targeted to such specialized compartments 
(60). In Chapter 4, we present data which highlights the role of PACS-1 in the sorting of 
ACTH to the regulated secretory pathway. This study revealed that upon knockdown of 
PACS-1, ACTH is routed to the unregulated secretion pathway, resulting in the 
constitutive secretion of ACTH (Fig. 4.1). Moreover, we identified that PACS-1 co-
localizes with ACTH in an AP-1 dependent fashion (Fig 4.4). It is still unclear to how 
PACS-1 may exert its sorting function on ACTH, as ACTH does not possess a 
cytoplasmic tail. This trafficking event may be a by-product of the mis-trafficking of an 
unknown cellular receptor mediating the formation of the DCSGs. Both PACS-1 and AP-
1 are capable of interacting with the tethering protein VAMP4, which is present at the 
TGN, and aids in the docking of vesicles within endosomal compartments (44, 61). It is 
unknown if knockdown of VAMP4 prevents proper docking of ACTH positive vesicles 
to the immature secretory granule, but such a possibility warrants further investigation.  
We did not observe a significant effect on ACTH secretion upon knockdown of AP-3. 
PACS-1 can interact with both AP-1 and AP-3 via the same PACS-1 motif (43, 46). The 
role of AP-3 in regulated DCSG release at the plasma membrane has been previously 
observed. The mechanism by which this occurs is not fully elucidated, but it is 
hypothesized to involve the calcium sensing receptor synaptotagmin-1 (SYT1) (27). 
SYT1 has a regulatory role in controlling the fusion of DSCGs and with the plasma 
membrane upon calcium stimulation due to its ability to signal the fusion of SNARE 
complexes (62-64). Although a knockdown of AP-3 did not result in a significant 
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unregulated release of ACTH akin to the knockdown of PACS-1 and AP-1 (Fig. 4.1), 
knockdown of AP-3 has been demonstrated to impact the fusion of DCSGs to the plasma 
membrane (27, 28). The precise trafficking itinerary of STY1 is not known, however, it 
does possess a canonical acidic cluster along with a tyrosine sorting motif, which 
suggests that it may also trafficked by PACS-1. Interestingly, a preliminary analysis of 
PACS-1 interaction partners by our lab has identified SYT1 as a potential interaction 
partner (65).  
5.1.5 Concluding remarks 
Overall, the data contained within this thesis represents two fascinating fields of research: 
HIV-1 pathogenesis and fundamental cell biology. I bridged these fields with a focused 
role for PACS-1 in regulating cellular membrane trafficking. In the context of HIV-1, I 
provided an unprecedented view of virus-host interactions. I generated a viral vector 
which enabled the study of Nef-interacting partners within the cell, and provided a 
platform to identify novel interactions (55, 66). Moreover, these studies led to the direct 
visualization of the Nef:MHC-I complex within the cell. MHC-I downregulation is an 
important process required to evade immune detection. Thus, understanding the PACS-1-
dependent mechanisms governing this process provides an important piece of the puzzle 
in determining how to more effectively treat HIV-1 infections (67). Importantly, we took 
a step back to evaluate the role of PACS-1 in protein trafficking during the uninfected 
state. The recent identification of de novo mutations in pacs-1 (23), leading to PACS-1 
syndrome, highlights the important physiological role of PACS-1 in growth and 
development. Overall, I believe that an enhanced understanding of PACS-1 biology 
during regulated secretion will aid in understanding the complexities and importance of 
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